

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2021 OF THE CONDITION AND AFFAIRS OF THE

Oxford Health Plans (NJ), Inc.

NAIC	· · · · · · · · · · · · · · · · · · ·	0707 NAIC Company (Code <u>95506</u> Employer's ID I	Number22-2745725			
Organized under the Laws of		· · ·	_, State of Domicile or Port of Entr	yNJ			
Country of Domicile		United Sta	ites of America				
Licensed as business type:		Health Mainten	nance Organization				
Is HMO Federally Qualified?	Yes[]No[X]						
Incorporated/Organized	04/17/1985		Commenced Business	09/12/1985			
Statutory Home Office	170 Wood Avenu			Iselin, NJ, US 08830			
	(Street and N	umber)	(City or T	own, State, Country and Zip Code)			
Main Administrative Office _			Drive, 5th Floor				
	Shelton, CT, US 06484	(Street a	and Number)	203-447-4500			
(City or	Town, State, Country and Zip	Code)	(Are	a Code) (Telephone Number)			
Mail Address	4 Research Drive, 5th			Shelton, CT, US 06484			
	(Street and Number or P	.O. Box)	(City or T	own, State, Country and Zip Code)			
Primary Location of Books and	Records		h Drive, 5th Floor				
	Shelton, CT, US 06484	(Street a	and Number)	203-447-4500			
(City or	Town, State, Country and Zip	Code)	(Are	a Code) (Telephone Number)			
Internet Website Address		www.oxf	ordhealth.com				
Statutory Statement Contact	Will A	nders Granrud		952-912-6815			
,		(Name)	'	(Area Code) (Telephone Number)			
·	will_granrud@uhc.com (E-mail Address)			952-931-4651 (FAX Number)			
	(constant)	05	FICERS				
President	Charles Reev			Peter Marshall Gill			
Secretary	Jessica Leig	h Zuba #	Chief Financial Officer	Richard Michael Hersch			
Heather Anastasia Lar	ng, Assistant Secretary		THER ington, Vice President	Sanford Paul Cohen M.D., Chief Medical Officer			
			OR TRUSTEES				
	e Johnson # wes Wayland		arie McGann # Corkum Winsor #	Donald Alan Stangler M.D.			
State of Califor	nia	State of <u>Vew</u>	Sersey	State of Connich cut			
County of Napo	a	County of Mind	Ulles ex	County of Farchuld			
above, all of the herein descri this statement, together with n of the condition and affairs of completed in accordance with that state rules or regulations respectively. Furthermore, th	bed assets were the absolute elated exhibits, schedules and the said reporting entity as of the NAIC Annual Statement I require differences in reportin e scope of this attestation by tting differences due to electr	property of the said report explanations therein cont the reporting period state instructions and Accounting on trelated to accounting the described officers also	ing entity, free and clear from any li ained, annexed or referred to, is a f d above, and of its income and de g Practices and Procedures manual practices and procedures, accordi includes the related corresponding	reporting entity, and that on the reporting period stated iens or claims thereon, except as herein stated, and that full and true statement of all the assets and liabilities and ductions therefrom for the period ended, and have been l except to the extent that: (1) state law may differ; or, (2) ng to the best of their information, knowledge and belief, electronic filing with the NAIC, when required, that is an may be requested by various regulators in lieu of or in			
Ilessica	Zala	Chan !	R Wyla	Madred Red			
Jessica Leigh Secretary			eeves Wayland	Richard Michael Hersch Chief Financial Officer			
Subscribed and sworn to b	before me this		orn to before me this of February 202 to B-	Subscribed and sworn to before me this day of <u>Fabric</u> 202			
	`````			0			

SEE CA JURAT CERTIFICATE ATTACHED

b lf no,

State the amendment number.....
 Date filed

a. Is this an original filing?....

3 Number of pages attached

CHRISTINE BANNON-IZZO NOTARY PUBLIC OF NEW JERSEY My Commission Expires 07/28/2023

122.00

CYNTHIA MARCANTONIO

Yes[X]No[]

1

110

My Commission Expires Aug. 31, 2025

	ASS	SETS			
			Current Year		Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)		0		
2.	Stocks (Schedule D):				
	2.1 Preferred stocks	0	0	0	0
	2.2 Common stocks	0	0	0	0
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens	0	0	0	0
		0	0	0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$0				
	encumbrances)	0	0	0	0
	4.2 Properties held for the production of income (less				
	\$0 encumbrances)	0	0	0	0
	4.3 Properties held for sale (less \$0				
	encumbrances)	0	0	0	0
5.	Cash (\$(15,727), Schedule E - Part 1), cash equivalents				
0.	(\$				
	investments (\$	69 374 317	0	69 374 317	44 254 574
6.	Contract loans, (including \$				
0. 7.	Derivatives (Schedule DB)				0
7. 8.	Other invested assets (Schedule BA)				0
	Receivables for securities				0
9. 10					
10.	Securities lending reinvested collateral assets (Schedule DL)				0
11.	Aggregate write-ins for invested assets				0
12.	Subtotals, cash and invested assets (Lines 1 to 11)		0	238,318,426	
13.	Title plants less \$0 charged off (for Title insurers				
	only)				
14.			0		
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection				
	15.2 Deferred premiums and agents' balances and installments booked but				
	deferred and not yet due (including \$0				
	earned but unbilled premiums)	0	0	0	0
	15.3 Accrued retrospective premiums (\$0 ) and				
	contracts subject to redetermination (\$53, 136, 777 )		0		
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers				0
	16.2 Funds held by or deposited with reinsured companies		0		0
	16.3 Other amounts receivable under reinsurance contracts		0		0
17.	Amounts receivable relating to uninsured plans			13,393,978	
	Current federal and foreign income tax recoverable and interest thereon		0	· · · ·	2,381,696
18.2	Net deferred tax asset	931,945	0		2,089,331
19.	Guaranty funds receivable or on deposit	0	0	0	0
20.	Electronic data processing equipment and software	0	0	0	0
21.	Furniture and equipment, including health care delivery assets				
	(\$0 )	0	0	0	0
22.	Net adjustment in assets and liabilities due to foreign exchange rates	0	0	0	0
23.	Receivables from parent, subsidiaries and affiliates				0
24.	Health care (\$		3,016,842		40,703,119
25.	Aggregate write-ins for other than invested assets				0
26.	Total assets excluding Separate Accounts, Segregated Accounts and				
	Protected Cell Accounts (Lines 12 to 25)		3,072,690		
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0	^
28.	Accounts	358,404,172	3,072,690		293,828,989
20.		330,404,172	3,072,090	333,331,402	293,020,909
	DETAILS OF WRITE-INS				
1101.					
1102.					
1103.					
1198.	Summary of remaining write-ins for Line 11 from overflow page			0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0	0
2501.	Prepaid Expenses	633	633	0	0
2502.					
2503.					
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	633	633	0	0

ASSETS

# LIABILITIES, CAPITAL AND SURPLUS

			Current Year	,	Prior Year
	F	1	2	3	4
		Covered	Uncovered	Total	Total
1.	Claims unpaid (less \$0 reinsurance ceded)				
	Accrued medical incentive pool and bonus amounts		0		
	Unpaid claims adjustment expenses				
	Aggregate health policy reserves, including the liability of				
	\$0 for medical loss ratio rebate per the Public				
	Health Service Act	1.676.445	0	1.676.445	1.178.394
5.	Aggregate life policy reserves				
	Property/casualty unearned premium reserves				
	Aggregate health claim reserves		0		
	Premiums received in advance		0		
	General expenses due or accrued		0		
	Current federal and foreign income tax payable and interest thereon			, ,	
	(including \$0 on realized capital gains (losses))	0	0	0	0
10.2	Net deferred tax liability			0	
	Ceded reinsurance premiums payable			0	
	Amounts withheld or retained for the account of others			0	
13.	Remittances and items not allocated.		0		
	Borrowed money (including \$0 current) and				
	interest thereon \$0 (including				
	\$0 current)	0	0	0	0
15.	Amounts due to parent, subsidiaries and affiliates				
	Derivatives				
	Payable for securities				0
	Payable for securities lending				0
	Funds held under reinsurance treaties (with \$0				0
19.	authorized reinsurers, \$0 unauthorized				
	reinsurers and \$0 certified reinsurers)	0	0	0	0
20	Reinsurance in unauthorized and certified (\$0 )				0
20.		0	0	0	0
	companies				
	Net adjustments in assets and liabilities due to foreign exchange rates			0	
	Liability for amounts held under uninsured plans		0		
23.	Aggregate write-ins for other liabilities (including \$45,006,458	45 000 450		45 000 450	04,000
	current)				
	Total liabilities (Lines 1 to 23)				
	Aggregate write-ins for special surplus funds				
	Common capital stock				
	Preferred capital stock				
	Gross paid in and contributed surplus				
	Surplus notes				
30.	Aggregate write-ins for other than special surplus funds				
31.	Unassigned funds (surplus)	XXX	XXX		
32.	Less treasury stock, at cost:				
	32.10 shares common (value included in Line 26				
	\$0 )	XXX	XXX	0	0
	32.20 shares preferred (value included in Line 27				
	\$0 )	XXX	XXX	0	0
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX		219,222,971
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	355,331,482	293,828,989
	DETAILS OF WRITE-INS				
2301.	Declared Dividend		0		0
2302.	Unclaimed Property		0	6,458	
2303.					
2398.	Summary of remaining write-ins for Line 23 from overflow page		0	0	0
	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	45,006,458	0	45,006,458	24,838
				, ,	,
	Summary of remaining write-ins for Line 25 from overflow page				0
	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)			0	0
	Totals (Lines 2501 tillu 2505 plus 2590)(Line 25 above)			•	•
	Summary of remaining write-ins for Line 30 from overflow page				
3000	Totals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0

# STATEMENT OF REVENUE AND EXPENSES

	STATEMENT OF REVENUE AN	Current		Prior Year
		1 Uncovered	2 Total	3 Total
1.	Member Months			
	Net premium income ( including \$			
3. (	Change in unearned premium reserves and reserve for rate credits	XXX	(1,165,526)	
4. F	ee-for-service (net of \$0 medical expenses)	XXX	0	0
5. F	Risk revenue	XXX	0	0
6. /	Aggregate write-ins for other health care related revenues	XXX	0	0
7. /	Aggregate write-ins for other non-health revenues	XXX	0	0
8.	Fotal revenues (Lines 2 to 7)	XXX	1,221,862,548	
	Hospital and Medical:			
	Hospital/medical benefits			
	Other professional services			
	Dutside referrals			
	Emergency room and out-of-area			
	Prescription drugs			
	Aggregate write-ins for other hospital and medical			
	ncentive pool, withhold adjustments and bonus amounts			
16. 5	Subtotal (Lines 9 to 15)	0		
	Less:		(22)	4 550
	Net reinsurance recoveries			
	Fotal hospital and medical (Lines 16 minus 17)			
	Non-health claims (net)			
	Claims adjustment expenses, including \$			
21. (	General administrative expenses	0		
22. I	ncrease in reserves for life and accident and health contracts (including \$0			
	increase in reserves for life only)			
23.	Total underwriting deductions (Lines 18 through 22)	0	1,094,976,403	
24. I	Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	126,886,145	
	Net investment income earned (Exhibit of Net Investment Income, Line 17)			
26. I	Net realized capital gains (losses) less capital gains tax of \$	0		(12,526)
	Net investment gains (losses) (Lines 25 plus 26)	0	1,370,924	2,457,208
28. I	Net gain or (loss) from agents' or premium balances charged off [(amount recovered			
	\$25,222 ) (amount charged off \$	0	(3,993)	
29. /	Aggregate write-ins for other income or expenses	0	0	(2,511)
30. I	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	XXX	128.253.076	
31. I	Federal and foreign income taxes incurred			
	Net income (loss) (Lines 30 minus 31)	XXX	101,714,602	90,308,152
	DETAILS OF WRITE-INS		, ,	- , - , -
0602.				
0603 .				
0698.	Summary of remaining write-ins for Line 6 from overflow page		0	0
0699.	Fotals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701				
0702		XXX		
0703 .		XXX		
0798. 3	Summary of remaining write-ins for Line 7 from overflow page	XXX	0	0
0799.	Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
				_
	Summary of remaining write-ins for Line 14 from overflow page			0
	Fotals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
	liscellaneous Expense			(2,511)
2903 -	Summary of remaining write-ins for Line 29 from overflow page			0
		0	0	(2,511)
2333.	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	v	v	(2,311)

# **STATEMENT OF REVENUE AND EXPENSES (Continued)**

		1 Current Year	2 Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year		
34.	Net income or (loss) from Line 32	101,714,602	
35.	Change in valuation basis of aggregate policy and claim reserves	0	0
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$0		0
37.	Change in net unrealized foreign exchange capital gain or (loss)		0
38.	Change in net deferred income tax	(1,157,386)	
39.	Change in nonadmitted assets	3,794,963	(1,645,245)
40	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles	0	0
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus	0	0
45.	Surplus adjustments:		
	45.1 Paid in	0	0
	45.2 Transferred to capital (Stock Dividend)	0	0
	45.3 Transferred from capital	0	0
46.	Dividends to stockholders	(45,000,000)	(45,000,000)
47.	Aggregate write-ins for gains or (losses) in surplus	(45,000,000)	0
48.	Net change in capital and surplus (Lines 34 to 47)		
49.	Capital and surplus end of reporting period (Line 33 plus 48)	233,575,151	219,222,971
	DETAILS OF WRITE-INS		
4701.	Dividend Declared	(45,000,000)	0
4702.			
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	(45,000,000)	0

## **CASH FLOW**

		1	2
		Current Year	Prior Year
	Cash from Operations	Current real	FIIOI Teal
1.	Premiums collected net of reinsurance	1,211,447,143	002 200 886
1. 2.	Net investment income		
2. 3.	Net investment income		2,973,792
3. 4.			995,373,678
	Total (Lines 1 through 3) Benefit and loss related payments		762,306,838
5.			
6. -	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions		
8.	Dividends paid to policyholders		0
9.	Federal and foreign income taxes paid (recovered) net of \$0 tax on capital gains (losses)		30,600,282
10.	Total (Lines 5 through 9)		924,613,662
11.	Net cash from operations (Line 4 minus Line 10)		70,760,016
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds		
	12.2 Stocks		0
	12.3 Mortgage loans		0
	12.4 Real estate		0
	12.5 Other invested assets		0
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		0
	12.7 Miscellaneous proceeds		0
	12.8 Total investment proceeds (Lines 12.1 to 12.7)		
13.	Cost of investments acquired (long-term only):		
	13.1 Bonds		
	13.2 Stocks	0	0
	13.3 Mortgage loans		0
	13.4 Real estate		0
	13.5 Other invested assets		0
	13.6 Miscellaneous applications	0	0
	13.7 Total investments acquired (Lines 13.1 to 13.6)		84,771,964
14.	Net increase (decrease) in contract loans and premium notes	0	0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(24,283,804)	(34,077,762)
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes	0	0
	16.2 Capital and paid in surplus, less treasury stock		0
	16.3 Borrowed funds	0	0
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0
	16.5 Dividends to stockholders		
	16.6 Other cash provided (applied)		(3,274,673)
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	(38,228,430)	(48,274,673)
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	25,119,743	(11,592,420)
19.	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year		
	19.2 End of year (Line 18 plus Line 19.1)	69,374,317	44,254,574

## ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

	1									1	
		1	2	3	4	5	6 Federal Employees	7 Title	8 Title	9	10
		Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Onlv	Vision Onlv	Health Benefits Plan	XVIII Medicare	XIX Medicaid	Other Health	Other Non-Health
1.	Net premium income	1,223,028,074		0	0		.0	1,221,627,591	0	0	0
	Change in unearned premium reserves and reserve for		, , ,					, , , , , ,			
	rate credit	(1,165,526)		0	0		.0	(1,621,856)	0	0	0
3.	Fee-for-service (net of \$0										
	medical expenses)	0	0	0	0		.0	0	0	0	XXX
4.	Risk revenue	0	0	0	0		.0	0	0	0	XXX
5.	Aggregate write-ins for other health care related revenues	0	0	0	0			0	0	ο	xxx
	Aggregate write-ins for other non-health care related revenues	0									Q
7.	Total revenues (Lines 1 to 6)	1,221,862,548		0	0		.00	1,220,005,735	0	0	α
8.	Hospital/medical benefits		1, 178, 115	0	Q				0	0	
9.	Other professional services	2,818,893		0	Q				0	0	
10.	Outside referrals	0	0	0	0			0	0	0	XXX
11.	Emergency room and out-of-area		0	0	0		.00		0	0	XXX
12.	Prescription drugs			0	0		.00		0	0	XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	0		.00		0	0	XXX
14.	Incentive pool, withhold adjustments and bonus amounts	1,777,633	(7,059)	0	0		00	1,784,692	0	0	XXX
15.	Subtotal (Lines 8 to 14)		1,352,039	0	0		00		0	0	XXX
16.	Net reinsurance recoveries	(62)	(62)	0	0		00	0	0	0	XXX
17.	Total medical and hospital (Lines 15 minus 16)		1,352,101	0	0		00		0	0	XXX
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
	Claims adjustment expenses including										
-	\$		78,924	0	0		0 0		0	0	0
20.	General administrative expenses		234,714	0	0		0 0	82,580,299	0	0	0
	Increase in reserves for accident and health contracts	0	0	0	0		0 0	0	0	0	XXX
22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	C
	Total underwriting deductions (Lines 17 to 22)	1,094,976,403		0	0		0 0	1,093,310,664	0	0	0
24.	Total underwriting gain or (loss) (Line 7 minus Line 23)	126,886,145	191.074	0	0		0 0	126.695.071	0	0	C
	DETAILS OF WRITE-INS							,,			
0501.											
0502.											XXX
0503.										<b>_</b>	XXX
	Summary of remaining write-ins for Line 5 from overflow										
	page	0	0	0	0		.00	0	0	0	
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0		0 0	0	0	0	XXX
0601.			XXX	XXX		XXX			XXX		
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
	Summary of remaining write-ins for Line 6 from overflow										
	page	0	XXX			XXX	XXX	XXX	XXX		c
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	C
1301.											
1302.											XXX
1303.											XXX
1398.	Summary of remaining write-ins for Line 13 from overflow page	٥	0	0	Ω		0 0	0	٥	0	XXX
1300	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	ی ۱		0	0		0	۰ ۱	بو ۱	۰ ۱	XXX
1099.		0	0	0	0		0	0	0	U	~~~~

7

## UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
1. Comprehensive (hospital and medical)	1,400,483	0	0	1,400,483
2. Medicare Supplement	0	0	0	0
3. Dental only	0	0	0	0
4. Vision only	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0
6. Title XVIII - Medicare	1,221,627,591	0	0	1,221,627,591
7. Title XIX - Medicaid	0	0	0	0
8. Other health	0	0	0	0
9. Health subtotal (Lines 1 through 8)	1,223,028,074	0	0	1,223,028,074
10. Life	0	0	0	0
11. Property/casualty	0	0	0	0
12. Totals (Lines 9 to 11)	1,223,028,074	0	0	1,223,028,074

### UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

		1	2 Comprehensive	3 Medicare	4	5	6 Federal Employees Health	7 Title XVIII	8 Title XIX	9	10 Other
		Total	(Hospital & Medical)	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
1.	Payments during the year:										
	1.1 Direct		1,568,101	0	0	0	0		0	0	
	1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	
	1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	
	1.4 Net		1,568,101	0	0	0	0		0	0	
2.	Paid medical incentive pools and bonuses	2,918,372		0	0	0	0		0	0	
3.	Claim liability December 31, current year from Part 2A:										
	3.1 Direct			0	0	0	0		0	0	
	3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	
	3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	
	3.4 Net			0	0	0	0		0	0	
4.	Claim reserve December 31, current year from Part 2D:										
	4.1 Direct			0	0	0	0		0	0	
	4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	
	4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	
	4.4 Net		22	0	0	0	0	133.360	0	0	
5	Accrued medical incentive pools and bonuses, current			_	_						
0.	year	1,066,849		0	0	0	0	1,055,556	0	0	
6.	Net healthcare receivables (a)		(3,892)	0	0	0	0	9,747,072	0	0	
	Amounts recoverable from reinsurers December 31,	,,									
	current year	0	0	0	0	0	0	0	0	0	
8.	Claim liability December 31, prior year from Part 2A:										
	8.1 Direct			0	0	0	0		0	0	
	8.2 Reinsurance assumed				.0	0	0		0	0	
	8.3 Reinsurance ceded			0	0	0	0	0	0	0	
	8.4 Net			0	0	0	0		0	0	
9.	Claim reserve December 31, prior year from Part 2D:	, ,	,					, , , , , , , , , , , , , , , , , , , ,			
	9.1 Direct		20	0	0	0	0	117.766	0	0	
	9.2 Reinsurance assumed	0	0	0	0	0	0	, 0	0	0	
	9.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	
	9.4 Net			0	0	0	0		0	0	
10.	Accrued medical incentive pools and bonuses, prior year	2,207,588	24,520	0	0	0	0	2,183,068	0	0	
	Amounts recoverable from reinsurers December 31,	2,207,000	21,020	•	•	•	, , , , , , , , , , , , , , , , , , ,	2,100,000	•	, , , , , , , , , , , , , , , , , , ,	
	prior year	0	0	0	0	0	0	0	0	0	
12.	Incurred Benefits:										
	12.1 Direct		1,358,637	0	0	0	0		0	0	
	12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	
	12.3 Reinsurance ceded	(62)	(62)	0	0	0	0	0	0	0	
	12.4 Net	970,676,482	1,358,699	0	0	0	0	969,317,783	0	0	
40	Incurred medical incentive pools and bonuses	1,777,633	(7,059)	0	0	0	0	1.784.692	0	0	

(a) Excludes \$ .....0 loans or advances to providers not yet expensed.

## UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1	2	3	4	5	6	7	8	9	10
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
1. Reported in Process of Adjustment:										
1.1 Direct			0	0	0	0		0	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
1.4 Net	20,872,211		0	0	0	0	20,772,450	0	0	0
2. Incurred but Unreported:										
2.1 Direct		63,991	0	0	0	0		0	0	0
2.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
2.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
2.4 Net	29, 192, 107	<u>6</u> 3,991	0	0	0	0	29, 128, 116	0	0	0
3. Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct	4,674,395	0	0	0	0	0	4,674,395	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
3.4 Net	4,674,395	0	0	0	0	0	4,674,395	0	0	0
4. TOTALS:										
4.1 Direct			0	0	0	0		0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
4.4 Net	54,738,713	163,752	0	0	0	0	54,574,961	0	0	0

## UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid D	uring the Year	Claim Reserve a December 31	nd Claim Liability of Current Year	5	6
Line of Business	1 On Claims Incurred Prior to January 1 of Current Year	2 On Claims Incurred During the Year	3 On Claims Unpaid December 31 of Prior Year	4 On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Estimated Claim Reserve and Claim Liability December 31 of Prior Year
1. Comprehensive (hospital and medical)		1,223,766		151,922		
2. Medicare Supplement	0	0	0	0	0	0
3. Dental Only	0	0	0	0	0	0
4. Vision Only	0	0	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0	0	0
6. Title XVIII - Medicare			2,307,549		10,264,041	
7 Title XIX - Medicaid	0	0	0	0	0	0
8. Other health	0	0	0	0	0	0
9. Health subtotal (Lines 1 to 8)			2,319,402	52,552,694	10,620,229	
10. Healthcare receivables (a)	1,405,847	46,341,635	0	5,202,857	1,405,847	
11. Other non-health	0	0	0	0	0	0
12. Medical incentive pools and bonus amounts				1,051,088	1,944,694	2,207,587
13. Totals (Lines 9 - 10 + 11 + 12)	8,823,914	925,836,942	2,335,162	48,400,925	11,159,076	12,942,826

(a) Excludes \$ .....0 loans or advances to providers not yet expensed.

1

## **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

#### Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

		Cur	Cumulative Net Amounts Paid					
	1	2	3	4	5			
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021			
1. Prior								
2. 2017								
3. 2018								
4. 2019		XXX						
5. 2020		XXX			1,817			
6. 2021	XXX	XXX	XXX	XXX	1,224			

#### Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuse Outstanding at End of Year						
Year in Which Losses Were Incurred	1 2017	2 2018	3 2019	4 2020	5 2021		
1. Prior			3,806		3,751		
2. 2017							
3. 2018							
4. 2019	XXX	XXX					
5. 2020	XXX	XXX	XXX	1,712	1,831		
6. 2021	XXX	XXX	XXX	XXX	1,385		

#### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

	Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1.	2017							0	0		
2.	2018							0	0		
3.	2019							0	0		
4.	2020				4.5			14	0		
5.	2021	1,856	1,224	64	5.2	1,288	69.4	161	1	1,450	78.1

## **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

#### Section A - Paid Health Claims - Title XVIII

	Cumulative Net Amounts Paid						
	1	2	3	4	5		
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021		
1. Prior							
2. 2017							
3. 2018							
4. 2019							
5. 2020		XXX					
6. 2021	XXX	XXX	XXX	XXX	970,955		

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bon Outstanding at End of Year					
	1	2	3	4	5	
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021	
1. Prior						
2. 2017						
3. 2018						
4. 2019		XXX				
5. 2020						
6. 2021	XXX	XXX	XXX	XXX	1,024,398	

#### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017							0	0		
2.	2018			61,436				0	0		
3.	2019							0	0		
4.	2020										
5.	2021	1,220,006	970,955	35,489	3.7	1,006,444	82.5	53,443	827	1,060,714	86.9

## **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

#### (\$000 Omitted)

#### Section A - Paid Health Claims - Grand Total

	Cumulative Net Amounts Paid							
	1	2	3	4	5			
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021			
1. Prior								
2. 2017								
3. 2018	XXX							
4. 2019	XXX							
5. 2020	XXX		XXX					
6. 2021	XXX	XXX	XXX	XXX	972,179			

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonu Outstanding at End of Year					
	1	2	3	4	5	
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021	
1. Prior	100,887					
2. 2017						
3. 2018						
4. 2019	XXX	XXX				
5. 2020	XXX	XXX				
6. 2021	XXX	XXX	XXX	XXX	1,025,783	

#### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017							0	0		
2.	2018							0	0		
3.	2019							0	0		
4.	2020										
5.	2021	1,221,862	972,179	35,553	3.7	1,007,732	82.5	53,604	828	1,062,164	86.9

# UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	1	2	3		5	6	7	8	9
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	, Title XVⅢ Medicare	Title XIX Medicaid	Other
1. Unearned premium reserves	0	0	0	0	0	0	0	0	0
2. Additional policy reserves (a)	0	0	0	0	0	0	0	0	0
3. Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0
4. Reserve for rate credits or experience rating refunds (including									
\$0 ) for investment income		0	0	0	0	0		0	0
5. Aggregate write-ins for other policy reserves			0	0	0	0		0	0
6. Totals (gross)	1,676,445		0	0	0	0	1,017,263	0	0
7. Reinsurance ceded	0	0	0	0	0	0	0	0	0
8. Totals (Net)(Page 3, Line 4)			0	0	0	0		0	0
9. Present value of amounts not yet due on claims	0	0	0	0	0	0	0	0	0
10. Reserve for future contingent benefits			0	0	0	0		0	0
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0
12. Totals (gross)			0	0	0	0		0	0
13. Reinsurance ceded	0	0	0	0	0	0	0	0	0
14. Totals (Net)(Page 3, Line 7)	133,382	22	0	0	0	0	133,360	0	0
DETAILS OF WRITE-INS									
0501. Medicare Part D Risk Adjustment Factor Payable		0	0	0	0	0		0	0
0502. Risk Adjustments Payable		614,752	0	0	0	0	0	0	0
0503. Wakely Risk Adjustment Data Validation			0	0	0	0	0	0	0
0598. Summary of remaining write-ins for Line 5 from overflow page			0	0	0	0	0	0	0
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	746,880	659,182	0	0	0	0	87,698	0	0
1101.									
1102.									
1103.									
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0
1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0

(a) Includes \$ _____0 premium deficiency reserve.

## **UNDERWRITING AND INVESTMENT EXHIBIT**

		PART 3 - ANAL Claim Adjustme	YSIS OF EXPENSE	<b>3</b>	4	5
		1	2	-	+	5
		Cost Containment Expenses	Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.						
	own building)			1,568,395	0	2,710,880
2.	Salary, wages and other benefits		4,266,849		0	47,259,942
3.	Commissions (less \$0					
	ceded plus \$0 assumed)	0	0		0	16,918,611
4.	Legal fees and expenses				0	418,641
5.	Certifications and accreditation fees	0	0	0	0	0
6.	Auditing, actuarial and other consulting services		456,484		0	5,056,053
7.	Traveling expenses				0	
8.	Marketing and advertising			1,610,125	0	2,783,008
9.	Postage, express and telephone			1, 149, 424	0	1,986,713
10.	Printing and office supplies	1,143,603		1,997,943	0	3,453,329
11.	Occupancy, depreciation and amortization				0	1,224,985
12.	Equipment				0	
13.	Cost or depreciation of EDP equipment and software			2,966,421	0	5, 127, 287
14.	Outsourced services including EDP, claims, and					
	other services					
15.	Boards, bureaus and association fees					
16.	Insurance, except on real estate		,		0	
17.	Collection and bank service charges				0	
18.	Group service and administration fees				0	1,112,551
19.	Reimbursements by uninsured plans		0	0	0	0
20.	Reimbursements from fiscal intermediaries	0	0	0	0	0
21.	Real estate expenses	0	0	0	0	0
22.	Real estate taxes				0	
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes	0	0		0	
	23.2 State premium taxes	0	0	0	0	0
	23.3 Regulatory authority licenses and fees	0	0		0	
	23.4 Payroll taxes			1,353,279	0	2,294,536
	23.5 Other (excluding federal income and real estate taxes)	0	0	0	0	0
24.	Investment expenses not included elsewhere	0	0	0		
25.	Aggregate write-ins for expenses		937,631	6,411,798	0	11,735,700
26.	Total expenses incurred (Lines 1 to 25)					(a)122,631,937
27.	Less expenses unpaid December 31, current year			4, 141,483		
28.	Add expenses unpaid December 31, prior year			4,841,354		
29.	Amounts receivable relating to uninsured plans.		0			
30.	Amounts receivable relating to uninsured plans, current year	0	0	13,393,978	0	13,393,978
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	31,298,092	8,395,274	79,246,642	49,792	118,989,800
	DETAILS OF WRITE-INS					
2501.	Information Technology				0	
2502.	Interest	3,843			0	
2503.	Managed Care & Network Access				0	
2598.	Summary of remaining write-ins for Line 25 from overflow page			6,139,623	0	11,247,520
2599.		4,386,271 c affiliates and \$	937,631	6,411,798 n-affiliates.	0	11,735,700

## **EXHIBIT OF NET INVESTMENT INCOME**

			1		2
					d During Year
1.	U.S. government bonds	(a)			
1.1	Bonds exempt from U.S. tax	(a)	0		0
1.2	Other bonds (unaffiliated)	(a)	1,077,540		1, 116, 136
1.3	Bonds of affiliates	(a)	0		0
2.1	Preferred stocks (unaffiliated)	(b)	0		0
2.11	Preferred stocks of affiliates	(b)	0		0
2.2	Common stocks (unaffiliated)		0		0
2.21	Common stocks of affiliates		0		0
3.	Mortgage loans	(c)	0		0
4.	Real estate	(d)	0		0
5	Contract Loans		0		0
6	Cash, cash equivalents and short-term investments	(e)			
7	Derivative instruments				0
8.	Other invested assets		0		0
9.	Aggregate write-ins for investment income		0		0
10.	Total gross investment income		1,510,571		1,480,235
11.	Investment expenses			(a)	109,648
12.	Investment taxes, licenses and fees, excluding federal income taxes			(0)	0
13.	Interest expense			(h)	0
14.	Depreciation on real estate and other invested assets			(i)	0
15.	Aggregate write-ins for deductions from investment income				0
16.	Total deductions (Lines 11 through 15)				109,648
17.	Net investment income (Line 10 minus Line 16)				1.370.587
	DETAILS OF WRITE-INS				, , , , , , , , , , , , , , , , , , , ,
0901.					
0902.					
0903.					
0998.	Summary of remaining write-ins for Line 9 from overflow page				0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9. above)		0		0
1501.					
1501.					
1502.					
1598.	Summary of remaining write-ins for Line 15 from overflow page				٥
1598.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)				0
1555.					0

(a) Includes \$		accrual of discount less \$37	0,551 amortization of premium and less \$		paid for accrued interest on purchases.
(b) Includes \$	0	accrual of discount less \$	0 amortization of premium and less \$	0	paid for accrued dividends on purchases.
(c) Includes \$	0	accrual of discount less \$	0 amortization of premium and less \$	0	paid for accrued interest on purchases.
(d) Includes \$	0	for company's occupancy of its own be	uildings; and excludes \$0	interest on encur	nbrances.
(e) Includes \$	67	accrual of discount less \$	0 amortization of premium and less \$	0	paid for accrued interest on purchases.
(f) Includes \$	0	accrual of discount less \$	0 amortization of premium.		
	and Separate Acco			es, excluding fede	ral income taxes, attributable to
(h) Includes \$	0	interest on surplus notes and \$	0 interest on capital notes.		
(i) Includes \$	0	depreciation on real estate and \$	0 depreciation on other investe	ed assets.	

# EXHIBIT OF CAPITAL GAINS (LOSSES)

		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds	0			0	0
1.1	Bonds exempt from U.S. tax	0	0	0	0	0
1.2	Other bonds (unaffiliated)		.0		0	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)		0	0	0	.0
2.21	Common stocks of affiliates		0	0	0	0
3.	Mortgage loans	0	0	0	0	0
4.	Real estate	0	0	0	0	.0
5.	Contract loans	0	0	0	0	0
6.	Cash, cash equivalents and short-term investments		0	0	0	0
7.	Derivative instruments	0	0	0	0	0
8.	Other invested assets		0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	427	0	427	0	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from					
	overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9,					
	above)	0	0	0	0	0

### ANNUAL STATEMENT FOR THE YEAR 2021 OF THE Oxford Health Plans (NJ), Inc. EXHIBIT OF NON-ADMITTED ASSETS

	EXHIBIT OF NON-ADMITTE	DASSEIS	2	3
		Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)		0	
2.	Stocks (Schedule D):			
	2.1 Preferred stocks	0	0	0
	2.2 Common stocks		0	
3.	Mortgage loans on real estate (Schedule B):		0	
0.	3.1 First liens	0	0	0
	3.2 Other than first liens			
4.		0	0	
4.	Real estate (Schedule A): 4.1 Properties occupied by the company	0	0	0
	4.1 Properties beld for the production of income			
	4.2 Properties held for sale			
		0	0	0
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			
6.	Contract loans		0	0
7.	Derivatives (Schedule DB)			
8.	Other invested assets (Schedule BA)			
9.	Receivables for securities		0	
10.	Securities lending reinvested collateral assets (Schedule DL)			0
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			0
14.	Investment income due and accrued	0	0	0
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection			14,921
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due	0	0	0
	15.3 Accrued retrospective premiums and contracts subject to redetermination	0	0	0
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers	0	0	0
	16.2 Funds held by or deposited with reinsured companies	0	0	0
	16.3 Other amounts receivable under reinsurance contracts	0	0	0
17.	Amounts receivable relating to uninsured plans			(20,057)
18.1	Current federal and foreign income tax recoverable and interest thereon	0	0	0
18.2	Net deferred tax asset	0	0	0
19.	Guaranty funds receivable or on deposit	0	0	0
20.	Electronic data processing equipment and software			0
21.	Furniture and equipment, including health care delivery assets			0
22.	Net adjustment in assets and liabilities due to foreign exchange rates			
23.	Receivable from parent, subsidiaries and affiliates			
24.	Health care and other amounts receivable			
25.	Aggregate write-ins for other than invested assets		4,313,533	
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)			
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			
28.	Total (Lines 26 and 27)	3,072,690	6,867,653	
20.	DETAILS OF WRITE-INS	0,072,000	0,007,000	0,704,000
1101.				
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Prepaid Expense	633	0	(633)
2502.	Prepaid Program Receivable	0	4,313,244	4,313,244
2503.	Miscellaneous Receivables	0		
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	633	4,313,533	4,312,900

# EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

				Total Members at End o	of		6
		1	2	3	4	5	Current Year
	Source of Enrollment	Prior Year	First Quarter	Second Quarter	Third Quarter	Current Year	Member Months
1.	Health Maintenance Organizations			60,393			
2.	Provider Service Organizations	0	0	0	0	0	0
3.	Preferred Provider Organizations	0	0	0	0	0	0
4.	Point of Service	0	0	0	0	0	0
5.	Indemnity Only	0	0	0	0	0	0
6.	Aggregate write-ins for other lines of business	54,017	0	0	0	0	0
7.	Total	54,362	58,320	60,393	62,064	62,565	724,437
	DETAILS OF WRITE-INS						
0601.	Medicare		0	0	0	0	0
0602.							
0603.							
0698.	Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	54,017	0	0	0	0	0

#### OXFORD HEALTH PLANS (NJ), INC.

#### NOTES TO STATUTORY BASIS FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020

### 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN

#### **Organization and Operation**

Oxford Health Plans (NJ), Inc. (the "Company"), licensed as a health maintenance organization ("HMO"), offers its enrollees a variety of managed care programs and products through contractual arrangements with health care providers. The Company is a wholly owned subsidiary of Oxford Health Plans, LLC. ("Oxford"). Oxford is a wholly owned subsidiary of UnitedHealth Group Incorporated ("UnitedHealth Group"). UnitedHealth Group is a publicly held company trading on the New York Stock Exchange.

The Company was incorporated on April 17, 1985, as an HMO and operations commenced in September 1985. The Company is certified as an HMO by the State of New Jersey Department of Banking and Insurance (the "Department"), Oregon Insurance Division, Missouri Department of Insurance, Pennsylvania Insurance Department, Delaware Department of Insurance, and Rhode Island Department of Business Regulation. The Company has entered into contracts with physicians, hospitals, and other health care provider organizations to deliver health care services for all enrollees.

The Company offers comprehensive commercial products to employer groups. Each contract outlines the coverage provided and renewal provisions.

The Company serves as a plan sponsor offering Medicare specialized programs including a Dual Special Needs Plan and a Fully Integrated Dual Eligible Special Needs Plan, and an Institutional Special Needs Plan collectively ("Medicare Plans") under contracts with the Centers for Medicare and Medicaid Services ("CMS").

### A. Accounting Practices

The statutory basis financial statements (herein referred to as "financial statements") of the Company are presented on the basis of accounting practices prescribed or permitted by the Department.

The Department recognizes only statutory accounting practices, prescribed or permitted by the State of New Jersey (the "State"), for determining and reporting the financial condition and results of operations of an HMO, for determining its solvency under New Jersey Insurance Law. The State prescribes the use of the National Association of Insurance Commissioners' ("NAIC") Accounting Practices and Procedures manual ("NAIC SAP") in effect for the accounting periods covered in the financial statements.

No significant differences exist between the practices prescribed or permitted by the State of New Jersey and the NAIC SAP which materially affect the statutory basis net income and capital and surplus, as illustrated in the table below:

Accounting Practices and Procedures manual ("NAIC SAP") in effect for the accounting periods covered in the statutory basis financial statements.

		SSAP #	F/S Page #	F/S Line #	December 31, 2021	December 31, 2020
Net	Income		l /o l ugo "		2021	2020
(1)	Company state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ 101,714,602	\$ 90,308,152
(2)	State prescribed practices that are an increase/(decrease) from NAIC SAP:					
(3)	Not Applicable State permitted practices that are an increase/(decrease) from NAIC SAP:				-	-
(4)	Not Applicable NAIC SAP (1 - 2 - 3 = 4)	XXX	XXX	XXX	<u> </u>	- \$ 90,308,152
Cap	ital and Surplus					
(5)	Company state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 233,575,151	\$ 219,222,971
(6)	State prescribed practices that are an increase/(decrease) from NAIC SAP: Not Applicable					
(7)	State permitted practices that are an increase/(decrease) from NAIC SAP:				-	-
(8)	Not Applicable NAIC SAP (5 - 6 - 7 = 8)	XXX	XXX	XXX	- <u>\$ 233,575,151</u>	- <u>\$219,222,971</u>

### B. Use of Estimates in the Preparation of the Financial Statements

The preparation of these statutory basis financial statements in conformity with the NAIC Annual Statement Instructions and the NAIC SAP include certain amounts that are based on the Company's estimates and judgments. These estimates require the Company to apply complex assumptions and judgments, often because the Company must make estimates about the effects of matters that are inherently uncertain and will change in subsequent periods. The most significant estimates relate to hospital and medical benefits, claims unpaid, aggregate health policy reserves, aggregate health claim reserves, risk corridor, and risk adjustment estimates. The Company adjusts these estimates each period as more current information becomes available. The impact of any changes in estimates is included in the determination of net income in the period in which the estimate is adjusted.

### C. Accounting Policy

**Basis of Presentation** — The Company prepares its financial statements on the basis of accounting practices prescribed or permitted by the Department. These statutory practices differ from accounting principles generally accepted in the United States of America ("GAAP").

Accounting policy disclosures that are required by the NAIC Annual Statement instructions are as follows:

- (1–2) Bonds and short-term investments are stated at book/adjusted carrying value if they meet NAIC designation of one or two and stated at the lower of book/adjusted carrying value or fair value if they meet an NAIC designation of three or higher. The Company does not have any mandatory convertible securities or Investment Analysis Office of the NAIC ("IAO") identified funds (i.e.: exchange traded funds or bond mutual funds) in its bond portfolio. Amortization of bond premium or accretion of discount is calculated using the constant-yield interest method. Bonds and short-term investments are valued and reported using market prices published by the IAO in accordance with the NAIC Valuation of Securities manual prepared by the IAO or an external pricing service;
- (3-4) The Company holds no common or preferred stock;
- (5) The Company holds no mortgage loans on real estate;
- (6) U.S. government and agency securities and corporate debt securities include loan-backed securities (mortgage-backed securities and asset-backed securities), which are valued using the retrospective adjustment methodology. Prepayment assumptions for the determination of the book/adjusted carrying value, commonly referred to as amortized cost, of loan-backed securities are based on a three-month constant prepayment rate history obtained from external data source vendors. The Company's investment policy limits investments in nonagency residential mortgage-backed securities, including home equity and sub-prime mortgages, to 10% of total cash and invested assets. Total combined investments in mortgage-backed securities and asset-backed securities cannot exceed more than 30% of total cash and invested assets;
- (7) The Company holds no investments in subsidiaries, controlled, or affiliated entities;
- (8) The Company has no investment interests with respect to joint ventures, partnerships, or limited liability companies;
- (9) The Company holds no derivatives;
- (10) Premium Deficiency Reserves ("PDR") (inclusive of conversion reserves) and the related expenses are recognized when it is probable that expected future health care expenses, claims adjustment expenses ("CAE"), direct administration costs, and an allocation of indirect administration costs under a group of existing contracts will exceed anticipated future premiums and reinsurance recoveries considered over the remaining lives of the contracts, and are recorded as aggregate health policy reserves in the financial statements. Indirect administration costs arise from activities that are not specifically identifiable to a specific group of existing contracts, and therefore, those costs are fully allocated among the various contract groupings. The allocation of indirect administration costs to each contract grouping is made proportionately to the expected margins remaining in the premiums after future health care expenses, CAE and direct administration costs are considered. The data and assumptions underlying such estimates and the resulting reserves are periodically updated, and any adjustments are reflected as an increase in reserves for life and accident and health contracts in the financial statements in the period in which the change in estimate is identified. The Company does anticipate investment income as a factor in the PDR calculation (see Note 30);
- (11) CAE are those costs expected to be incurred in connection with the adjustment and recording of accident and health claims. Pursuant to the terms of a management agreement (the "Agreement") (see Note 10), the Company pays a management fee to its affiliate, United HealthCare Services, Inc. ("UHS"), in exchange for administrative and management services. A detailed review of the administrative expenses of the Company and UHS is performed to determine the allocation between CAE and general administrative expenses ("GAE") to be reported in the financial statements. It is the responsibility of UHS to pay CAE in the event the Company ceases operations. The Company has recorded an estimate of unpaid CAE associated with incurred but unpaid claims, which is included in unpaid CAE in the financial statements. Management believes the amount of the liability for unpaid CAE as of December 31, 2021 is adequate to cover the Company's cost for the adjustment and recording of unpaid claims; however, actual expenses may differ from those established estimates. Adjustments to the estimates for unpaid CAE are reflected in operating results in the period in which the change in estimate is identified;
- (12) The Company does not carry any fixed assets in the financial statements;
- (13) Health care and other amounts receivable consist of pharmacy rebates receivable estimated based on the most currently available data from the Company's claims processing systems and from data provided by the Company's affiliated pharmaceutical benefit manager, OptumRx, Inc. ("OptumRx"). Health care and other amounts receivable also include receivables for amounts due to the Company for provider advances and claim

overpayments to providers, hospitals and other health care organizations. Health care and other amounts receivable are considered nonadmitted assets under the NAIC SAP if they do not meet admissibility requirements. Accordingly, the Company has excluded receivables that do not meet the admissibility criteria from the financial statements (see Note 28).

The Company has also deemed the following to be significant accounting policies:

### <u>ASSETS</u>

#### Cash and Invested Assets

- Bonds include securities with a maturity of greater than one year at the time of purchase;
- Cash equivalents include securities that have original maturity dates of three months or less from the date of acquisition. Cash equivalents also consist of the Company's share of a qualified cash pool sponsored and administered by UHS. The investment pool is recorded at cost or book/adjusted carrying value depending on the composition of the underlying securities. Interest income from the pool accrues daily to participating members based upon ownership percentage. Cash equivalents, excluding money-market funds, are reported at cost or book/adjusted carrying value depending on the nature of the underlying security, which approximates fair value. Money-market funds are reported at fair value or net asset value ("NAV") as a practical expedient;
- Realized capital gains and losses on sales of investments are calculated based upon specific identification of the investments sold. These gains and losses are reported as net realized capital gains (losses) less capital gains tax (benefit) ("net realized capital gains (losses) less taxes");
- The Company continually monitors the difference between amortized cost and estimated fair value of its investments. If any of the Company's investments experience a decline in value that the Company has determined is other-than-temporary, or if the Company has determined it will sell a security that is in an impaired status, the Company will record a realized loss in net realized capital gains (losses) less taxes;

### Other Assets

• **Premiums and Considerations** — The Company reports uncollected premium balances from its insured members and CMS as premiums and considerations in the financial statements. Uncollected premium balances that are over 90 days past due, with the exception of amounts due from government insured plans, are considered nonadmitted assets. In addition to those balances, current balances are also considered nonadmitted if the corresponding balance greater than 90 days past due is deemed more than inconsequential. Premiums and considerations also include amounts for commercial risk adjustment receivables as defined in Section 1343 of the Affordable Care Act ("ACA"), CMS risk corridor receivables, and CMS risk adjustment receivables for the Medicare Plans.

Premium adjustments for the CMS risk corridor program are accounted for as premium adjustments subject to retrospectively rated features (see Note 24). Premium adjustments for the commercial ACA Section 1343 risk adjustment and CMS risk adjustment programs are accounted for as premium adjustments subject to redetermination (see Note 24).

#### LIABILITIES

• Claims Unpaid and Aggregate Health Claim Reserves — Claims unpaid and aggregate health claim reserves include claims processed but not yet paid, estimates for claims received but not yet processed, estimates for the costs of health care services enrollees have received but for which claims have not yet been submitted, and payments and liabilities for physician, hospital, and other medical costs disputes.

The estimates for incurred but not yet reported claims are developed using an actuarial process that is consistently applied, centrally controlled, and automated. The actuarial models consider factors such as historical submission and payment data, cost trends, customer and product mix, seasonality, utilization of health care services, contracted service rates, and other relevant factors. The Company estimates such liabilities for physician, hospital, and other medical cost disputes based upon an analysis of potential outcomes, assuming a combination of litigation and settlement strategies. These estimates may change as actuarial methods change or as underlying facts upon which estimates are based change. The Company did not change actuarial methods during 2021 and 2020. Management believes the amount of claims unpaid and aggregate health claim reserves is a best estimate of the Company's liability for unpaid claims and aggregate health claim reserves as of December 31, 2021; however, actual payments may differ from those established estimates.

The Company contracts with hospitals, physicians, and other providers of health care under capitated or discounted fee for service arrangements, including a hospital per diem to provide medical care services to enrollees. Some of these contracts are with related parties (see Note 10). Capitated providers are at risk for the cost of medical care services provided to the Company's enrollees; however, the Company is ultimately responsible for the provision of services to its enrollees should the capitated provider be unable to provide the contracted services.

• Aggregate Write-Ins for Other Liabilities – Aggregate write-ins for other liabilities consists of a declared extraordinary cash dividend to Oxford, which remains unpaid as of December 31, 2021. Aggregate write-ins for other liabilities also includes unclaimed property where the Company still owes an amount to an individual, but a claim has not been made after a specified period of time.

#### CAPITAL AND SURPLUS AND MINIMUM STATUTORY REQUIREMENTS

#### • Restricted Cash Reserves —

The Company is in compliance with the various states regulatory deposit requirements as of December 31, 2021 and 2020, respectively, for qualification purposes as a domestic and foreign insurer. These restricted cash reserves are stated at book/adjusted carrying value, which approximates fair value. These restricted deposits are included in bonds in the financial statements. Interest earned on these deposits accrues to the Company (see Note 5).

The New Jersey Administrative Code also requires the Company to maintain minimum insolvency and administrative deposits with the State of New Jersey. The Company had bonds, which are stated at book/adjusted carrying value, on deposit with the State of New Jersey and is in compliance with the New Jersey requirements as of December 31, 2021 and 2020, respectively. This reserve is included in bonds in the financial statements. Interest earned on this deposit accrues to the Company (see Note 5).

#### • Minimum Capital and Surplus —

Under the laws of the State of New Jersey, the Company's domiciliary state, the Department requires the Company to maintain a minimum capital and surplus equal to the greater of \$2,338,084; 2% of the first \$150 million of annual premium revenue and 1% of annual premium revenue over \$150 million; three months of uncovered health care expenditures; or an amount equal to the sum of 8% of the annual health care expenditures (not including those expenditures paid on a capitated basis or those on a managed hospital plan basis), plus 4% of the annual hospital expenditures paid on a managed hospital payment basis. The minimum capital and surplus requirement was \$59,042,984 and \$61,317,184, for December 31, 2021 and 2020, respectively, which was based on health care and hospital expenditures, as that produced the highest minimum requirement.

Risk-based capital ("RBC") is a regulatory tool for measuring the minimum amount of capital appropriate for a managed care organization to support its overall business operations in consideration of its size and risk profile. The Department requires the Company to maintain minimum capital and surplus equal to the greater of the state statute as outlined above, or the company action level as calculated by the RBC formula, or the level needed to avoid action pursuant to the trend test in the RBC formula.

The Company is also subject to minimum capital and surplus requirements in other states where it is licensed to do business.

The Company is in compliance with the minimum required capital and surplus amounts where it is licensed to do business, as of December 31, 2021 and 2020.

### **STATEMENTS OF OPERATIONS**

• Net Premium Income and Change in Unearned Premium Reserves and Reserve for Rate Credits — Revenues consist of net premium income that is recognized in the period in which enrollees are entitled to receive health care services. Net premium income is shown net of reinsurance premiums paid and reinsurance premiums incurred but not paid in the financial statements. The corresponding change in unearned premium from year to year is reflected as a change in unearned premium reserves and reserve for rate credits in the financial statements. Comprehensive commercial health plans with medical loss ratio ("MLR") on fully insured products, as calculated under the definitions in the ACA and implementing regulations, that fall below certain targets are required to rebate ratable portions of premiums annually. The Company classifies changes to the estimated rebates and retrospective premium adjustments as change in unearned premium reserves and reserve for rate credits in the financial statements (see Note 24). In addition, pursuant to Section 1343 of the ACA, the Company records premium adjustments for changes to the commercial risk adjustment balances which are reflected in change in unearned premium reserves and reserves and reserve for rate credits and net premium income, respectively, in the financial statements (see Note 24).

Medicare Plans with MLRs on fully insured products, as calculated under the definitions in the ACA and implementing regulations, that fall below certain targets are required to rebate ratable portions of premiums annually. In addition, the Company records premium adjustments for changes to the CMS Medicare Plans risk corridor program. Changes to these estimates are reflected in change in unearned premium reserves and reserve for rate credits in the financial statements (see Note 24). Net premium income also includes premium under the Medicare Plans which includes CMS premiums, including amounts pursuant to the CMS risk adjustment program (see Note 24), and member premiums, and the CMS low-income premium subsidy for the Company's insurance risk coverage.

 Total Hospital and Medical Expenses — Total hospital and medical expenses include claims paid, claims processed but not yet paid, estimates for claims received but not yet processed, estimates for the costs of health care services enrollees have received but for which claims have not yet been submitted, and payments and liabilities for physician, hospital, and other medical costs disputes.

Total hospital and medical expenses also include amounts incurred for incentive pool, withhold adjustments, and bonus amounts that are based on the underlying contractual provisions with the respective providers. In addition, adjustments to claims unpaid estimates and aggregate health claim reserves are reflected in the period once the change in estimate is identified and included in total hospital and medical expenses in the financial statements.

- **General Administrative Expenses** General expenses that have been paid as of the reporting date in addition to general expenses that have been incurred but are not due until a subsequent period are reported as general administrative expenses. Pursuant to the terms of the Agreement (see Note 10), the Company pays a management fee to UHS in exchange for administrative and management services. Costs for items not included within the scope of the Agreement are directly expensed as incurred. State income taxes are also a component of GAE. A detailed review of the administrative expenses of the Company and UHS is performed to determine the allocation between CAE and GAE to be reported in the financial statements.
- Federal Income Taxes Incurred— The provision for federal income taxes incurred is calculated based on applying the statutory federal income tax rate of 21% to net income before federal income taxes and net realized capital gains (losses) subject to certain adjustments (see Note 9).

#### **OTHER**

• **Vulnerability Due to Certain Concentrations** — The Company is subject to substantial federal and state government regulation, including licensing and other requirements relating to the offering of the Company's existing products in new markets and offerings of new products, both of which may restrict the Company's ability to expand its business.

The Company has no commercial customers that individually exceed 10% of total direct premiums written and uncollected premiums, including receivables for contracts subject to redetermination, for the years ended December 31, 2021 and 2020.

Direct premiums written and uncollected premiums, including receivables for contracts subject to redetermination, from members and CMS related to the Medicare Plans as a percentage of total direct premiums written and total uncollected premiums, including receivables for contracts subject to redetermination, are 99% and 99% as of December 31, 2021 and 99% and 100% as of December 31, 2020, respectively.

**Recently Issued Accounting Standards** — In July 2020, the NAIC revised Statement of Statutory Accounting Principles ("SSAP") No. 106, *Affordable Care Act Section 9010 Assessment* for the repeal of the Affordable Care Act Section 9010 Assessment, effective January 1, 2021. The Company adopted the revision on the effective date.

The Company reviewed all other recently issued guidance in 2021 and 2020 that has been adopted for 2021 or subsequent years' implementation and has determined that none of the items would have a significant impact to the financial statements.

#### D. **Going Concern**

The Company has the ability and will continue to operate for a period of time sufficient to carry out its commitments, obligations and business objectives.

#### ACCOUNTING CHANGES AND CORRECTIONS OF ERRORS 2.

No changes in accounting principles or corrections of errors have been recorded during the years ended December 31, 2021 and 2020.

#### 3. **BUSINESS COMBINATIONS AND GOODWILL**

**A–E.** The Company was not party to a business combination during the years ended December 31, 2021 and 2020, and does not carry goodwill in its financial statements.

#### **DISCONTINUED OPERATIONS** 4.

#### Α. Discontinued Operation Disposed of or Classified as Held for Sale

(1-4) The Company did not have any discontinued operations disposed of or classified as held for sale during 2021 and 2020.

- В. Change in Plan of Sale of Discontinued Operation — Not applicable.
- C. Nature of any Significant Continuing Involvement with Discontinued Operations after Disposal — Not applicable.
- D. Equity Interest Retained in the Discontinued Operation after Disposal — Not applicable.

#### **INVESTMENTS** 5.

For purposes of calculating gross realized gains and losses on sales of investments, the amortized cost of each investment sold is used. The gross realized gains and losses on sales of long-term investments were \$360 and \$0, respectively, for 2021 and \$9 and \$15,864, respectively, for 2020. There were no gross realized gains and losses on sales of short-term investments in 2021 or 2020. The net realized gain (loss) is included in net realized capital gain (losses) less taxes in the statutory basis statements of operations. Total proceeds on the sale of long-term investments were \$801,488 and \$984,136 and for short-term investments were \$0 and \$616,603,404 in 2021 and 2020, respectively.

As of December 31, 2021 and 2020, the book/adjusted carrying value, fair value, and gross unrecognized unrealized gains and losses of the Company's investments, excluding cash and cash equivalents of \$69,374,317 and \$43,254,641 respectively, are disclosed in the table below:

	Book/Adjusted Carrying Value	Unreco	oss ognized alized ins	2021 Gross nrecognized salized Losses < 1 Year	Unrea	Gross recognized alized Losses > 1 Year	Fair Value
U.S. government and agency securities State and agency municipal securities City and county municipal securities Corporate debt securities Total bonds	\$ 29,863,693 6,707,526 6,226,199 126,146,691 <u>\$ 168,944,109</u>		140,608 298,116 267,192 48,350 754,266	\$  155,030 10,713 22,350 592,127 780,220	\$ 	-	\$ 29,849,271 6,994,929 6,471,041 <u>125,602,914</u> <u>\$ 168,918,155</u>
	Book/Adjusted Carrving Value	Unreco	oss ognized alized ins	2021 Gross nrecognized salized Losses < 1 Year	Unrea	Gross recognized alized Losses > 1 Year	Fair Value

	Carrying Value	Gains	Unro	< 1 Year	> 1 Year	Value	
Less than one year	\$ 18,201,680	\$ 88,406	\$	3,779	\$ -	\$ 18,286,307	
One to five years	132,180,659	48,570		703,812	-	131,525,417	
Five to ten years	9,672,023	593,551		1,794	-	10,263,780	
Over ten years	8,889,747	 23,739		70,835	 -	8,842,651	
Total bonds	\$ 168,944,109	\$ 754,266	\$	780,220	\$ 	<u>\$ 168,918,155</u>	

		2020						
	Book/Adjusted Carrying Value	Gross Unrecognized Unrealized Gains	Gross Unrecognized Unrealized Losses < 1 Year	Gross Unrecognized Unrealized Losses > 1 Year	Fair Value			
U.S. government and agency securities	\$ 36,258,997	\$ 442,412	\$ 1,379	\$ -	\$ 36,700,030			
State and agency municipal securities	6,298,042	375,212	-	-	6,673,254			
City and county municipal securities	4,754,813	341,682	-	-	5,096,495			
Corporate debt securities	98,699,590	479,908	260	39,132	99,140,106			
Total bonds and short-term investments	<u>\$ 146,011,442</u>	\$ 1,639,214	\$ 1,639	\$ 39,132	\$ 147,609,885			

Included in U.S. government and agency securities and corporate debt securities in the tables above are mortgage-related loan-backed securities, which do not have a single maturity date. For the years to maturity table above, these securities have been presented in the maturity group based on the securities' final maturity date and at a book/adjusted carrying value of \$10,068,126 and fair value of \$10,065,371.

The following table illustrates the fair value and gross unrecognized unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous unrecognized unrealized loss position as of December 31, 2021 and 2020:

	<1	Year	> 1 Year	Tot	Total		
	Fair Value	Gross Unrecognized Unrealized Losses	Gross Unrecognized Fair Unrealized Value Losses	Fair Value	Gross Unrecognized Unrealized Losses		
U.S. government and agency securities State and agency municipal securities City and county municipal securities Corporate debt securities	\$20,697,751 2,239,288 1,537,650 104,309,383	\$ 155,030 10,713 22,350 592,127	\$ - \$ -   	\$ 20,697,751 2,239,288 1,537,650 104,309,383	\$ 155,030 10,713 22,350 592,127		
Total bonds	<u>\$ 128,784,072</u>	\$ 780,220	<u>\$ - </u> \$ 2020	<u>\$ 128,784,072</u>	\$ 780,220		
	<1	Year	> 1 Year	Total			
	Fair Value	Gross Unrecognized Unrealized Losses	Gross Unrecognized Fair Unrealized Value Losses	Fair Value	Gross Unrecognized Unrealized Losses		
U.S. government and agency securities City and county municipal securities	\$ 2,782,578 999,740	\$ 1,379 	\$ - \$ - <u>1,160,868</u> <u>39,132</u>	\$ 2,782,578 2,160,608	\$    1,379 39,392		
Total bonds and short-term investments	<u>\$ 3,782,318</u>	\$ 1,639	<u>\$ 1,160,868</u> <u>\$ 39,132</u>	\$ 4,943,186	\$ 40,771		

The unrecognized unrealized losses on investments in U.S. government and agency securities, state and agency municipal securities, city and county municipal securities, and corporate debt securities at December 31, 2021 and 2020, were mainly caused by interest rate fluctuations and not by unfavorable changes in the credit ratings associated with these securities. The Company evaluates impairment at each reporting period for each of the securities whereby the fair value of the investment is less than its book/adjusted carrying value. The contractual cash flows of the U.S. government and agency securities are guaranteed either by the U.S. government or an agency of the U.S. government. It is expected that the securities would not be settled at a price less than the cost of the investment, and the Company does not intend to sell the investment until the unrealized loss is fully recovered. The Company assessed the credit quality of the state and agency municipal securities, city and county municipal securities and corporate debt securities, noting whether a significant deterioration since purchase or other factors that may indicate an other-than-temporary impairment ("OTTI"), such as the length of time and extent to which fair value has been less than cost, the financial condition, and near-term prospects of the issuer as well as specific events or circumstances that may influence the operations of the issuer and the Company's intent to sell the investment. Additionally, the Company evaluated its intent and ability to retain loan-backed securities for a period of time sufficient to recover the amortized cost. As a result of these reviews, no OTTIs were recorded by the Company as of December 31, 2021 and 2020.

A-C. The Company has no mortgage loans, real estate loans, restructured debt, or reverse mortgages. The Company also has no real estate property occupied by the Company, real estate property held for the production of income, or real estate property held for sale.

#### D. Loan-Backed Securities

(1) U.S. government and agency securities and corporate debt securities include loan-backed securities (mortgage-backed securities and asset-backed securities), which are valued using the retrospective adjustment methodology. Prepayment assumptions for the determination of the book/adjusted carrying value, commonly referred to as amortized cost, of loan-backed securities are based on a three-month constant prepayment rate history obtained from external data source vendors.

- (2) The Company did not recognize any OTTIs on loan-backed securities as of December 31, 2021 and 2020.
- (3) The Company did not have any loan-backed securities with OTTIs to report by CUSIP as of December 31, 2021 or 2020.
- (4) The following table illustrates the fair value, gross unrecognized unrealized losses, and length of time that the loan-backed securities have been in a continuous unrecognized unrealized loss position as of December 31, 2021 and 2020:

	2021
The aggregate amount of unrealized losses: 1. Less than 12 months 2. 12 months or longer	\$ 129,536 -
The aggregate related fair value of securities with unrealized losses: 1. Less than 12 months 2. 12 months or longer	28,783,599 -
	2020
The second se	
The aggregate amount of unrealized losses: 1. Less than 12 months 2. 12 months or longer	\$ 1,224 39,132

- (5) The Company believes that it will continue to collect timely the principal and interest due on its loan-backed securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate changes and not by unfavorable changes in the credit quality associated with these securities that impacted the assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows and the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of December 31, 2021, the unrealized loss on any security that the Company classified as intent to sell was not material to the Company's investment portfolio. Any other securities in an unrealized loss position as of December 31, 2021, the Company considers to be temporary.
- E. Dollar Repurchase Agreements and/or Securities Lending Transactions Not applicable.
- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing Not applicable.
- G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing Not applicable.
- H. Repurchase Agreements Transactions Accounted for as a Sale Not applicable.
- I. Reverse Repurchase Agreements Transactions Accounted for as a Sale Not applicable.
- J. Real Estate Not applicable.
- K. Low-Income Housing Tax Credits Not applicable.
- L. Restricted Assets
  - (1) Restricted assets, including pledged securities as of December 31, 2021 and 2020, are presented below:

	1	2	3	4	5	6 Gross	7
	Total Gross (Admitted & Nonadmitted) Restricted From	Total Gross (Admitted & Nonadmitted) Restricted From	Increase/ (Decrease)	Total Current Year Nonadmitted	Total Current Year Admitted Restricted	(Admitted & Nonadmitted) Restricted to Total Assets	Admitted Restricted to Total Admitted
Restricted Asset Category	Current Year	Prior Year	(1 Minus 2)	Restricted	(1 minus 4)	(a)	Assets (b)
a. Subject to contractual obligation for which							
liability is not shown b. Collateral held under security lending	\$-	\$ -	\$-	\$ -	\$-	-	-
agreements c. Subject to repurchase	-	-	-	-	-	-	-
agreements d. Subject to reverse	-	-	-	-	-	-	-
repurchase agreements e. Subject to dollar		-	-	-	-	-	-
repurchase agreements f. Subject to dollar reverse		-	-	-	-	-	-
repurchase agreements g. Placed under option contracts	-	-	-	-	-	-	-
<ul> <li>Letter stock or securities restricted as to sale—</li> </ul>	-	-	-	-		-	-
excluding FHLB capital stock	-	-	-	-	-	-	-
<ul> <li>FHLB capital stock</li> <li>On deposit with states</li> </ul>	- 211,795,520	- 167,287,882	- 44,507,638	-	- 211,795,520	- 59 %	- 60 %
<ul> <li>k. On deposit with other regulatory bodies</li> <li>I. Pledged as collateral to FHLB (including</li> </ul>	-	-	-	-	-	-	-
assets backing funding agreements) m. Pledged as collateral not		-		-		-	
captured in other categories n. Other restricted assets				-	-	-	:
o. Total restricted assets	<u>\$ 211,795,520</u>	<u>\$ 167,287,882</u>	\$ 44,507,638	<u>\$ -</u>	<u>\$ 211,795,520</u>	<u>59 %</u>	<u>60 %</u>

(a) Column 1 divided by Asset Page, Column 1, Line 28
(b) Column 5 divided by Asset Page, Column 3, Line 28

(2–4) The Company has no assets pledged as collateral not captured in other categories and no other restricted assets as of December 31, 2021 or 2020.

#### M. Working Capital Finance Investments — Not applicable.

#### N. Offsetting and Netting of Assets and Liabilities

The Company does not have any offsetting or netting of assets and liabilities as it relates to derivatives, repurchase and reverse repurchase agreements, and securities borrowing and securities lending activities.

### O. 5GI Securities

The Company does not have any investments with an NAIC designation of 5GI as of December 31, 2021 and 2020.

#### P. Short Sales — Not applicable.

#### Q. Prepayment Penalty and Acceleration Fees

The following table illustrates prepayment penalty and acceleration fees as of December 31, 2021:

	Gen	eral Account
1. Number of CUSIPs		1
2. Aggregate Amount of Investment Income	\$	1,488

#### R. Reporting Entity's Share of Cash Pool by Asset Type —

The Company's investment in the qualified cash pool is reported in cash equivalents. The Company's investment in the qualified cash pool is \$26,538,634 and \$21,809,506 as of December 31, 2021 and December 31, 2020, respectively. The following table presents the percent share distribution by underlying asset type of the total qualified cash pool balance as of December 31, 2021:

Asset Type	Percent Share			
(1) Cash	-			
(2) Cash Equivalents	52%			
(3) Short-Term Investments	48%			
(4) Total	100%			

### 6. JOINT VENTURES, PARTNERSHIPS, AND LIMITED LIABILITY COMPANIES

**A–B**. The Company has no investments in joint ventures, partnerships, or limited liability companies that exceed 10% of admitted assets and did not recognize any impairment write-down for its investments in joint ventures, partnerships, and limited liability companies during the statement periods.

### 7. INVESTMENT INCOME

- **A.** The Company excludes all investment income due and accrued amounts that are over 90 days past due from the financial statements.
- B. There were no investment income amounts excluded from the financial statements.

#### 8. DERIVATIVE INSTRUMENTS

A-B. The Company has no derivative instruments.

#### 9. INCOME TAXES

#### A. Deferred Tax Asset/Liability

(1) The components of the net deferred tax asset at December 31, 2021 and 2020 are as follows:

		2021			2020			Change	
-	1	2	3 (Col 1+2)	4	5	6 (Col 4+5)	7 (Col 1 - 4)	8 (Col 2 - 5)	9 (Col 7+8)
	Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total
(a) Gross deferred tax assets (b) Statutory valuation	\$ 973,132	\$ -	\$ 973,132	\$ 2,140,815	\$-	\$ 2,140,815	\$ (1,167,683)	\$-	\$ (1,167,683)
allowance adjustments		<u> </u>				-			<u> </u>
(c) Adjusted gross deferred tax assets									
(1a - 1b)	973,132	-	973,132	2,140,815	-	2,140,815	(1,167,683)	-	(1,167,683)
(d) Deferred tax assets nonadmitted		<u> </u>						<u> </u>	
(e) Subtotal net admitted deferred									
tax asset (1c - 1d)	973,132	-	973,132	2,140,815	-	2,140,815	(1,167,683)	-	(1,167,683)
(f) Deferred tax liabilities	41,187		41,187	51,484		51,484	(10,297)		(10,297)
(g) Net admitted deferred tax asset/(net deferred									
tax liability) (1e - 1f)	<u>\$ 931,945</u>	<u>\$ -</u>	<u>\$ 931,945</u>	\$ 2,089,331	<u>\$ -</u>	\$ 2,089,331	<u>\$ (1,157,386)</u>	\$ -	<u>(1,157,386</u> )

# (2) The components of the adjusted gross deferred tax assets admissibility calculation under SSAP No. 101, *Income Taxes,* are as follows:

		2021			2020			Change	
	1	2	3	4	5	6	7	8	9
Admission Calculation	<b>.</b>		(Col 1 + 2)	<b>.</b>		(Col 4 + 5)	(Col 1 - 4)	(Col 2 - 5)	(Col 7 + 8)
Components SSAP No. 101	Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total
<ul> <li>(a) Federal income taxes paid in prior years recoverable through loss carrybacks</li> </ul>	\$ 973,132	\$-	\$ 973,132	\$ 2,140,815	\$-	\$ 2,140,815	\$ (1,167,683)	\$ -	\$ (1,167,683)
(b) Adjusted gross deferred tax assets expected to be realized (excluding the amount of deferred tax assets from 2(a) above) after application of the threshold limitation. (The lesser of 2(b)1 and									
2(b)2 below) 1. Adjusted gross deferred tax assets expected to be realized following	-	-	-	-	-	-	-	-	-
the balance sheet date 2. Adjusted gross deferred tax assets allowed per	-	-	-	-	-	-	-	-	-
limitation threshold	XXX	XXX	34,896,481	XXX	XXX	32,570,046	XXX	XXX	2,326,435
(c) Adjusted gross deferred tax assets (excluding the amount of deferred tax assets from 2(a) and 2(b) above) offset by gross deferred tax liabilities								<u> </u>	<u> </u>
(d) Deferred tax assets admitted as the result of application of SSAP No. 101 Total (2(a) + 2(b) + 2(c))	<u>\$ 973,132</u>	<u>\$ -</u>	<u>\$   973,132</u>	<u>\$ 2,140,815</u>	<u>\$ -</u>	<u>\$ 2,140,815</u>	<u>\$ (1,167,683)</u>	<u>\$ -</u>	<u>\$ (1,167,683)</u>

(3) The ratio percentage and adjusted capital and surplus used to determine the recovery period and threshold limitations for the admissibility calculation are presented below:

	2021	2020
<ul> <li>(a) Ratio percentage used to determine recovery period and threshold limitation amount</li> <li>(b) Amount of adjusted capital and surplus used to</li> </ul>	>300%	>300%
determine recovery period and threshold limitation in 2(b)(2) above	\$ 232,643,206	\$ 217,133,640

(4) The impact to the gross deferred tax assets balances as a result of tax-planning strategies as of December 31, 2021 and 2020 is presented below:

	20	21		202	0		Chang	je
	1		2	3		4	5	6
Impact of Tax-Planning Strategies	Ordinary	С	apital	Ordinary	(	Capital	(Col 1 - 3) Ordinary	(Col 2 - 4) Capital
<ul> <li>(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets by tax character as a percentage.</li> <li>1. Adjusted gross DTAs amount from Note 9A1(c)</li> <li>2. Percentage of adjusted gross DTAs</li> </ul>	\$973,132	\$	-	\$2,140,815	\$	-	\$ (1,167,683)	\$-
by tax character attributable to the impact of tax-planning strategies 3. Net admitted adjusted gross DTAs	- %		- %	- %		- %	- %	- %
amount from Note 9A1(e) 4. Percentage of net admitted adjusted gross DTAs by tax character admitted	\$973,132	\$	-	\$2,140,815	\$	-	\$ (1,167,683)	\$-
because of the impact of tax-planning strategies	- %		- %	- %		- %	- %	- %
(b) Does the Company's tax-planning strategies include the use of reinsurance?				Yes			No	Х

#### B. Unrecognized Deferred Tax Liabilities

(1–4) There are no unrecognized deferred tax liabilities for the years ended December 31, 2021 and 2020.

### C. Significant Components of Income Taxes

(1) The current federal income taxes incurred for the years ended December 31, 2021 and 2020 are as follows:

	1	2	3 (Col 1 - 2)
	2021	2020	Change
<ol> <li>Current income tax         <ul> <li>(a) Federal</li> <li>(b) Foreign</li> </ul> </li> </ol>	\$ 26,538,473 -	\$ 27,618,633 -	\$ (1,080,160) -
(c) Subtotal	26,538,473	27,618,633	(1,080,160)
(d) Federal income tax on net capital gains (losses) (e) Utilization of capital loss carryforwards (f) Other	89 - -	(3,330) - -	3,419 
(g) Total federal and foreign income taxes incurred	<u>\$ 26,538,562</u>	\$ 27,615,303	<u>\$ (1,076,741)</u>

		1		2		3 (Col 1 - 2)
		2021		2020		Change
2 Deferred tax assets:						
(a) Ordinary:	¢	107.040	¢	404 500	¢	(44 504)
<ul><li>(1) Discounting of unpaid losses</li><li>(2) Unearned premium reserve</li></ul>	\$	167,012 4,513	\$	181,536 6,094	\$	(14,524) (1,581)
(3) Policyholder reserves		-		-		-
(4) Investments		-		-		-
<ul><li>(5) Deferred acquisition costs</li><li>(6) Policyholder dividends accrual</li></ul>		-		-		-
(7) Fixed assets		-		-		-
<ul><li>(8) Compensation and benefits accrual</li><li>(9) Pension accrual</li></ul>		-		-		-
(10) Receivables — nonadmitted		- 645,133		- 1,442,147		(797,014)
(11) Net operating loss carryforward		-		-		-
(12) Tax credit carryforward (13) Other (including items <5% of total ordinary tax assets)		-		-		-
(15) Other (including items <5% of total ordinary tax assets)		156,474		511,038		(354,564)
(99) Subtotal		973,132		2,140,815		(1,167,683)
(b) Statutory valuation allowance adjustment (c) Nonadmitted		-		-		-
(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)		973,132		2,140,815		(1,167,683)
(e) Capital:						
(1) Investments		-		-		-
(2) Net capital loss carryforward (3) Real estate		-		-		-
(4) Other (including items <5% of total capital tax assets)				_		-
(99) Subtotal		-		-		-
(f) Statutory valuation allowance adjustment		-		-		-
(g) Nonadmitted				-		-
(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)				-		-
(i) Admitted deferred tax assets (2d + 2h)		973,132		2,140,815		(1,167,683)
3 Deferred tax liabilities:						
(a) Ordinary:						
(1) Investments (2) Fixed assets		-		-		-
(3) Deferred and uncollected premium		-		-		-
<ul><li>(4) Policyholder reserves</li><li>(5) Other (including items &lt;5% of total ordinary tax liabilities)</li></ul>		- 41,187		- 51,484		(10,297)
		41,107		51,404		(10,297)
(99) Subtotal		41,187		51,484		(10,297)
(b) Capital:						
(1) Investments (2) Real estate		-		-		-
(3) Other (including items <5% of total capital tax liabilities)		-		-		-
(99) Subtotal						
(c) Deferred tax liabilities (3a99 + 3b99)		41,187		51,484		(10,297)
4 Net deferred tax assets/liabilities (2i - 3c)	\$	931,945	\$	2,089,331	\$	(1,157,386)

The other ordinary deferred tax asset of \$156,474 for 2021 consists of intangibles of \$156,428 and accrued expenses of \$46. The other ordinary deferred tax asset of \$511,038 for 2020 consists of intangibles of \$510,507, bad debt of \$483, and accrued expenses of \$48. The other ordinary deferred tax liability of \$41,187 and \$51,484 for 2021 and 2020, respectively, consists of loss reserve discounting.

The Company assessed the potential realization of the gross deferred tax asset and as a result no statutory valuation allowance was required and no allowance was established as of December 31, 2021 and 2020.

⁽²⁻⁴⁾ The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2021 and 2020, are as follows:

**D.** The provision for federal income taxes incurred is different from that which would be obtained by applying the statutory federal income tax rate of 21% to net income before federal income taxes incurred, less capital gains tax (benefit). A summarization of the significant items causing this difference as of December 31, 2021 and 2020 is as follows:

	202	1	2020		
		Effective		Effective	
	Amount	Tax Rate	Amount	Tax Rate	
Tax provision at the federal statutory rate	\$ 26,933,165	21%	\$ 24,763,926	21%	
Tax-exempt interest	(34,157)	-	(34,897)	-	
Health insurer fee	-	-	3,235,205	3	
Tax effect of nonadmitted assets	796,940	1	(345,501)	-	
Change in statutory valuation allowance			(14,976)		
Total statutory income taxes	\$ 27,695,948	22%	\$ 27,603,757	24%	
Federal income taxes incurred	\$ 26,538,473	21%	\$ 27,618,633	24%	
Capital gains tax	89	-	(3,330)	-	
Change in net deferred income tax	1,157,386	1	(11,546)	-	
Total statutory income taxes	\$ 27,695,948	22%	\$ 27,603,757	24%	

E. At December 31, 2021, the Company had no net operating loss carryforwards.

Current federal income taxes recoverable of \$166,437 and \$2,381,696 as of December 31, 2021 and 2020, respectively, are included in the financial statements. Federal income taxes paid, net of refunds, were \$24,323,303 and \$30,600,282 in 2021 and 2020, respectively.

Federal income taxes incurred of \$26,538,562 and \$27,615,303 for 2021 and 2020, respectively, are available for recoupment in the event of future net losses.

The Company has not admitted any aggregate amounts of deposits that are included within Section 6603 ("Deposits made to suspend running of interest on potential underpayments, etc.") of the Internal Revenue Service ("IRS") Code.

- F. The Company is included in the consolidated federal income tax return with its ultimate parent, UnitedHealth Group. The entities included within the consolidated return are included in the NAIC Statutory Statement Schedule Y - Information Concerning Activities of Insurer Members Of A Holding Company Group. Federal income taxes are paid to or refunded by UnitedHealth Group pursuant to the terms of a tax-sharing agreement, approved by the Board of Directors, under which taxes approximate the amount that would have been computed on a separate company basis, with the exception of net operating losses and capital losses. For these losses the Company receives a benefit at the federal rate in the current year for current taxable losses incurred in that year to the extent losses can be utilized in the consolidated federal return of UnitedHealth Group. UnitedHealth Group currently files income tax returns in the U.S. federal jurisdiction, various states, and foreign jurisdictions. The U.S. IRS has completed exams on UnitedHealth Group's consolidated income tax returns for fiscal years 2016 and prior. UnitedHealth Group's 2017 through 2020 tax returns are under review by the IRS under its Compliance Assurance Program. With the exception of a few states, UnitedHealth Group is no longer subject to income tax examinations prior to the 2014 tax year. In general, the Company is subject to examination in non-U.S. jurisdictions for years 2015 and forward. The Company does not believe any adjustments that may result from these examinations will be material to the Company.
- G. Tax Contingencies Not applicable.
- H. Repatriation Transition Tax Not applicable.
- I. Alternative Minimum Tax Credit Not applicable.

### 10. INFORMATION CONCERNING PARENT, SUBSIDIARIES, AND AFFILIATES

**A–B.** In the ordinary course of business, the Company contracts with several affiliates to provide a wide variety of services to the Company's members. These agreements are filed with and approved by the Department according to Management's understanding of the current requirements and standards. Within the confines of the applicable filed and approved agreements (including subsequent amendments thereto), the amount and types of services provided by these affiliated entities can change year over year.

UHS maintains a private short-term investment pool in which affiliated companies may participate (see Note 1). At December 31, 2021 and 2020, the Company's portion was \$26,538,633 and \$21,809,506, respectively and is included in cash equivalents in the financial statements.

The Company has a tax-sharing agreement with UnitedHealth Group (see Note 9).

The Company paid dividends of \$45,000,000 and \$45,000,000 in 2021 and 2020, respectively, to its parent (see Note 13).

The Company holds a \$65,000,000 subordinated revolving credit agreement with UnitedHealth Group at an interest rate of London InterBank Offered Rate plus a margin of 0.50%. This credit agreement is subordinate to the extent it does not conflict with any credit facility held by either party. The credit agreement is for a one-year term and automatically renews annually, unless terminated by either party. No amounts were outstanding under the line of credit as of December 31, 2021 and 2020.

The Company has entered into a reinsurance agreement with an affiliated entity.

#### C. Transactions With Related Party Who Is Not Reported On Schedule Y

The Company has no material related party transactions that meet the disclosure requirements pursuant to SSAP No. 25, *Affiliates and Other Related Parties* ("SSAP No. 25") that are not included in NAIC Statutory Statement Schedule Y—Part 2 Summary Of Insurer's Transactions With Any Affiliates.

- D. At December 31, 2021 and 2020, the Company reported \$13,173,758 and \$10,716,065, respectively, as amounts due to parent, subsidiaries, and affiliates, which are included in the financial statements. These balances are generally settled within 90 days from the incurred date. Any balances due to the Company that are not settled within 90 days are considered nonadmitted assets.
- E. The administrative services, access fees, and cost of care services provided by affiliates are calculated using one or more of the following methods: (1) a percentage of premiums; (2) use of assets; (3) direct pass-through of charges; (4) per member per month ("PMPM"); (5) per employee per month; (6) per claim; or (7) a combination thereof consistent with the provisions contained in each contract. These amounts are included in GAE, CAE, and hospital and medical expenses in the financial statements. The following table identifies the amounts reported for the administrative services, access fees, and cost of care services provided by related parties for the years ended December 31, 2021 and 2020, which meet the disclosure requirements pursuant to SSAP No. 25, regardless of the effective date of the contract:

	2021	2020
LifePrint Health, Inc.	\$ 456,185,552	\$ 339,651,998
OptumRx	94,865,822	51,085,816
UHS	77,814,729	77,585,577
naviHealth, Inc.	17,887,352	-
XLHome Northeast, P.C.	4,586,984	-
Riverside Pediatric Group, P.C.	3,413,058	2,305,068

LifePrint Health, Inc. provides services that may include, but are not limited to, care management services to eligible members and/or arranging for the delivery of clinical services to the Company's enrollees.

OptumRx provides services that may include, but are not limited to, administrative services related to pharmacy management and pharmacy claims processing for enrollees, manufacturer rebate administration, pharmacy incentive services, specialty drug pharmacy services, durable medical equipment services including orthotics and prosthetics and personal health products

catalogues showing the healthcare products and benefit credits enrollees needed to redeem the respective products.

UHS provides, or arranges for the provision of, management, administrative, and other services deemed necessary or appropriate for UHS to provide management and operational support to the Company. The services can include, but are not limited to, the categories of management and operational services outlined in the Agreement, such as human resources, legal, facilities, general administration, treasury and investment functions, claims adjudication and payment, benefit administration, disease management, health care decision support, medical management, credentialing, preventative health services, utilization management reporting and expenses incurred for new business that will be effective in the subsequent year.

naviHealth, Inc. provides comprehensive post-acute services and care delivery.

XLHome Northeast, P.C. provides medical services to the Company's members.

Riverside Pediatric Group, P.C. provides medical assistance for children.

The Company has premium payments that are received and claim payments and direct expenses such as broker commissions, Department exam fees, ACA assessments and premium taxes that are processed and paid by an affiliated UnitedHealth Group entity. Premiums, claims, and direct expenses applicable to the Company are settled at regular intervals throughout the month via the intercompany settlement process and any amounts outstanding are reflected in payable amounts due to parent, subsidiaries, and affiliates, in the financial statements.

- **F.** The Company has not extended any guarantees or undertakings for the benefit of an affiliate or related party.
- **G.** The Company is part of an insurance holding company system with UnitedHealth Group as the ultimate parent. Management believes that the Company's transactions with affiliates are fair and reasonable; however, operations of the Company may not be indicative of those that would have occurred if it had operated as an independent company.
- **H.** The Company does not have any amount deducted from the value of an upstream intermediate entity or ultimate parent owned, either directly or indirectly, via a downstream subsidiary, controlled, or affiliated entity.
- I. The Company does not have any investments in a subsidiary, controlled, or affiliated entity that exceeds 10% of admitted assets.
- J. The Company does not have any investments in impaired subsidiaries, controlled, or affiliated entities.
- K. The Company does not have any investments in foreign insurance subsidiaries.
- L. The Company does not hold any investments in a downstream noninsurance holding company.
- **M.** The Company does not have any investments in noninsurance subsidiaries, controlled, or affiliated entities.
- **N.** The Company does not have any investments in insurance subsidiaries, controlled, or affiliated entities.
- **O.** The Company does not have any investments in subsidiary, controlled, or affiliated entities or joint ventures, partnerships and limited liability companies in which the Company's share of losses exceeds the investment.

#### 11. DEBT

**A–B.** The Company had no outstanding debt with third-parties or outstanding Federal Home Loan Bank agreements during 2021 and 2020.

# 12. RETIREMENT PLANS, DEFERRED COMPENSATION, POSTEMPLOYMENT BENEFITS AND COMPENSATED ABSENCES AND OTHER POSTRETIREMENT BENEFIT PLANS

A-I. The Company has no defined benefit plans, defined contribution plans, multiemployer plans, consolidated/holding company plans, postemployment benefits, or compensated absences plans and is not impacted by the Medicare Modernization Act on postretirement benefits, since all personnel are employees of UHS, which provides services to the Company under the terms of the Agreement (see Note 10).

### 13. CAPITAL AND SURPLUS, DIVIDEND RESTRICTIONS, AND QUASI-REORGANIZATIONS

- A-B. The Company has 1,000 shares authorized and 500 shares issued and outstanding of \$0.10 par value common stock. The Company has no preferred stock outstanding. All issued and outstanding shares of common stock are held by the Company's parent, Oxford.
- C. Dividend payment requirements are outlined in the domiciliary state statutes and may be further restricted by the Department.
- The Company paid an ordinary cash dividend of \$45,000,000 on September 15, 2021 to Oxford, D. which was approved by the Department and recorded as a reduction to unassigned surplus in the financial statements.

On November 16, 2021, the Company declared an ordinary cash dividend of \$45,000,000 to Oxford which remains unpaid as of December 31, 2021. The ordinary dividend complied with the provisions set forth in the statutes of New Jersey and is reported as an accrued liability and as a reduction to unassigned surplus in the financial statements. As of December 31, 2021, the Company is awaiting approval from the Department to pay the dividend.

The Company paid an ordinary dividend of \$45,000,000 on May 15, 2020 to Oxford, which was approved by the Department and reported as a reduction to unassigned surplus in the financial statements.

- Ε. The amount of ordinary dividends that may be paid out during any given period is subject to certain restrictions as specified by state statute.
- F. There are no restrictions placed on the Company's unassigned surplus.
- G. The Company is not a mutual reciprocal or a similarly organized entity and does not have advances to surplus not repaid.
- The Company does not hold any stock, including stock of affiliated companies for special Н. purposes, such as conversion of preferred stock, employee stock options, or stock purchase warrants.
- I. The Company does not have any special surplus funds.
- J. The portion of unassigned surplus, excluding net income and dividends, represented (or reduced) by each item below is as follows:

	2021	2020
Net deferred income taxes Nonadmitted assets	\$    931,945 (3,072,690)	\$   2,089,331 (6,867,654)
Total	<u>\$ (2,140,745)</u>	<u>\$ (4,778,323)</u>

K-M. The Company does not have any outstanding surplus notes and has never been a party to a quasi-reorganization.

#### 14. LIABILITIES, CONTINGENCIES AND ASSESSMENTS

#### Α. **Contingent Commitments**

The Company has no contingent commitments.

#### В. Assessments

The Company is not aware of any guaranty fund assessments or premium tax offsets, potential or accrued, that could have a material financial effect on the operations of the entity.

#### C. **Gain Contingencies**

The Company is not aware of any gain contingencies that should be disclosed in the financial statements.

#### D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits — Not applicable.

Joint and Several Liabilities — Not applicable. Ε.

## F. All Other Contingencies

The Company's business is regulated at the federal, state, and local levels. The laws and rules governing the Company's business and interpretations of those laws and rules are subject to frequent change. Broad latitude is given to the agencies administering those regulations. Further, the Company must obtain and maintain regulatory approvals to market and sell many of its products.

The Company has been, or is currently involved, in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by CMS state insurance and health and welfare departments and other governmental authorities. The Company cannot reasonably estimate the range of loss, if any, that may result from any material government investigations, audits and reviews in which it is currently involved given the inherent difficulty in predicting regulatory action, fines and penalties, if any, and the various remedies and levels of judicial review available to the Company in the event of an adverse finding.

On February 14, 2017, the Department of Justice ("DOJ") announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower's complaint, which was unsealed on February 15, 2017, alleges that the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company's motion to dismiss. In May 2018, the DOJ moved to dismiss the Company's counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government's motion for partial summary judgment and dismissed the Company's counterclaims without prejudice. The Company cannot reasonably estimate the outcome that may result from this matter given its procedural status.

Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company's businesses, including management and administration of health benefit plans and other services.

The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters involve: indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility, or it is probable that a loss may be incurred. Although the outcomes of any such legal actions cannot be predicted, in the opinion of management, the resolution of any currently pending or threatened actions will not have a material adverse effect on the financial statements of the Company.

The Company routinely evaluates the collectability of all receivable amounts included in the financial statements. Impairment reserves are established for those amounts where collectability is uncertain. Based on the Company's past experience, exposure related to uncollectible balances and the potential of loss for those balances not currently reserved for is not material to the Company's statutory basis financial condition.

There are no assets that the Company considers to be impaired at December 31, 2021 and 2020, except as disclosed in Note 5 and Note 20.

#### 15. LEASES

**A–B.** According to the Agreement between the Company and UHS (see Note 10), operating leases for the rental of office facilities and equipment are the responsibility of UHS. Fees associated with the lease agreements are included as a component of the Company's management fee.

# 16. INFORMATION ABOUT FINANCIAL INSTRUMENTS WITH OFF-BALANCE-SHEET RISK AND FINANCIAL INSTRUMENTS WITH CONCENTRATIONS OF CREDIT RISK

(1–4) The Company does not hold any financial instruments with off-balance-sheet risk or have any concentrations of credit risk.

# 17. SALE, TRANSFER, AND SERVICING OF FINANCIAL ASSETS AND EXTINGUISHMENTS OF LIABILITIES

A-C. The Company did not participate in any transfer of receivables, financial assets or wash sales.

# 18. GAIN OR LOSS TO THE REPORTING ENTITY FROM UNINSURED PLANS AND THE UNINSURED PORTION OF PARTIALLY INSURED PLANS

**A–B.** The Company has no operations from Administrative Services Only Contracts or Administrative Services Contracts in 2021 and 2020.

#### C. Medicare or Other Similarly Structured Cost Based Reimbursement Contract

The Medicare Part D program is a partially insured plan. The Company recorded a receivable of \$13,386,508 and \$17,648,625 at December 31, 2021 and 2020, respectively, for cost reimbursement under the Medicare Part D program for the catastrophic reinsurance and low-income member cost-sharing subsidies. The Company also recorded a receivable of \$7,470 and \$13,595 and also a payable of \$74,635 and \$6,243 at December 31, 2021 and 2020, respectively, for the Medicare Part D coverage gap discount program. The receivables and payables are recorded in amounts receivable relating to uninsured plans and liability for amounts held under uninsured plans, respectively, in the financial statements.

### 19. DIRECT PREMIUM WRITTEN/PRODUCED BY MANAGING GENERAL AGENTS/THIRD-PARTY ADMINISTRATORS

The Company did not have any direct premiums written or produced by managing general agents or third-party administrators in 2021 and 2020.

## 20. FAIR VALUE MEASUREMENTS

The NAIC SAP defines fair value, establishes a framework for measuring fair value, and outlines the disclosure requirements related to fair value measurements. The fair value hierarchy is as follows:

Level 1 — Quoted (unadjusted) prices for identical assets in active markets.

Level 2 — Other observable inputs, either directly or indirectly, including:

- Quoted prices for similar assets in active markets;
- Quoted prices for identical or similar assets in nonactive markets (few transactions, limited information, noncurrent prices, high variability over time, etc.);
- Inputs other than quoted prices that are observable for the asset (interest rates, yield curves, volatilities, default rates, etc.);
- Inputs that are derived principally from or corroborated by other observable market data.

Level 3 — Unobservable inputs that cannot be corroborated by observable market data.

The estimated fair values of bonds, cash equivalents, and short-term investments are based on quoted market prices, where available. The Company obtains one price for each security primarily from a thirdparty pricing service ("pricing service"), which generally uses quoted prices or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, making adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, non-binding broker quotes, benchmark yields, credit spreads, default rates, and prepayment speeds. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to a secondary pricing source, prices reported by its custodian, its investment consultant, and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company's internal price verification procedures and review of fair value methodology documentation provided by independent pricing services have not historically resulted in an adjustment in the prices obtained from the pricing service.

In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest-level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

## A. Fair Value

## (1) Fair Value Measurements at Reporting Date

The following tables present information about the Company's financial assets that are measured and reported at fair value at December 31, 2021 and 2020, in the financial statements according to the valuation techniques the Company used to determine their fair values:

	December 31, 2021										
Description for Each Class of Asset or Liability	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Total						
a. Assets at fair value: Perpetual preferred stock: Industrial and misc Parent, subsidiaries, and affiliates	\$ - 	\$ - 	\$ - 	\$ - -	\$						
Total perpetual preferred stocks			-								
Bonds: U.S. governments Industrial and misc Hybrid securities Parent, subsidiaries, and affiliates	- - -	- -	- - -	- - -	- - -						
Total bonds											
Common stock: Industrial and misc Parent, subsidiaries, and affiliates	-		-	-	-						
Total common stocks											
Derivative assets: Interest rate contracts Foreign exchange contracts Credit contracts Commodity futures contracts Commodity forward contracts	-	- - - -	- - - -	- - - -	- - - -						
Total derivatives	-	-	-	-	-						
Money-market funds Qualified cash pool	42,851,411 26,538,633		-	-	42,851,411 26,538,633						
Total assets at fair value/NAV	<u>\$ 69,390,044</u>	\$ -	<u>\$ -</u>	\$ -	\$ 69,390,044						
b. Liabilities at fair value: Derivative liabilities Additional write-ins	\$ - -	\$ - 	\$ - -	\$ - -	\$						
Total liabilities at fair value	<u>\$</u> -	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$</u>						

	December 31, 2020									
Description for Each Class of Asset or Liability	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Total					
a. Assets at fair value: Perpetual preferred stock: Industrial and misc Parent, subsidiaries, and affiliates	\$ - 	\$ - 	\$ - 	\$ - 	\$ <u>-</u>					
Total perpetual preferred stocks										
Bonds: U.S. governments Industrial and misc Hybrid securities Parent, subsidiaries, and affiliates	-			- - -	- - -					
Total bonds										
Common stock: Industrial and misc Parent, subsidiaries, and affiliates	-		-	-	-					
Total common stocks										
Derivative assets: Interest rate contracts Foreign exchange contracts Credit contracts Commodity futures contracts Commodity forward contracts	- - - -	- - - -	- - - -	- - - -	- - - - -					
Total derivatives	-	-	-	-	-					
Money-market funds Qualified cash pool Separate account assets	21,276,439 21,809,506 -	-	-	- - -	- 21,809,506 -					
Total assets at fair value/NAV	\$43,085,945	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 21,809,506</u>					
b. Liabilities at fair value: Derivative liabilities Additional write-ins	\$	\$ - -	\$ - -	\$ - -	\$ - -					
Total liabilities at fair value	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>					

- (2) The Company does not have any financial assets with a fair value hierarchy of Level 3 that were measured and reported at fair value.
- (3) Transfers between fair value hierarchy levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs. There were no transfers between Levels 1, 2 or 3 of any financial assets or liabilities during the years ended December 31, 2021 or 2020.
- (4) The Company has no investments reported with a fair value hierarchy of Level 2 or Level 3 and therefore has no valuation technique to disclose.
- (5) The Company has no derivative assets and liabilities to disclose.

**B.** Fair Value Combination — Not applicable.

## C. Aggregate Fair Value Hierarchy

The aggregate fair value by hierarchy of all financial instruments as of December 31, 2021 and 2020 is presented in the table below:

				December 31, 2021			
Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
U.S. government and agency securities	\$ 29,849,271	\$ 29,863,693	\$ 23,985,592	\$ 5,863,679	\$-	\$-	\$-
State and agency municipal securities	6,994,929	6,707,526	-	6,994,929	-	-	-
City and county municipal securities	6,471,041	6,226,199	-	6,471,041	-	-	-
Corporate debt securities	125,602,914	126,146,691	-	125,602,914	-	-	-
Cash equivalents	69,390,044	69,390,044	69,390,044	<u> </u>	<u> </u>	-	<u> </u>
Total bonds and cash equivalents	\$ 238,308,199	<u>\$ 238,334,153</u>	<u>\$ 93,375,636</u>	<u>\$ 144,932,563</u>	<u>\$ -</u>	<u>\$</u> -	<u>\$-</u>
				December 31, 2020			
Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
U.S. government and agency securities	\$ 36,700,030	\$ 36,258,997	\$ 28,846,727	\$ 7,853,303	\$-	\$-	\$-
State and agency municipal securities	6,673,254	6,298,042	-	6,673,254	-	-	-
City and county municipal securities	5,096,495	4,754,813	-	5,096,495	-	-	-
Corporate debt securities	99,140,106	98,699,590	-	99,140,106	-	-	-
Cash equivalents	43,085,945	43,085,945	43,085,945	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Total bonds, short-term investments,							
and cash equivalents	\$ 190,695,830	\$ 189,097,387	\$ 71,932,672	<u>\$ 118,763,158</u>	ş -	<u>\$ -</u>	<u>\$ -</u>

#### D. Not Practicable to Estimate Fair Value — Not applicable.

## E. Investments Measured Using the NAV Practical Expedient — Not applicable.

## 21. OTHER ITEMS

#### **COVID-19 Trends and Uncertainties**

The COVID-19 pandemic continues to evolve and the ultimate overall impact to the Company's financial statements is uncertain and dependent on the future pacing, intensity and duration of the pandemic, the severity of new variants of the COVID-19 virus, the effectiveness and extent of administration of vaccination and treatments and general economic uncertainty.

Throughout 2020, the Company's ultimate parent announced a number of programs to directly support people affected by the COVID-19 pandemic, including a plan to grant premium credits to the Company's fully insured commercial customers. The total amount of premium credits granted through December 31, 2020 of \$29,530 has been reflected as a reduction to net premium income in the financial statements.

#### A. Unusual or Infrequent Items

The Company did not encounter any unusual or infrequent items for the years ended December 31, 2021 and 2020.

#### B. Troubled Debt Restructuring: Debtors

The Company has no troubled debt restructurings as of December 31, 2021 and 2020.

## C. Other Disclosures

The Company does not have any amounts not recorded in the financial statements that represent segregated funds held for others. The Company also does not have any exposures related to forward commitments that are not derivative instruments.

#### D. Business Interruption Insurance Recoveries

The Company has not received any business interruption insurance recoveries during 2021 and 2020.

#### E. State Transferable and Non-transferable Tax Credits

The Company has no transferable or non-transferable state tax credits.

## F. Sub-Prime Mortgage-Related Risk Exposure

(1-4) The investment policy for the Company limits investments in loan backed securities, which can include sub prime issuers. Further, the policy limits investments in private issuer mortgage securities to 10% of the portfolio, which also includes sub prime issuers. The Company does not have any sub-prime mortgage-related risk exposure as of December 31, 2021 and 2020.

## G. Retained Assets

The Company does not have any retained asset accounts for beneficiaries.

## H. Insurance-Linked Securities Contracts

As of December 31, 2021, the Company is not aware of any possible proceeds of insurancelinked securities.

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy — Not applicable.

## 22. EVENTS SUBSEQUENT

Subsequent events have been evaluated through February 28, 2022, which is the date these financial statements were available for issuance.

## **TYPE I — Recognized Subsequent Events**

Any material Type I events subsequent to December 31, 2021, have been recognized in the financial statements and corresponding disclosures.

## TYPE II — Non-Recognized Subsequent Events

There are no material non-recognized Type II events that require disclosure.

## 23. REINSURANCE

**A–D.** The Company does not have any material affiliated or unaffiliated reinsurance agreements in place as of December 31, 2021 or 2020.

#### E. Reinsurance Credit

- (1) The Company has no ceding reinsurance contracts subject to Appendix A-791 *Life and Health Reinsurance Agreements* ("A-791") that includes a provision which limits the reinsurer's assumption of significant risk.
- (2) The Company has no ceding reinsurance contracts not subject to A-791, for which reinsurance accounting was applied and which include provisions that limit the reinsurer's assumption of risk.
- (3) The Company's reinsurance contracts do not contain features which result in delays in payment in form or in fact.
- (4) The Company has not reflected a reinsurance accounting credit for any assumption reinsurance contracts not subject to Appendix A-791 and not yearly renewable term, which meet the risk transfer requirements of SSAP No. 61R, *Life, Deposit-Type, and Accident and Health Reinsurance* ("SSAP No. 61R").
- (5) The Company did not cede any risk which is not subject to A-791 and not yearly renewable term reinsurance, under any reinsurance contract during the period covered by these financial statements, for which the statutory accounting treatment and GAAP accounting treatment were not the same.
- (6) The Company's ceded reinsurance contracts which are not subject to A-791 and not yearly renewable term reinsurance, are treated the same for GAAP and statutory accounting principles.

## 24. RETROSPECTIVELY RATED CONTRACT AND CONTRACT SUBJECT TO REDETERMINATION

**A**. The Company estimates accrued retrospective premium adjustments for its group health insurance business based on mathematical calculations in accordance with contractual terms.

- **B**. Estimated accrued retrospective premiums due to the Company are recorded in aggregate health policy reserves in the financial statements and as an adjustment to change in unearned premium reserves and reserve for rate credits in the financial statements.
- **C.** Pursuant to the ACA, the Company's commercial and Medicare business is subject to retrospectively rated features based on the actual MLR experienced on the commercial and Medicare lines of business and redetermination features for premium adjustments for changes to each member's health scores based on guidelines determined by the ACA. The total amount of direct premiums written for the commercial and Medicare lines of business for which a portion is subject to the retrospectively rated and redetermination features was \$1,400,483 and \$7,710,689, and \$1,221,627,591 and \$983,907,137, representing 1% and 1%, and 99% and 99% of total direct premiums written as of December 31, 2021 and December 31, 2020, respectively.

The Company has Medicare Part D risk-corridor amounts from CMS which are subject to a retrospectively rated feature. The Company has estimated accrued retrospective premiums related to certain Part D premiums based on guidelines determined by CMS. The formula is tiered and based on the bid MLR. The amount of Medicare Part D direct premiums written subject to the retrospectively rated feature was \$50,886,331 and \$39,626,700, representing 4% and 4% of total direct premiums written as of December 31, 2021 and December 31, 2020, respectively.

**D.** The Company is required to maintain specific minimum loss ratios on the comprehensive commercial and Medicare lines of business.

The Company's actual loss ratios on the comprehensive commercial and Medicare lines of business were in excess of the minimum requirements and as a result, no minimum MLR rebate liability was required to be established at December 31, 2021 and 2020.

In addition to the ACA minimum loss ratio requirements, all Corporations and HMOs shall submit to the State, reports showing loss ratios for the previous calendar year for small group and individual direct pay standardized business. For small group and individual direct pay contracts, a minimum loss ratio of 80% must be met. The Company paid \$550,536 as of December 31, 2020, related to the 2019 small group loss ratio which was filed with the Department on August 27, 2020. Additionally, the Company accrued \$456,330 in small group estimated minimum loss ratio rebates for the year ended December 31, 2020, which is included in aggregate health policy reserves in the statutory basis statements of admitted assets, liabilities, and capital and surplus. The Company exceeded the required minimum loss ratio related to the 2020 small group loss ratio, and therefore there was no accrual necessary in 2021.

## E. Risk-Sharing Provisions of the Affordable Care Act

(1) The Company has accident and health insurance premiums in 2021 and 2020 subject to the risk-sharing provisions of the ACA.

The ACA imposed fees and premium stabilization provisions on health insurance issuers offering comprehensive commercial health insurance. The three premium stabilization programs are commonly referred to as the 3Rs — risk adjustment, reinsurance, and risk corridors.

**Risk Adjustment** — The risk adjustment program is a permanent program designed to mitigate the potential impact of adverse selection that generally applies to nongrandfathered individual and small group plans inside and outside of exchanges. The program helps to stabilize market premiums by transferring funds from plans with relatively low-risk enrollees to plans with relatively high-risk enrollees. The data used by CMS to determine the risk adjustment transfer amount is subject to audits along with the true-up to the final CMS report, which may result in a material change to arrive at the final risk adjustment amount from the initial risk adjustment estimate recorded. Premium adjustments pursuant to the risk adjustment program are accounted for as premium subject to redetermination and user fees are accounted for as assessments.

**Reinsurance and Risk Corridors** — The transitional reinsurance program and risk corridors program were temporary programs which expired at the end of 2016. The details of the years impacted and the amounts received are included in Note 24E 4 and Note 24E 5 below.

(2) The following table presents the current year impact of risk-sharing provisions of the ACA on assets, liabilities, and operations:

a.	Permanent ACA Risk Adjustment Program	Decemb	er 31, 2021
	Assets		
	<ol> <li>Premium adjustments receivable due to ACA Risk Adjustment (including high-risk pool payments)</li> </ol>	\$	9,307
	Liabilities		
	2. Risk adjustment user fees payable for ACA Risk Adjustment		706
	<ol><li>Premium adjustments payable due to ACA Risk Adjustment (including high-risk pool premium)</li></ol>		659,182
	<u>Operations (Revenue &amp; Expense)</u>		
	4. Reported as revenue in premium for accident and health		(054 404)
	contracts (written/collected) due to ACA Risk Adjustment 5. Reported in expenses as ACA Risk Adjustment user fees		(854,491)
	(incurred/paid)		708
b.	Transitional ACA Reinsurance Program		
	Assets		
	1. Amounts recoverable for claims paid due to ACA Reinsurance	\$	-
	2. Amounts recoverable for claims unpaid due to ACA Reinsurance (Contra Liability)		-
	<ol><li>Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance</li></ol>		-
	Liabilities		
	4. Liabilities for contributions payable due to ACA Reinsurance		
	<ul> <li>- not reported as ceded premium</li> <li>5. Ceded reinsurance premiums payable due to ACA Reinsurance</li> </ul>		-
	6. Liabilities for amounts held under uninsured plans contributions		
	for ACA Reinsurance		-
	Operations (Revenue & Expense)		
	7. Ceded reinsurance premiums due to ACA Reinsurance		-
	8. Reinsurance recoveries (income statement) due to ACA		
	reinsurance payments or expected payments 9. ACA Reinsurance contributions - not reported as ceded premium		-
C.	Temporary ACA Risk Corridors Program		
	Assets		
	1. Accrued retrospective premium due to ACA Risk Corridors	\$	-
	Liabilities		
	<ol><li>Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors</li></ol>		-
	Operations (Revenue & Expense)		
	<ol> <li>Effect of ACA Risk Corridors on net premium income (paid/received)</li> <li>Effect of ACA Risk Corridors on change in reserves for rate credits</li> </ol>		-
	-		

The following table is a rollforward of the prior year ACA risk-sharing provisions for asset and liability balances, along with reasons for adjustments to prior year balances:

					Diffe	rences	Adjus	stments			alances as of rting Date
	Accrued During the Prior Year on Business Written before December 31 of the Prior Year		before December 31 of the Prior Year		Prior Year Accrued Less Payments (Col 1 - 3)	Prior Year Accrued Less Payments (Col 2 - 4)	To Prior Year Balances	To Prior Year Balances	-	Cumulative Balance from Prior Years (Col 1 - 3 + 7)	Cumulative Balance from Prior Years (Col 2 - 4 + 8)
	1 Receivable	2 (Payable)	3 Receivable	4 (Payable)	5 Receivable	6 (Payable)	7 Receivable	8 (Payable)	Ref	9 Receivable	10 (Payable)
<ul> <li>Permanent ACA Risk Adjustment</li> <li>Program</li> <li>Premium adjustment receivable</li> </ul>											
(including high-risk pool payments) 2. Premium adjustment (payable)	\$ 60,654	\$-	ş -	\$-	\$ 60,654	\$-	\$ (35,595)	\$ -	A	\$ 25,059	\$ -
(including high-risk pool premium)		(603,325)		(728,673)		125,348		(160,645)	в		(35,297)
3. Subtotal ACA Permanent Risk Adjustment Program	60,654	(603,325)		(728,673)	60,654	125,348	(35,595)	(160,645)		25,059	(35,297)
<ul> <li>b. Transitional ACA Reinsurance Program</li> <li>1. Amounts recoverable for claims paid</li> <li>2. Amounts recoverable for claims</li> </ul>	-	-	-	-	-	-	-	-	С	-	-
unpaid (contra liability)	-	-	-	-	-	-	-	-	D	-	-
<ol> <li>Amounts receivable relating to uninsured plans</li> <li>Liabilities for contributions payable due to ACA Reinsurance—not</li> </ol>	-	-	-	-	-	-	-	-	Е	-	-
reported as ceded premium	-	-	-	-	-	-	-	-	F	-	-
<ol> <li>Ceded reinsurance premiums payable</li> <li>Liability for amounts held under</li> </ol>	-	-	-	-	-	-	-	-	G	-	-
uninsured plans					<u> </u>				н	<u> </u>	
7. Subtotal ACA Transitional Reinsurance Program											
<ul> <li>c. Temporary ACA Risk Corridors Program</li> <li>1. Accrued retrospective premium</li> <li>2. Reserve for rate credits or policy experience rating refunds</li> </ul>	-	-	-	-	-	-	-	-	ı ı	-	-
3. Subtotal ACA Risk Corridors Program									5		
d. Total for ACA Risk-Sharing Provisions	\$ 60,654	\$ (603,325)	\$ -	\$ (728,673)	\$ 60,654	\$ 125,348	\$ (35,595)	\$ (160,645)		\$ 25,059	\$ (35,297)

Explanation of Adjustments

The risk adjustment receivable as of December 31, 2020 utilized paid claims through October 31, 2020. As of the Reporting Date, the risk adjustment receivable related to prior periods was adjusted based on the CMS' Summary Report on Permanent Risk Adjustment Transfers for the 2020 Benefit Year. The risk adjustment receivable was further adjusted based on CMS' Updated Summary Report of 2017 Benefit Year Risk A. Adjustment Data Validation Adjustments to Risk Adjustment Transfers published January 15, 2021, CMS' Final Rule amending Risk Adjustment Data Validation beginning with the 2019 Benefit Year, and Benefit Year 2019 Risk Adjustment Data Validation IVA results, as well as CMS' Updated Summary Report of 2018 Benefit Year Risk Adjustment Data Validation Adjustments to Risk Adjustment Transfers published January 20, 2022.

The risk adjustment payable as of December 31, 2020 utilized paid claims through October 31, 2020. As of the Reporting Date, the risk adjustment payable related to prior periods was adjusted based on the CMS' Summary Report on Permanent Risk Adjustment Transfers for the 2020 Benefit Year. The risk adjustment payable was further adjusted based on CMS' Updated Summary Report of 2017 Benefit Year Risk B. Adjustment Data Validation Adjustments to Risk Adjustment Transfers published January 15, 2021, CMS' Final Rule amending Risk Adjustment Data Validation beginning with the 2019 Benefit Year, and Benefit Year 2019 Risk Adjustment Data Validation IVA results, as well as CMS' Updated Summary Report of 2018 Benefit Year Risk Adjustment Data Validation Adjustments to Risk Adjustment Transfers published January 20, 2022.

Janu C. N/A D. N/A E. N/A F. N/A G. N/A H. N/A J. N/A

⁽³⁾ 

# (4) The Company does not have any risk corridor receivables or payables to present in the table below.

		Accrued During the				Received or Paid as of			Differences			Adjustments					Unsettled Balances as of the Reporting Date				
	1	Prior Year on Business Written Before I December 31 of the Prior Year		Busir	the Current Year on Business Written Before December 31 of the Prior Year		Accr Paym	or Year ued Less nents (Col 1–3)	ents (Col Payments		To Prior Year Balances		To Prior Year Balances			Cumulative Balance from Prior Years (Col 1–3+7)		Balan Prior	ulative ice from r Years 2–4+8)		
		1		2		3		4		5		6		7		8	-		9		10
Risk Corridors Program Year:	Rece	ivable	(Pag	yable)	Rece	eivable	(Pa	yable)	Rec	ceivable	(Pay	/able)	Reco	eivable	(Pa	yable)	Ref	Rec	eivable	(Pa	yable)
a. 2014																					
1. Accrued retrospective premium	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	А	\$	-	\$	-
2. Reserve for rate credits or policy experience rating refunds		-		-		-		-		-		-		-		-	В		-		-
b. 2015																					
1. Accrued retrospective premium		-		-		-		-		-		-		-		-	С		-		-
2. Reserve for rate credits or policy experience rating refunds		-		-		-		-		-		-		-		-	D		-		-
c. 2016																					
1. Accrued retrospective premium		-		-		-		-		-		-		-		-	Е		-		-
2. Reserve for rate credits or policy experience rating refunds		-		-		-		-		-		-		-		-	F		-		-
d. Total for Risk Corridors	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	-	\$	-	\$	-

Explanation of Adjustments

А. В. С. Е. F.

(5) The following table discloses ACA risk corridor receivable balances by risk corridor program year:

	Fs	1 timated		2	3		4	5		6
Risk Corridors Program Year:	Amo Fileo Amour	ount to be d or Final nt Filed with CMS	Amo Impai	Accrued unts for rment or Reasons	ounts received from CMS	(Gro	et Balance oss of Non- missions) (1-2-3)	 n-admitted Amount	N	et Admitted Asset (4-5)
a.2014	\$	-	\$	-	\$ -	\$	-	\$ -	\$	-
b.2015		1,357,527		-	1,357,527		-	-		-
c. 2016		4,561,830		-	4,561,830		-	-		-
d. Total (a+b+c)	\$	5,919,357	\$	-	\$ 5,919,357	\$	-	\$ -	\$	-

#### 25. CHANGE IN INCURRED CLAIMS AND CLAIMS ADJUSTMENT EXPENSES

A. Changes in estimates related to the prior year incurred claims are included in total hospital and medical expenses in the current year in the financial statements. The following tables disclose paid claims, incurred claims, and the balance in claims unpaid, accrued medical incentive pool and bonus amounts, aggregate health claim reserves, health care and other amounts receivable for the years ended December 31, 2021 and 2020:

		2021	
	Current Year Incurred Claims	Prior Years Incurred Claims	Total
Beginning of year claim reserve Paid claims—net of health care receivables End of year claim reserve	\$	, ,	\$ (56,149,986) 982,408,337 55,938,943
Incurred claims excluding the change in health care receivables as presented below	1,025,782,357	7 (43,585,063)	982,197,294
Beginning of year health care receivables End of year health care receivables	(51,544,492	43,207,159 2) (1,405,847)	43,207,159 (52,950,339)
Total incurred claims	\$ 974,237,865	<u>\$ (1,783,751)</u>	\$ 972,454,114

		2020	
	 Current Year Incurred Claims	Prior Years Incurred Claims	Total
Beginning of year claim reserve Paid claims—net of health care receivables End of year claim reserve	\$ - 752,188,919 53,956,342	\$ (59,923,841) 10,117,919 2,193,644	\$ (59,923,841) 762,306,838 56,149,986
Incurred claims excluding the change in health care receivables as presented below	806,145,261	(47,612,278)	758,532,983
Beginning of year health care receivables End of year health care receivables	 - (42,463,307)	 37,040,410 (743,852)	 37,040,410 (43,207,159)
Total incurred claims	\$ 763,681,954	\$ (11,315,720)	\$ 752,366,234

The liability for claims unpaid, accrued medical incentive pool and bonus amounts, aggregate health claim reserves, net of health care and other amounts receivable as of December 31, 2020 was \$12,942,827. As of December 31, 2021, \$10,229,761 has been paid for incurred claims attributable to insured events of prior years. Reserves remaining for prior years, health care and other amounts receivable are now \$929,315, as a result of re-estimation of unpaid claims. Therefore, there has been \$1,783,751 favorable prior year development since December 31, 2020 to December 31, 2021. The primary drivers consist of favorable development as a result of a change in the provision for adverse deviations in experience of \$3,927,066 and favorable development of \$3,161,650 in retroactivity for inpatient, outpatient, physician, and pharmacy claims and unfavorable development of \$831,574 in Medicare Part D expenses.

At December 31, 2020, the Company recorded \$11,315,720 of favorable development. The primary drivers consist of favorable development as a result of a change in the provision for adverse deviations in experience of \$3,849,372, favorable development of \$4,567,524 in retroactivity for inpatient, outpatient, physician, and \$2,383,498 favorable development in provider settlements. Original estimates are increased or decreased, as additional information becomes known regarding individual claims, which could have an impact to the accruals for MLR rebates and retrospectively rated contracts. As a result of the prior year effects, on a regular basis, the Company adjusts revenue and the corresponding liability and/or receivable related to retrospectively rated policies and the impact of the change is included as a component of change in unearned premium reserves and reserve for rate credits in the financial statements.

The Company incurred CAE of \$39,707,276 and \$36,135,024 in 2021 and 2020, respectively. These costs are included in the management service fees paid by the Company to UHS as a part of the Agreement (see Note 10). The following table discloses paid CAE, incurred CAE, and the balance in unpaid CAE reserve for 2021 and 2020:

	2021	2020
Total claims adjustment expenses Less: current year unpaid claims adjustment expenses	\$ 39,707,276 (863,802)	\$ 36,135,024 (849,892)
Add: prior year unpaid claims adjustment expenses	849,892	788,780
Total claims adjustment expenses paid	\$ 39,693,366	\$ 36,073,912

**B.** The Company did not make any significant changes in methodologies and assumptions used in the calculation of the liability for claims unpaid and unpaid CAE in 2021.

#### 26. INTERCOMPANY POOLING ARRANGEMENTS

**A–G.** The Company did not have any intercompany pooling arrangements in 2021 or 2020.

## 27. STRUCTURED SETTLEMENTS

A-B. The Company did not have structured settlements in 2021 or 2020.

## 28. HEALTH CARE AND OTHER AMOUNTS RECEIVABLE

A. Pharmacy rebates receivable are recorded when reasonably estimated or billed by the affiliated pharmaceutical benefit manager in accordance with pharmaceutical rebate contract provisions. Information used to support rebates billed to the manufacturer is based on utilization information gathered by the pharmaceutical benefit manager and adjusted for significant changes in pharmaceutical contract provisions.

The Company evaluates admissibility of all pharmacy rebates receivable based on the administration of each underlying pharmaceutical benefit management agreement. The Company has nonadmitted and excluded all pharmacy rebates receivable that do not meet the admissibility criteria of SSAP No. 84, *Health Care and Government Insured Plan Receivables* ("SSAP No. 84") from the financial statements.

For each pharmaceutical management agreement for which a portion of the total pharmacy rebates receivable can be admitted based on the admissibility criteria of SSAP No. 84, the pharmacy rebate transaction history is summarized as follows:

Rebates asRebates asReceivedReceivedReceivedReported onBilled orwithin 90within 91 toMorFinancialOtherwiseDays of180 Days of180	bates ceived re than Days Billing
12/31/2021 \$ 36,838,072 \$ 11,852,163 \$ - \$ - \$	-
9/30/2021 35,452,635 36,240,761 22,679,386 -	-
6/30/2021 34,461,678 34,885,582 31,209,963 2,777,772	-
3/31/2021 32,310,533 31,994,850 26,863,156 3,884,297	500,045
12/31/2020 29.784.793 29.424.298 25.024.470 4.262.043	37,717
	408,404
	865.022
	508,224
12/31/2019 25,225,762 25,737,073 20,552,513 3,336,317 1,	277,942
9/30/2019 25,078,151 25,454,321 19,960,950 3,807,400 1,	344,683
6/30/2019 24,497,826 24,668,901 18,413,034 5,650,953	353,219
3/31/2019 22,389,349 22,744,799 18,927,944 2,227,288 1,	252,048

Of the amount reported as health care and other amounts receivable, \$49,679,452 and \$40,393,642 relates to pharmacy rebates receivable as of December 31, 2021 and 2020, respectively. This change is primarily due to increased membership along with the change in generic/name brand mix.

## **B.** The Company does not have any risk-sharing receivables.

The Company also admitted \$254,045 and \$309,478 of provider receivables resulting from claim overpayments as of December 31, 2021 and December 31, 2020, respectively, which are included in health care and other amounts receivable in the financial statements.

#### 29. PARTICIPATING POLICIES

The Company did not have any participating contracts in 2021 or 2020.

#### **30. PREMIUM DEFICIENCY RESERVES**

The Company has not recorded any PDR as of December 31, 2021 or 2020. The analysis of PDR was completed as of December 31, 2021 and 2020. The Company did consider anticipated investment income when calculating the PDR.

~~~~

The following table summarizes the Company's PDR as of December 31, 2021 and 2020:

|                                                                    | 20    | )21    |
|--------------------------------------------------------------------|-------|--------|
| 1. Liability carried for premium deficiency reserves               | \$    | -      |
| 2. Date of the most recent evaluation of this liability            | 12/3  | 1/2021 |
| 3. Was anticipated investment income utilized in this calculation? | Yes X | No 🗌   |
|                                                                    | 20    | )20    |
| 1. Liability carried for premium deficiency reserves               | \$    | -      |
| 2. Date of the most recent evaluation of this liability            | 12/3  | 1/2020 |
| 3. Was anticipated investment income utilized in this calculation? | Yes X | No     |

## 31. ANTICIPATED SALVAGE AND SUBROGATION

Due to the type of business being written, the Company has no salvage. As of December 31, 2021 and 2020, the Company had no specific accruals established for outstanding subrogation, as it is considered a component of the actuarial calculations used to develop the estimates of claims unpaid and aggregate health claim reserves.

## **GENERAL INTERROGATORIES**

# PART 1 - COMMON INTERROGATORIES

## GENERAL

| 12       If yes, data to reporting only register and its with its denoising: Solar hearters Commissions: Discost on Superintendent, or with providing disclosure statement of use and missions provides the statement of the reporting entry has been been been been been been been bee                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.1 | .1 Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of whis an insurer?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                 |                                                                                           |                                                                      |           | Yes [ X | (] No [ ]   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------------------------------------------------------|----------------------------------------------------------------------|-----------|---------|-------------|
| 14       Is the reporting entity publicly traded or a member of a publicly traded group?       Yes [ X ] for [ N ]         15       If the response to 14 is yes, provide the CiK (Central Index Key) code issued by the SEC for the entity/group.       0000731796         14       It as any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of selforment of the response to 14 is yes, fait of change:       000731796         13       State as of what date the latest financial examination of the reporting entity. This date in the latest financial examination in port bacame available to other states of choncide or the recording entity. This is the relatest date with the latest financial examination inport bacame available to other states of the public from either the state of domicide or the recording entity. This is the relatest date or completion date of the examination report headine sublicit to other states of the public from either the state of domicide or the recording entity. This is the relatest financial examination report bacame available to other states of the public from either the state of domicide or the recording entity. This is the relatest date or completion date of the examination report and not the date of the examination report and not the date of the examination report bacame available to other states of the public from either the state of domicide or the recording entity. This is the relatest date or completion date of the examination report bacame available to other states of the public from either the state of domicide or the recording entity. This is the relatest date or completion date of the examination report bacame available to other states or the public from either the state of domicide or the recording entity. New daresequent financial statements?     Y                                                                                                                                                                                                | 1.2 | such regulatory official of the state of domicile of the principal insurer in<br>providing disclosure substantially similar to the standards adopted by the<br>its Model Insurance Holding Company System Regulatory Act and model<br>and the standards adopted by the standards adopted by the<br>standards adopted by the standards adopted by the<br>standards adopted by the<br>standards adopted by the<br>standards adopted by the<br>standards adopted by<br>standards adopted by<br>the standards adopted by<br>the | the Holding C<br>Ne National Ass<br>del regulations             | ompany System, a regis<br>sociation of Insurance Co<br>pertaining thereto, or is t        | stration statement<br>ommissioners (NAIC) in<br>the reporting entity | . Yes [ X | (] No [ | ] N/A [ ]   |
| 1.5       If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group0000731786         2.1       Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?       Yes [] No [X]         2.1       Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?       Yes [] No [X]         2.1       Hys, date of change:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1.3 | State Regulating?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                 |                                                                                           |                                                                      | -         | rsey    |             |
| 2.1       Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?       Yes [] No [X]         2.1       Hyse, date of change:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1.4 | Is the reporting entity publicly traded or a member of a publicly traded g                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Jroup?                                                          |                                                                                           |                                                                      |           | Yes [ X | [] No []    |
| reporting entity?       Yes [] No [X]         22       If yes, date of change:       12/31/2021         31       State as of what date the latest financial examination of the reporting entity was made or is being made.       12/31/2021         32       State as of what date the latest financial examination report became available from either the state of domicile or the reporting entity. This is the release date or completed or released.       12/31/2016         33       State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completed of the examination report and not the date of the examination (balance sheet date).       06/14/2018         34       By what departments?       New Jensey Department of Statemag and funzance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1.5 | If the response to 1.4 is yes, provide the CIK (Central Index Key) code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | issued by the S                                                 | EC for the entity/group.                                                                  |                                                                      |           | 000073  | 31766       |
| 3.1       State as of what date the latest financial examination of the reporting entity was made or is being made.       12/31/2016         3.2       State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examination report became available to other states or the public from either the state of dominicile or the report present either the state of dominicities of dominicities of the examination report became available to other states or the public from either the state of dominicities of the examination report became available to other states or the public from either the state of dominicities of the examination report became available to other states or the public from either the state of dominicities of the examination report been accounted for in a subsequent financial statement either within the latest financial examination report been accounted for in a subsequent financial statement either within the latest financial examination report been accounted for in a subsequent financial statement either within the latest financial examination report been accounted for in a subsequent financial substantial part (more than 20 percent of any major line of business?       Yes [] No [] N/A [X]         14       During the period covered by this statement, did any spacer, busices, sales toprose of the routing entity. Increase credit or commissions for or control a substantial part (more than 20 percent of any major line of business?       Yes [] No [X]         15       Have all financial coverned by this statement, did any spacer consolidation during the period covered by this statement, did any spacer consolidation during the period covered by the statement, and any sales/ereth valescore space accountes cond or commissions for o                                                                                                                                                                                       | 2.1 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                 |                                                                                           |                                                                      |           | Yes [   | ] No [ X ]  |
| <ul> <li>3.2 State the as of date that the latest financial examination report became available form either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released.</li> <li>3.3 State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date).</li> <li>3.4 By what departments?</li> <li>New Jersey Department of Banking and Insurance</li> <li>3.5 Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement field with Departments?</li> <li>Yes [] No [] N/A [X]</li> <li>3.6 Have all of the recommendations within the latest financial examination report been complied with?</li> <li>Yes [] No [] N/A [X]</li> <li>1.0 During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business?</li> <li>4.21 renewals?</li> <li>2.4.21 sales of new business?</li> <li>4.21 sales of new business?</li> <li>4.21 sales of new business?</li> <li>4.22 renewals?</li> <li>Yes [] No [X]</li> <li>Yes (] No [X]</li> <li>Yes [] No [X]</li> <li>Yes provide the name of the e</li></ul> | 2.2 | If yes, date of change:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                 |                                                                                           |                                                                      |           |         |             |
| entity. This date should be the date of the examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report hecame available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date).       06/14/2018         3.3< Bit as of what departments?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 3.1 | State as of what date the latest financial examination of the reporting e                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ntity was made                                                  | or is being made                                                                          |                                                                      |           | 12/31/  | /2021       |
| domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance shed date).       06/14/2018         34       By what department or departments?<br>New Jersey Department of Banking and Insurance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3.2 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                 |                                                                                           |                                                                      |           | 12/31/  | /2016       |
| New Jersey Department of Banking and Insurance         3.5       Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial       Yes [] No [] N/A [X]         3.6       Have all of the recommendations within the latest financial examination report been compiled with?       Yes [] No [] N/A [X]         3.1       Have all of the recommendations within the latest financial examination report been compiled with?       Yes [] No [] N/A [X]         3.1       Have all of the recommendations within the latest financial examination report been compiled with?       Yes [] No [] N/A [X]         3.2       During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:       4.11 sales of new business?       Yes [] No [X]         4.20       During the period covered by this statement, did any sales/service organization order of any major line of business measured on direct premiums) of:       4.21 sales of new business?       Yes [] No [X]         4.21       During the period covered by this statement, did any sales/service organization order of any major line of business measured on direct premiums) of:       4.21 sales of new business?       Yes [] No [X]         4.22       renewals?       Yes [] No [X]       Yes [] No [X]                                                                                                                                                                                                                                                                                                                                                                                                                                              | 3.3 | domicile or the reporting entity. This is the release date or completion of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | late of the exar                                                | nination report and not t                                                                 | he date of the                                                       |           | 06/14/  | /2018       |
| statement filed with Departments?       Yes       ]       No       ]       N/A [ X ]         3.6       Have all of the recommendations within the latest financial examination report been complied with?       Yes       ]       No       ]       N/A [ X ]         3.6       Have all of the recommendations within the latest financial examination report been complied with?       Yes       ]       No       [       N/A [ X ]         4.1       During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than saleried on filed period) receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business?       Yes       [       No [ X ]         4.2       Tenewals?       Yes       [       No [ X ]       Yes       [       No [ X ]         4.2       Tenewals?       Yes       [       No [ X ]       Yes       [       No [ X ]         4.2       transmassized on field period covered by this statement, did any sales/service organization owned in whole or in path by the reporting entity or an affiliate, receive credit or commissions for or control a substantial pat (more than 20 percent of any major line of business measured on direct premiums) of.       Yes [       ] No [ X ]         5.1       Has the reporting entity been a party to a merger or consolidation during the period covered by this statement? <td>3.4</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 3.4 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                 |                                                                                           |                                                                      |           |         |             |
| <ul> <li>4.1 During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaride employees of the reporting entity), receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business?</li> <li>4.11 sales of new business?</li> <li>4.21 renewals?</li> <li>4.21 sales of new business?</li> <li>4.22 renewals?</li> <li>5.1 Has the reporting entity ben a party to a merger or consolidation during the period covered by this statement?</li> <li>4.21 sales of new business?</li> <li>4.22 renewals?</li> <li>5.2 If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.</li> <li>1 Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period?</li> <li>6.1 Has the reporting entity data states of numericity control 10% or more of the reporting entity?</li> <li>4.1 No [X]</li> <li>6.2 If yes, revoked by any governmental entity during the reporting period?</li> <li>7.1 Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting e</li></ul> | 3.5 | Have all financial statement adjustments within the latest financial exar statement filed with Departments?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | nination report                                                 | been accounted for in a                                                                   | subsequent financial                                                 | Yes [     | ] No [  | ] N/A [ X ] |
| combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 3.6 | Have all of the recommendations within the latest financial examination                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | n report been c                                                 | omplied with?                                                                             |                                                                      | Yes [     | ] No [  | ] N/A [ X ] |
| premiums) of:       4.21 sales of new business?       Yes [] No [X]         4.22 renewals?       Yes [] No [X]         5.1       Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?       Yes [] No [X]         5.1       Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?       Yes [] No [X]         5.2       If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.       Image: Company Code in the entity of the merger or consolidation.         6.1       Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period?       Yes [] No [X]         6.2       If yes, give full information:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |     | combination thereof under common control (other than salaried employ<br>a substantial part (more than 20 percent of any major line of business r<br>4.11 sale:<br>4.12 rene<br>During the period covered by this statement, did any sales/service orga                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | vees of the report<br>measured on d<br>s of new busine<br>wals? | orting entity), receive cre<br>irect premiums) of:<br>ess?<br>d in whole or in part by th | edit or commissions for or                                           | control   |         |             |
| <ul> <li>5.1 Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?</li></ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |     | premiums) of:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | ·                                                               |                                                                                           |                                                                      |           |         |             |
| If yes, complete and file the merger history data file with the NAIC.         5.2       If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                 |                                                                                           |                                                                      |           | -       |             |
| ceased to exist as a result of the merger or consolidation.       1       2       3         1       Name of Entity       NAIC Company Code       State of Domicile         6.1       Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period?       Yes [] No [X]         6.2       If yes, give full information:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 5.1 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | g the period co                                                 | vered by this statement                                                                   | ?                                                                    |           | Yes [   | ] No [ X ]  |
| Name of Entity       NAIC Company Code       State of Domicile         6.1       Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period?       Yes [] No [X]         6.2       If yes, give full information:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 5.2 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | of domicile (us                                                 | e two letter state abbrev                                                                 | iation) for any entity that I                                        | าลร       |         |             |
| 6.1       Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period?       Yes [] No [X]         6.2       If yes, give full information:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                 |                                                                                           |                                                                      |           |         |             |
| revoked by any governmental entity during the reporting period?       Yes [] No [X]         6.2       If yes, give full information:         7.1       Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity?         7.2       If yes,<br>7.21 State the percentage of foreign control;         7.2.2 State the nationality(s) of the foreign person(s) or entity(s) or if the entity is a mutual or reciprocal, the nationality of its manager or<br>attorney-in-fact; and identify the type of entity(s) (e.g., individual, corporation or government, manager or attorney in fact).         1       2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                 |                                                                                           |                                                                      |           |         |             |
| 7.1       Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity?       Yes [] No [X]         7.2       If yes,<br>7.21 State the percentage of foreign control;       0.0 %         7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the entity is a mutual or reciprocal, the nationality of its manager or<br>attorney-in-fact; and identify the type of entity(s) (e.g., individual, corporation or government, manager or attorney in fact).         1       2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 6.1 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                 |                                                                                           |                                                                      |           | Yes [   | ] No [ X ]  |
| <ul> <li>7.2 If yes,</li> <li>7.21 State the percentage of foreign control;</li></ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 6.2 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                 |                                                                                           |                                                                      |           |         |             |
| 7.21 State the percentage of foreign control;       0.0 %         7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the entity is a mutual or reciprocal, the nationality of its manager or attorney-in-fact; and identify the type of entity(s) (e.g., individual, corporation or government, manager or attorney in fact).       0.0 %         1       2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 7.1 | Does any foreign (non-United States) person or entity directly or indirect                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | ctly control 10%                                                | or more of the reporting                                                                  | g entity?                                                            |           | Yes [   | ] No [ X ]  |
| attorney-in-fact; and identify the type of entity(s) (e.g., individual, corporation or government, manager or attorney in fact).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 7.2 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                 |                                                                                           |                                                                      |           | (       | D.O%        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                 |                                                                                           |                                                                      | . –       |         | "           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                 |                                                                                           | ntity                                                                |           |         |             |

# **GENERAL INTERROGATORIES**

| 8.1<br>8.2 | Is the company a subsidiary of a depository institution holding compan<br>If the response to 8.1 is yes, please identify the name of the DIHC.                                                                                                                                                     |                                                                                                                               |                     |                      |             | Yes [     | ]   | No [  | X ] |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|---------------------|----------------------|-------------|-----------|-----|-------|-----|
| 8.3<br>8.4 | Is the company affiliated with one or more banks, thrifts or securities fi<br>If response to 8.3 is yes, please provide below the names and location<br>regulatory services agency [i.e. the Federal Reserve Board (FRB), the<br>Insurance Corporation (FDIC) and the Securities Exchange Commissi | irms?<br>n (city and state of the main office) of any affiliates re<br>Office of the Comptroller of the Currency (OCC), th    | egulateo<br>e Feder | by a feo<br>al Depo  | deral       | Yes [ X   | ]   | No [  | ]   |
|            | 1                                                                                                                                                                                                                                                                                                  | 2                                                                                                                             | 3                   | 4                    | 5           | 6         | 1   |       |     |
|            | Affiliate Name Optum Bank, Inc                                                                                                                                                                                                                                                                     | Location (City, State)                                                                                                        | FRB                 | OCC<br>N0            | FDIC<br>YES | SEC<br>NO | -   |       |     |
|            |                                                                                                                                                                                                                                                                                                    |                                                                                                                               |                     |                      | 1E0         | INU       | -   |       |     |
| 8.5        | Is the reporting entity a depository institution holding company with sig<br>Federal Reserve System or a subsidiary of the reporting entity?                                                                                                                                                       |                                                                                                                               |                     |                      |             | Yes [     | ]   | No [  | X ] |
| 8.6        | If response to 8.5 is no, is the reporting entity a company or subsidiary<br>Federal Reserve Board's capital rule?                                                                                                                                                                                 | of a company that has otherwise been made subje                                                                               | ct to the           | ۱                    | es [        | ] No [    | X ] | N/A   | []  |
| 9.         | What is the name and address of the independent certified public according                                                                                                                                                                                                                         | ountant or accounting firm retained to conduct the a                                                                          | nnual ai            | udit?                |             |           |     |       |     |
|            | Deloitte & Touche LLP, Minneapolis, MN                                                                                                                                                                                                                                                             |                                                                                                                               |                     |                      |             |           |     |       |     |
| 10.1       | Has the insurer been granted any exemptions to the prohibited non-au requirements as allowed in Section 7H of the Annual Financial Report law or regulation?                                                                                                                                       | ing Model Regulation (Model Audit Rule), or substan                                                                           | ntially si          | milar sta            | te          | Yes [     | ]   | No [  | X ] |
| 10.2       | If the response to 10.1 is yes, provide information related to this exem                                                                                                                                                                                                                           | ption:                                                                                                                        |                     |                      |             |           |     |       |     |
| 10.3       | Has the insurer been granted any exemptions related to the other requallowed for in Section 18A of the Model Regulation, or substantially sir                                                                                                                                                      | uirements of the Annual Financial Reporting Model F<br>nilar state law or regulation?                                         | Regulati            | on as                |             | Yes [     | ]   | No [  | X ] |
| 10.4       | If the response to 10.3 is yes, provide information related to this exem                                                                                                                                                                                                                           | ption:                                                                                                                        |                     |                      |             |           |     |       |     |
| 10.5       | Has the reporting entity established an Audit Committee in compliance                                                                                                                                                                                                                              | e with the domiciliary state insurance laws?                                                                                  |                     |                      | /es [ X     | 1 No [    | 1   | N/A   | r 1 |
| 10.6       | If the response to 10.5 is no or n/a, please explain                                                                                                                                                                                                                                               |                                                                                                                               |                     |                      | 00 [ 7      | ] 110 [   | ,   | 11,77 |     |
| 11.        | What is the name, address and affiliation (officer/employee of the reportirm) of the individual providing the statement of actuarial opinion/certil Gary A. lannone, Vice President of Actuarial Services of United Health Asylum Street, Hartford, CT 06103                                       | orting entity or actuary/consultant associated with an<br>fication?<br>nCare Services Inc., an affiliate of Oxford Health Pla | actuari<br>ns (NJ)  | al consu<br>Inc., 18 | 5           |           |     |       |     |
| 12.1       | Does the reporting entity own any securities of a real estate holding co                                                                                                                                                                                                                           |                                                                                                                               |                     |                      |             | Yes [     | ]   | No [  | X ] |
|            |                                                                                                                                                                                                                                                                                                    | estate holding company                                                                                                        |                     |                      |             | 0         |     |       |     |
|            |                                                                                                                                                                                                                                                                                                    | rcels involved                                                                                                                |                     |                      |             |           |     |       | 0   |
| 12.2       | If, yes provide explanation:                                                                                                                                                                                                                                                                       | lusted carrying value                                                                                                         |                     |                      | 3           | )         |     |       | 0   |
| 13.        | FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITI                                                                                                                                                                                                                                               | IES ONLY:                                                                                                                     |                     |                      |             |           |     |       |     |
| 13.1       | What changes have been made during the year in the United States n                                                                                                                                                                                                                                 | nanager or the United States trustees of the reportin                                                                         | g entity            | ?                    |             |           |     |       |     |
| 13.2       | Does this statement contain all business transacted for the reporting e                                                                                                                                                                                                                            |                                                                                                                               |                     |                      |             | Yes [     | ]   | No [  | ]   |
| 13.3       | Have there been any changes made to any of the trust indentures duri                                                                                                                                                                                                                               |                                                                                                                               |                     |                      |             | Yes [     | ]   | No [  | ]   |
| 13.4       | If answer to (13.3) is yes, has the domiciliary or entry state approved the                                                                                                                                                                                                                        |                                                                                                                               |                     |                      |             | ] No [    | ]   | N/A   | []  |
| 14.1       | Are the senior officers (principal executive officer, principal financial of similar functions) of the reporting entity subject to a code of ethics, whi                                                                                                                                           | ficer, principal accounting officer or controller, or pe                                                                      | rsons p             | erforming            | g           |           | 1   | No I  | 1   |
|            | <ul> <li>a. Honest and ethical conduct, including the ethical handling of actual<br/>relationships;</li> </ul>                                                                                                                                                                                     | or apparent conflicts of interest between personal a                                                                          | nd profe            | ssional              |             | Yes [ X   | 1   | NO [  | 1   |
|            | b. Full, fair, accurate, timely and understandable disclosure in the period                                                                                                                                                                                                                        |                                                                                                                               | ty;                 |                      |             |           |     |       |     |
|            | c. Compliance with applicable governmental laws, rules and regulation                                                                                                                                                                                                                              |                                                                                                                               |                     |                      |             |           |     |       |     |
|            | d. The prompt internal reporting of violations to an appropriate person<br>e. Accountability for adherence to the code.                                                                                                                                                                            | or persons identified in the code; and                                                                                        |                     |                      |             |           |     |       |     |
| 14.11      | If the response to 14.1 is No, please explain:                                                                                                                                                                                                                                                     |                                                                                                                               |                     |                      |             |           |     |       |     |
| 14.2       | Has the code of ethics for senior managers been amended?                                                                                                                                                                                                                                           |                                                                                                                               |                     |                      |             | Voc [ V   | 1   | No T  | 1   |
|            | If the response to 14.2 is yes, provide information related to amendme                                                                                                                                                                                                                             |                                                                                                                               |                     |                      |             | Yes [ X   | 1   | NU [  | 1   |
|            | Non-material updates to the existing code. Amendments include expansion                                                                                                                                                                                                                            |                                                                                                                               | ng pract            | ces, ado             | ding        |           |     |       |     |
|            | a commitment to ethical marketing, defining intellectual property, and a                                                                                                                                                                                                                           | articulating our commitments to human rights, inclus                                                                          | sion and            | diversit             | y           |           |     |       |     |
|            | Have any provisions of the code of ethics been waived for any of the s                                                                                                                                                                                                                             | pecified officers?                                                                                                            |                     |                      |             | Yes [     | ]   | No [  | X ] |

14.31 If the response to 14.3 is yes, provide the nature of any waiver(s).

## **GENERAL INTERROGATORIES**

|      | Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing or confirming bank is not on the SVO Bank List?<br>If the response to 15.1 is yes, indicate the American Bankers Association (ABA) Routing Number and the name of the issuing or confirming bank of the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered. |                                                                                                                                    |                                      | Yes [                                                               | ] No [ X ]         | ]          |     |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|---------------------------------------------------------------------|--------------------|------------|-----|
|      | 1<br>American<br>Bankers<br>Association<br>(ABA) Routing                                                                                                                                                                                                                                                                                                                                                             | 2                                                                                                                                  |                                      | 3                                                                   |                    | 4          |     |
|      | Number                                                                                                                                                                                                                                                                                                                                                                                                               | Issuing or Confirming Bank Name                                                                                                    |                                      | Can Trigger the Letter of Credit                                    | Am                 | ount       |     |
|      |                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                    |                                      | ·                                                                   |                    |            | -   |
| 16.  | la tha nurahaaa                                                                                                                                                                                                                                                                                                                                                                                                      | BOARD OF<br>or sale of all investments of the reporting entity passed upon e                                                       | DIRECTORS                            | estera er a subordinata committas                                   |                    |            |     |
|      | thereof?                                                                                                                                                                                                                                                                                                                                                                                                             | · · · · · ·                                                                                                                        | -                                    |                                                                     | Yes [ X            | ] No [     | ]   |
| 17.  |                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                    |                                      |                                                                     |                    |            | 1   |
| 18.  | Has the reportir                                                                                                                                                                                                                                                                                                                                                                                                     | g entity an established procedure for disclosure to its board of officers, directors, trustees or responsible employees that is in | directors or trustees of a           | any material interest or affiliation on the                         | Yes [ X<br>Yes [ X | ] No [     | ]   |
|      |                                                                                                                                                                                                                                                                                                                                                                                                                      | FINA                                                                                                                               | NCIAL                                |                                                                     |                    |            |     |
| 19.  |                                                                                                                                                                                                                                                                                                                                                                                                                      | ent been prepared using a basis of accounting other than Statu ciples)?                                                            | tory Accounting Princip              |                                                                     | Yes [              | ] No [ X ] | 1   |
| 20.1 |                                                                                                                                                                                                                                                                                                                                                                                                                      | aned during the year (inclusive of Separate Accounts, exclusive                                                                    | e of policy loans): 20.              | 11 To directors or other officers                                   | \$                 |            | 0   |
|      |                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                    | 20.                                  | 12 To stockholders not officers                                     | .\$                |            | 0   |
|      |                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                    | 20.                                  | 13 Trustees, supreme or grand                                       |                    |            | _   |
| ~~~~ | <b>-</b>                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                    |                                      | (Fraternal Only)                                                    | <u>.\$</u>         |            | 0   |
| 20.2 | policy loans):                                                                                                                                                                                                                                                                                                                                                                                                       | loans outstanding at the end of year (inclusive of Separate Acc                                                                    | counts, exclusive of 20              | 21 To directors or other officers                                   | \$                 |            | 0   |
|      | policy loans).                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                    | 20.                                  | 22 To stockholders not officers                                     | .φ<br>\$           |            | 0   |
|      |                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                    |                                      | 23 Trustees, supreme or grand<br>(Fraternal Only)                   |                    |            |     |
| 21.1 | Were any asset obligation being                                                                                                                                                                                                                                                                                                                                                                                      | s reported in this statement subject to a contractual obligation t<br>reported in the statement?                                   | o transfer to another pa             | rty without the liability for such                                  |                    |            |     |
| 21.2 | If yes, state the                                                                                                                                                                                                                                                                                                                                                                                                    | amount thereof at December 31 of the current year:                                                                                 |                                      | 21 Rented from others                                               |                    |            |     |
|      |                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                    | 21.                                  | 22 Borrowed from others                                             | .\$                |            | 0   |
|      |                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                    | 21.                                  | 23 Leased from others                                               | \$                 |            | 0   |
|      |                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                    | 21.                                  | 24 Other                                                            | .\$                |            | 0   |
|      | guaranty associ                                                                                                                                                                                                                                                                                                                                                                                                      | nent include payments for assessments as described in the An ation assessments?                                                    |                                      |                                                                     |                    |            |     |
| 22.2 | If answer is yes                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                    |                                      | Amount paid as losses or risk adjustment<br>Amount paid as expenses |                    |            |     |
|      |                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                    | 22.23                                | Other amounts paid                                                  | \$                 |            | 481 |
| 23.1 |                                                                                                                                                                                                                                                                                                                                                                                                                      | ing entity report any amounts due from parent, subsidiaries or a                                                                   |                                      |                                                                     |                    |            |     |
| 23.2 |                                                                                                                                                                                                                                                                                                                                                                                                                      | ny amounts receivable from parent included in the Page 2 amo                                                                       |                                      |                                                                     | \$                 |            | 0   |
| 24.1 | Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days?                                                                                                                                                                                                                                                           |                                                                                                                                    |                                      |                                                                     | Yes [              | ] No [ X   | ]   |
| 24.2 | If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party.                                                                                                                                                                                                                                                                                                  |                                                                                                                                    |                                      |                                                                     |                    |            |     |
|      |                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                    | Is the                               |                                                                     |                    |            |     |
|      |                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                    | Third-Party Agent<br>a Related Party |                                                                     |                    |            |     |
|      |                                                                                                                                                                                                                                                                                                                                                                                                                      | Name of Third-Party                                                                                                                | (Yes/No)                             |                                                                     |                    |            |     |

## INVESTMENT

| 25.01 | Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in |                  |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------|------------------|
|       | the actual possession of the reporting entity on said date? (other than securities lending programs addressed in 25.03)                      | Yes [ X ] No [ ] |

## **GENERAL INTERROGATORIES**

25.02 If no, give full and complete information relating thereto

25.03 For securities lending programs, provide a description of the program including value for collateral and amount of loaned securities, and whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this information is also provided)

| 25.04 | For the reporting entity's securities lending program, repo                                                                                                                                 | ort amount of collateral for | conforming programs as outlined in the Risk-Based 0                               | Capital  |           |     |      |        |    |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|-----------------------------------------------------------------------------------|----------|-----------|-----|------|--------|----|
|       | Instructions.                                                                                                                                                                               |                              |                                                                                   |          | \$        |     |      |        | 0_ |
| 25.05 | For the reporting entity's securities lending program, repo                                                                                                                                 | ort amount of collateral for | other programs.                                                                   |          | \$        |     |      |        | 0  |
| 25.06 | Does your securities lending program require 102% (dom<br>outset of the contract?                                                                                                           |                              |                                                                                   | Yes [    | ] N       | 0 [ | ] N/ | ′A [ X | ]  |
| 25.07 | Does the reporting entity non-admit when the collateral re                                                                                                                                  | eceived from the counterpa   | arty falls below 100%?                                                            | Yes [    | ] N       | 0[  | ] N/ | Ά[Χ    | ]  |
| 25.08 | Does the reporting entity or the reporting entity 's securitie<br>conduct securities lending?                                                                                               |                              |                                                                                   | Yes [    | ] N       | 0 [ | ] N/ | ′A [ X | ]  |
| 25.09 | For the reporting entity's securities lending program state                                                                                                                                 | the amount of the followin   | ng as of December 31 of the current year:                                         |          |           |     |      |        |    |
|       | 25.091 Total fair value of reinvested colla                                                                                                                                                 | ateral assets reported on \$ | Schedule DL, Parts 1 and 2.                                                       | \$       |           |     |      |        | _0 |
|       | 25.092 Total book adjusted/carrying valu                                                                                                                                                    | e of reinvested collateral   | assets reported on Schedule DL, Parts 1 and 2                                     | \$       |           |     |      |        | .0 |
|       |                                                                                                                                                                                             |                              | page.                                                                             |          |           |     |      |        |    |
| 26.1  | Were any of the stocks, bonds or other assets of the report<br>control of the reporting entity, or has the reporting entity s<br>force? (Exclude securities subject to Interrogatory 21.1 a | sold or transferred any ass  | sets subject to a put option contract that is currently in                        |          | Yes       | [X] | No   | []     |    |
| 26.2  | If yes, state the amount thereof at December 31 of the cu                                                                                                                                   | irrent year:                 | 26.21 Subject to repurchase agreements                                            |          | \$        |     |      |        | 0  |
|       |                                                                                                                                                                                             |                              | 26.22 Subject to reverse repurchase agreements                                    |          | \$        |     |      |        | 0  |
|       |                                                                                                                                                                                             |                              | 26.23 Subject to dollar repurchase agreements                                     |          | \$        |     |      |        | 0  |
|       |                                                                                                                                                                                             |                              | 26.24 Subject to reverse dollar repurchase agreem                                 |          |           |     |      |        |    |
|       |                                                                                                                                                                                             |                              | 26.26 Placed under option agreements                                              |          | \$        |     |      |        | 0  |
|       |                                                                                                                                                                                             |                              | 26.26 Letter stock or securities restricted as to sale                            | _        |           |     |      |        |    |
|       |                                                                                                                                                                                             |                              | excluding FHLB Capital Stock                                                      |          |           |     |      |        | 0  |
|       |                                                                                                                                                                                             |                              | 26.27 FHLB Capital Stock                                                          |          | \$        |     |      |        | 0  |
|       |                                                                                                                                                                                             |                              | 26.28 On deposit with states                                                      |          | \$        |     | 211, | 795,5  | 20 |
|       |                                                                                                                                                                                             |                              | 26.29 On deposit with other regulatory bodies                                     |          | <u>\$</u> |     |      |        | 0  |
|       |                                                                                                                                                                                             |                              | 26.30 Pledged as collateral - excluding collateral pl                             | edged to |           |     |      |        |    |
|       |                                                                                                                                                                                             |                              | an FHLB                                                                           |          | .\$       |     |      |        | 0  |
|       |                                                                                                                                                                                             |                              | 26.31 Pledged as collateral to FHLB - including ass<br>backing funding agreements | ets      | ¢         |     |      |        | ٥  |
|       |                                                                                                                                                                                             |                              |                                                                                   |          | .φ        |     |      |        | 0  |

26.32 Other .....

\$ ....

...0

#### 26.3 For category (26.26) provide the following:

|         | 1<br>Nature of Restriction                                                                                                                                                                                                                                                                                                                                                        | 2<br>Description                                                                                                                           |         | 3<br>ount                  |             |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|---------|----------------------------|-------------|
| 27.1    | Does the reporting entity have any hedging transactions reported on So                                                                                                                                                                                                                                                                                                            | shedule DB?                                                                                                                                | Yes [   | ] No [                     | X ]         |
| 27.2    | If yes, has a comprehensive description of the hedging program been r<br>If no, attach a description with this statement.                                                                                                                                                                                                                                                         | nade available to the domiciliary state?                                                                                                   | ] No [  | ] N/A                      | []          |
| LINES 2 | 7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ON                                                                                                                                                                                                                                                                                                                        | LY:                                                                                                                                        |         |                            |             |
| 27.3    | Does the reporting entity utilize derivatives to hedge variable annuity gu                                                                                                                                                                                                                                                                                                        | arantees subject to fluctuations as a result of interest rate sensitivity?                                                                 | Yes [   | ] No [                     | ]           |
| 27.4    | 27.42 Per                                                                                                                                                                                                                                                                                                                                                                         | ecial accounting provision of SSAP No. 108<br>mitted accounting practice<br>er accounting guidance                                         | Yes [   | ] No [<br>] No [<br>] No [ | ]<br>]<br>] |
| 27.5    | <ul> <li>The reporting entity has obtained explicit approval from the do</li> <li>Hedging strategy subject to the special accounting provisions</li> <li>Actuarial certification has been obtained which indicates that the reserves and provides the impact of the hedging strategy within</li> <li>Financial Officer Certification has been obtained which indicates</li> </ul> | miciliary state.<br>is consistent with the requirements of VM-21.<br>he hedging strategy is incorporated within the establishment of VM-21 | Yes [   | ] No [                     | ]           |
| 28.1    | Were any preferred stocks or bonds owned as of December 31 of the or issuer, convertible into equity?                                                                                                                                                                                                                                                                             | surrent year mandatorily convertible into equity, or, at the option of the                                                                 | Yes [   | ] No [                     | X ]         |
| 28.2    | If yes, state the amount thereof at December 31 of the current year                                                                                                                                                                                                                                                                                                               |                                                                                                                                            | \$      |                            | 0           |
| 29.     | Excluding items in Schedule E - Part 3 - Special Deposits, real estate, offices, vaults or safety deposit boxes, were all stocks, bonds and other custodial agreement with a qualified bank or trust company in accordar Outsourcing of Critical Functions, Custodial or Safekeeping Agreement                                                                                    | securities, owned throughout the current year held pursuant to a                                                                           | Yes [ ) | (] No [                    | ]           |

29.01 For agreements that comply with the requirements of the NAIC Financial Condition Examiners Handbook, complete the following:

| 1                    | 2                                |
|----------------------|----------------------------------|
| Name of Custodian(s) | Custodian's Address              |
| Northern Trust       | 50 S. LaSalle, Chicago, IL 60675 |
|                      |                                  |

## **GENERAL INTERROGATORIES**

29.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:

| 1       | 2           | 3                       |
|---------|-------------|-------------------------|
| Name(s) | Location(s) | Complete Explanation(s) |
|         |             |                         |

29.03 Have there been any changes, including name changes, in the custodian(s) identified in 29.01 during the current year?... 29.04 If yes, give full and complete information relating thereto:

| 1             | 2             | 3              | 4      |
|---------------|---------------|----------------|--------|
| Old Custodian | New Custodian | Date of Change | Reason |
|               |               |                |        |
|               |               |                |        |

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

| 1                                       | 2           |
|-----------------------------------------|-------------|
| Name of Firm or Individual              | Affiliation |
| DWS Investment Management Americas Inc. | U           |
| BlackRock Financial Management, Inc     | U           |
| J.P. Morgan Asset Management            | U           |
| Internally Managed                      | 1           |
|                                         |             |

29.0597 For those firms/individuals listed in the table for Question 29.05, do any firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") manage more than 10% of the reporting entity's invested assets?..... Yes [ X ] No [ ]

29.0598 For firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") listed in the table for Question 29.05, does the total assets under management aggregate to more than 50% of the reporting entity's invested assets?..... Yes [ X ] No [ ]

#### 29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

| 1                    | 2                                       | 3                             | 4               | 5           |
|----------------------|-----------------------------------------|-------------------------------|-----------------|-------------|
|                      |                                         |                               |                 | Investment  |
|                      |                                         |                               |                 | Management  |
| Central Registration |                                         |                               |                 | Agreement   |
| Depository Number    | Name of Firm or Individual              | Legal Entity Identifier (LEI) | Registered With | (IMA) Filed |
| 107105               | BlackRock Financial Management, Inc     | 549300LVXY1VJKE13M84          | SEC             | NO          |
|                      |                                         | 549300W78QHV4XMM6K69          | SEC             | NO          |
| 104518               | DWS Investment Management Americas Inc. | CZ83K4EEEX8QVCT3B128          | SEC             | NO.         |
|                      |                                         |                               |                 |             |

Does the reporting entity have any diversified mutual funds reported in Schedule D, Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])? 30.1

30.2 If yes, complete the following schedule: Yes [ ] No [ X ]

Yes [ ] No [ X ]

| 1              | 2                   | 3              |
|----------------|---------------------|----------------|
|                |                     | Book/Adjusted  |
| CUSIP #        | Name of Mutual Fund | Carrying Value |
| 30.2999 - Tota |                     | 0              |

30.3 For each mutual fund listed in the table above, complete the following schedule:

| 1                                      | 2                                  | 3                    | 4         |
|----------------------------------------|------------------------------------|----------------------|-----------|
|                                        |                                    | Amount of Mutual     |           |
|                                        |                                    | Fund's Book/Adjusted |           |
|                                        |                                    | Carrying Value       |           |
|                                        | Name of Significant Holding of the | Attributable to the  | Date of   |
| Name of Mutual Fund (from above table) | Mutual Fund                        | Holding              | Valuation |
|                                        |                                    |                      |           |

## **GENERAL INTERROGATORIES**

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

|                       | 1                    | 2           | 3                       |
|-----------------------|----------------------|-------------|-------------------------|
|                       |                      |             | Excess of Statement     |
|                       |                      |             | over Fair Value (-), or |
|                       | Statement (Admitted) |             | Fair Value over         |
|                       | Value                | Fair Value  | Statement (+)           |
| 31.1 Bonds            |                      |             | (25,954)                |
| 31.2 Preferred stocks | 0                    | 0           | 0                       |
| 31.3 Totals           | 168,944,109          | 168,918,155 | (25,954)                |

Describe the sources or methods utilized in determining the fair values: 314 For those securities that had prices in the NAIC SVO ISIS database, those prices were used; for those securities that did not have prices in the NAIC SVO ISIS database, pricing was obtained from Hub which is an external data sources vendor. Hub utilizes various pricing sources. 32.1 Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?. Yes [ ] No [ X ] If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source? 322 Yes [ ] No [ ] If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair 32.3 value for Schedule D. 33.1 Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?..... Yes [X] No [] 33.2 If no, list exceptions: By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: 34 a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments. c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal. Has the reporting entity self-designated 5GI securities? Yes [ ] No [ X ] By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: 35. a. The security was purchased prior to January 1, 2018. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators.
 d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO. Has the reporting entity self-designated PLGI securities? Yes [ ] No [ X ] 36. By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.

d. The fund only or predominantly holds bonds in its portfolio.

37.

ŀ

- e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO.
- f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?.

By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following:

a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.

b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the

discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review.

which documentation is available for regulator review. d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a -37.c are reported as long-term investments.

| Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria? | Yes [ | ] No [ | ] N/A [X] |
|----------------------------------------------------------------------------------------------------------------------|-------|--------|-----------|

Yes [ ] No [ X ]

## **GENERAL INTERROGATORIES**

## OTHER

| 38.1         | Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any?                                                                                                               |                     | \$           |   |
|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|--------------|---|
| 38.2         | List the name of the organization and the amount paid if any such payment represented 25% or more of the total paym service organizations and statistical or rating bureaus during the period covered by this statement. | ents to trade a     | ssociations, |   |
|              | 1                                                                                                                                                                                                                        | 2                   |              |   |
|              | Name Amo<br>Maxim Health Systems, ЦС                                                                                                                                                                                     | ount Paid<br>25,200 |              |   |
| 39.1<br>39.2 | Amount of payments for legal expenses, if any?<br>List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for<br>during the period covered by this statement.    |                     |              | 0 |
|              |                                                                                                                                                                                                                          |                     |              |   |
|              | 1<br>Name Amo                                                                                                                                                                                                            | 2<br>ount Paid      |              |   |
| 40.1         | Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of g                                                                                                   | overnment, if a     | ny?\$        | 0 |
| 40.2         | List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expe                                                                                                      | enditures in        |              |   |

connection with matters before legislative bodies, officers or departments of government during the period covered by this statement.

| 1    | 2           |
|------|-------------|
| Name | Amount Paid |
|      |             |

# **GENERAL INTERROGATORIES**

## PART 2 - HEALTH INTERROGATORIES

|   | Does the reporting entity have any direct Medicare Supplement Insurance in force'                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                    | . 1                                                                     |  |
|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|--|
|   | If yes, indicate premium earned on U.S. business only<br>What portion of Item (1.2) is not reported on the Medicare Supplement Insurance F                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                    |                                                                         |  |
| 3 | 1.31 Reason for excluding                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | φ                                                                                                                                                                  |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                    |                                                                         |  |
| Ļ | Indicate amount of earned premium attributable to Canadian and/or Other Alien no                                                                                                                                                                                                                                                                                                                                                                                                                                 | t included in Item (1.2) above                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | \$                                                                                                                                                                 |                                                                         |  |
| ; | Indicate total incurred claims on all Medicare Supplement Insurance.                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                    |                                                                         |  |
| 5 | Individual policies:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Most current three years:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.61 Total premium earned                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.62 Total incurred claims                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.63 Number of covered lives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | All years prior to most current three years:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.64 Total premium earned                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.65 Total incurred claims                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | \$                                                                                                                                                                 |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.66 Number of covered lives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                    |                                                                         |  |
|   | Group policies:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Most current three years:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.71 Total premium earned                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.72 Total incurred claims                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.73 Number of covered lives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | All years prior to most current three years:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.74 Total premium earned                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.75 Total incurred claims                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.76 Number of covered lives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                    |                                                                         |  |
|   | Health Test:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                    |                                                                         |  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1 2<br>Current Year Prior Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                    |                                                                         |  |
|   | 2.1 Premium Numerator                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                    |                                                                         |  |
|   | 2.2 Premium Denominator                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                    |                                                                         |  |
|   | 2.3 Premium Ratio (2.1/2.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1 000 1 000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                    |                                                                         |  |
|   | 2.4 Reserve Numerator                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                    |                                                                         |  |
|   | 2.5 Reserve Denominator                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                    |                                                                         |  |
|   | 2.6 Reserve Ratio (2.4/2.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                    |                                                                         |  |
|   | Has the reporting entity received any endowment or gift from contracting hospitals, returned when, as and if the earnings of the reporting entity permits?                                                                                                                                                                                                                                                                                                                                                       | physicians, dentists, or others that is agreed will be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Yes [ ] No [ X                                                                                                                                                     | []                                                                      |  |
|   | returned when, as and if the earnings of the reporting entity permits?                                                                                                                                                                                                                                                                                                                                                                                                                                           | physicians, dentists, or others that is agreed will be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Yes [ ] No [X                                                                                                                                                      | []                                                                      |  |
|   | returned when, as and if the earnings of the reporting entity permits?                                                                                                                                                                                                                                                                                                                                                                                                                                           | physicians, dentists, or others that is agreed will be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                    | -                                                                       |  |
|   | returned when, as and if the earnings of the reporting entity permits?                                                                                                                                                                                                                                                                                                                                                                                                                                           | physicians, dentists, or others that is agreed will be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                    | -                                                                       |  |
|   | returned when, as and if the earnings of the reporting entity permits?<br>If yes, give particulars:<br>Have copies of all agreements stating the period and nature of hospitals', physicial<br>dependents been filed with the appropriate regulatory agency?                                                                                                                                                                                                                                                     | physicians, dentists, or others that is agreed will be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Yes [X] No [                                                                                                                                                       | ]                                                                       |  |
|   | returned when, as and if the earnings of the reporting entity permits?<br>If yes, give particulars:<br>Have copies of all agreements stating the period and nature of hospitals', physicial<br>dependents been filed with the appropriate regulatory agency?<br>If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these                                                                                                                                                             | physicians, dentists, or others that is agreed will be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Yes [X] No [<br>Yes [] No [                                                                                                                                        | ]                                                                       |  |
|   | returned when, as and if the earnings of the reporting entity permits?<br>If yes, give particulars:<br>Have copies of all agreements stating the period and nature of hospitals', physicial<br>dependents been filed with the appropriate regulatory agency?<br>If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these<br>Does the reporting entity have stop-loss reinsurance?<br>If no, explain:<br>Oxford Health Plans (NJ), Inc. is not required to have stop loss reinsurance | physicians, dentists, or others that is agreed will be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Yes [ X ] No [<br>Yes [ ] No [<br>Yes [ ] No [ X                                                                                                                   | י<br>נ<br>נ                                                             |  |
|   | returned when, as and if the earnings of the reporting entity permits?<br>If yes, give particulars:<br>Have copies of all agreements stating the period and nature of hospitals', physicia<br>dependents been filed with the appropriate regulatory agency?<br>If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these<br>Does the reporting entity have stop-loss reinsurance?                                                                                                     | physicians, dentists, or others that is agreed will be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Yes [X] No [<br>Yes [] No [<br>Yes [] No [X<br>\$                                                                                                                  | [<br>]                                                                  |  |
|   | returned when, as and if the earnings of the reporting entity permits?<br>If yes, give particulars:<br>Have copies of all agreements stating the period and nature of hospitals', physicial<br>dependents been filed with the appropriate regulatory agency?<br>If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these<br>Does the reporting entity have stop-loss reinsurance?<br>If no, explain:<br>Oxford Health Plans (NJ), Inc. is not required to have stop loss reinsurance | physicians, dentists, or others that is agreed will be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Yes [ X ] No [<br>Yes [ ] No [<br>Yes [ ] No [ X<br>\$                                                                                                             | [<br>]                                                                  |  |
|   | returned when, as and if the earnings of the reporting entity permits?<br>If yes, give particulars:<br>Have copies of all agreements stating the period and nature of hospitals', physicial<br>dependents been filed with the appropriate regulatory agency?<br>If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these<br>Does the reporting entity have stop-loss reinsurance?<br>If no, explain:<br>Oxford Health Plans (NJ), Inc. is not required to have stop loss reinsurance | physicians, dentists, or others that is agreed will be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Yes [ X ] No [<br>Yes [ ] No [<br>Yes [ ] No [ X<br>\$<br>\$                                                                                                       | [<br>]                                                                  |  |
|   | returned when, as and if the earnings of the reporting entity permits?<br>If yes, give particulars:<br>Have copies of all agreements stating the period and nature of hospitals', physicial<br>dependents been filed with the appropriate regulatory agency?<br>If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these<br>Does the reporting entity have stop-loss reinsurance?<br>If no, explain:<br>Oxford Health Plans (NJ), Inc. is not required to have stop loss reinsurance | physicians, dentists, or others that is agreed will be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Yes [ X ] No [<br>Yes [ ] No [<br>Yes [ ] No [ X<br>\$<br>\$<br>\$                                                                                                 | [<br>]<br>]                                                             |  |
|   | returned when, as and if the earnings of the reporting entity permits?<br>If yes, give particulars:<br>Have copies of all agreements stating the period and nature of hospitals', physicial<br>dependents been filed with the appropriate regulatory agency?<br>If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these<br>Does the reporting entity have stop-loss reinsurance?<br>If no, explain:<br>Oxford Health Plans (NJ), Inc. is not required to have stop loss reinsurance | physicians, dentists, or others that is agreed will be<br>ns', and dentists' care offered to subscribers and<br>agreements include additional benefits offered?<br>5.31 Comprehensive Medical<br>5.32 Medical Only<br>5.33 Medicare Supplement<br>5.34 Dental & Vision                                                                                                                                                                                                                                                                                                                                                                                                                | Yes [ X ] No [<br>Yes [ ] No [<br>Yes [ ] No [ X<br>\$<br>\$<br>\$<br>\$<br>\$                                                                                     | [<br>]                                                                  |  |
|   | returned when, as and if the earnings of the reporting entity permits?                                                                                                                                                                                                                                                                                                                                                                                                                                           | physicians, dentists, or others that is agreed will be<br>ns', and dentists' care offered to subscribers and<br>agreements include additional benefits offered?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Yes [ X ] No [<br>Yes [ ] No [<br>Yes [ ] No [ X<br>\$<br>\$<br>\$<br>\$<br>\$                                                                                     | [<br>]                                                                  |  |
|   | returned when, as and if the earnings of the reporting entity permits?                                                                                                                                                                                                                                                                                                                                                                                                                                           | physicians, dentists, or others that is agreed will be<br>ms', and dentists' care offered to subscribers and<br>agreements include additional benefits offered?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Yes [ X ] No [<br>Yes [ ] No [<br>Yes [ ] No [ X<br>Yes [ ] No [ X<br>\$                                                                                           | []                                                                      |  |
|   | returned when, as and if the earnings of the reporting entity permits?                                                                                                                                                                                                                                                                                                                                                                                                                                           | physicians, dentists, or others that is agreed will be<br>ms', and dentists' care offered to subscribers and<br>agreements include additional benefits offered?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Yes [ X ] No [<br>Yes [ ] No [<br>Yes [ ] No [ X<br>Yes [ ] No [ X<br>\$                                                                                           | 1                                                                       |  |
|   | returned when, as and if the earnings of the reporting entity permits?                                                                                                                                                                                                                                                                                                                                                                                                                                           | physicians, dentists, or others that is agreed will be<br>ms', and dentists' care offered to subscribers and<br>agreements include additional benefits offered?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Yes [ X ] No [<br>Yes [ ] No [<br>Yes [ ] No [ X<br>Yes [ ] No [ X<br>\$                                                                                           | 1                                                                       |  |
|   | returned when, as and if the earnings of the reporting entity permits?                                                                                                                                                                                                                                                                                                                                                                                                                                           | physicians, dentists, or others that is agreed will be<br>ns', and dentists' care offered to subscribers and<br>agreements include additional benefits offered?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Yes [ X ] No [<br>Yes [ ] No [<br>Yes [ ] No [ X<br>\$                                                                                                             | [<br>]<br>]<br>]<br>]<br>]<br>]<br>]<br>]<br>]<br>]<br>]                |  |
|   | returned when, as and if the earnings of the reporting entity permits?                                                                                                                                                                                                                                                                                                                                                                                                                                           | physicians, dentists, or others that is agreed will be         ns', and dentists' care offered to subscribers and         agreements include additional benefits offered?         5.31 Comprehensive Medical         5.32 Medical Only         5.33 Medicare Supplement         5.34 Dental & Vision         5.35 Other Limited Benefit Plan         5.36 Other         and their dependents against the risk of insolvency including th providers to continue rendering services, and any other         rseements in reinsurance agreements.         date basis?         8.1 Number of providers at start of reporting year         8.1 Number of providers at end of reporting year | Yes [ X ] No [<br>Yes [ ] No [<br>Yes [ ] No [ X<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$ | ]<br>]<br>]<br>]<br>]<br>]<br>]<br>]<br>]<br>]<br>]<br>]<br>]<br>]<br>] |  |
|   | returned when, as and if the earnings of the reporting entity permits?                                                                                                                                                                                                                                                                                                                                                                                                                                           | physicians, dentists, or others that is agreed will be         ns', and dentists' care offered to subscribers and         agreements include additional benefits offered?         5.31 Comprehensive Medical         5.32 Medical Only         5.33 Medicare Supplement         5.34 Dental & Vision         5.35 Other Limited Benefit Plan         5.36 Other         and their dependents against the risk of insolvency including th providers to continue rendering services, and any other         rseements in reinsurance agreements.         date basis?         8.1 Number of providers at start of reporting year         8.1 Number of providers at end of reporting year | Yes [ X ] No [<br>Yes [ ] No [<br>Yes [ ] No [ X<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$<br>\$ | ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ]                                 |  |
|   | returned when, as and if the earnings of the reporting entity permits?                                                                                                                                                                                                                                                                                                                                                                                                                                           | physicians, dentists, or others that is agreed will be         ns', and dentists' care offered to subscribers and         agreements include additional benefits offered?         5.31 Comprehensive Medical         5.32 Medical Only         5.33 Medicare Supplement         5.34 Dental & Vision         5.35 Other Limited Benefit Plan         5.36 Other         and their dependents against the risk of insolvency including th providers to continue rendering services, and any other         rseements in reinsurance agreements.         date basis?         8.1 Number of providers at start of reporting year         8.1 Number of providers at end of reporting year | Yes [ X ] No [<br>Yes [ ] No [<br>Yes [ ] No [ X<br>\$                                                                                                             | ]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]                                 |  |

## **GENERAL INTERROGATORIES**

| 10.1 | Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts? |                                                     |           | No [ ]     |
|------|----------------------------------------------------------------------------------------------------------|-----------------------------------------------------|-----------|------------|
| 10.2 | If yes:                                                                                                  | 10.21 Maximum amount payable bonuses                | \$        | 1,066,848  |
|      |                                                                                                          | 10.22 Amount actually paid for year bonuses         | \$        | 2,918,372  |
|      |                                                                                                          | 10.23 Maximum amount payable withholds              | \$        | 4,674,395  |
|      |                                                                                                          | 10.24 Amount actually paid for year withholds       | \$        | 3,881,102  |
| 11.1 | Is the reporting entity organized as:                                                                    |                                                     |           |            |
|      |                                                                                                          | 11.12 A Medical Group/Staff Model,                  | Yes [ ]   | No [ X ]   |
|      |                                                                                                          | 11.13 An Individual Practice Association (IPA), or, | Yes [ ]   | No [ X ]   |
|      |                                                                                                          | 11.14 A Mixed Model (combination of above)?         | Yes [ ]   | No [ X ]   |
| 11.2 | Is the reporting entity subject to Statutory Minimum Capital and Surplus Requirement                     | s?                                                  | Yes [ X ] | No [ ]     |
| 11.3 | If yes, show the name of the state requiring such minimum capital and surplus                            |                                                     |           | New Jersey |
| 11.4 | If yes, show the amount required.                                                                        |                                                     | \$        | 59,042,984 |
| 11.5 | Is this amount included as part of a contingency reserve in stockholder's equity?                        |                                                     | Yes [ ]   | No [ X ]   |
| 11.6 | If the amount is calculated, show the calculation                                                        |                                                     |           |            |
|      |                                                                                                          |                                                     |           |            |

125% of the sum of 40,781,838(8% fee for service and hospital non contracted costs) and 6,452,549(4% of contracted hospital costs).

12. List service areas in which reporting entity is licensed to operate:

| 1                         |  |  |  |  |  |
|---------------------------|--|--|--|--|--|
| Name of Service Area      |  |  |  |  |  |
| New Castle, DE            |  |  |  |  |  |
| New Jersey = All Counties |  |  |  |  |  |
| Lane County, OR           |  |  |  |  |  |
| Alleghany, PA             |  |  |  |  |  |
| Beaver, PA                |  |  |  |  |  |
| Berks, PA                 |  |  |  |  |  |
| Butler, PA                |  |  |  |  |  |
| Erie, PA                  |  |  |  |  |  |
| Fayette, PA               |  |  |  |  |  |
| Greene, PA                |  |  |  |  |  |
| Lancaster, PA             |  |  |  |  |  |
| Lawrence, PA              |  |  |  |  |  |
| Lehigh, PA                |  |  |  |  |  |
| Northampton, PA           |  |  |  |  |  |
| Westmoreland, PA          |  |  |  |  |  |
| York, PA                  |  |  |  |  |  |
| Bristol, RI               |  |  |  |  |  |
| Kent, RI                  |  |  |  |  |  |
| Newport, RI               |  |  |  |  |  |
| Providence, RI            |  |  |  |  |  |
| Washington, RI            |  |  |  |  |  |
| 1                         |  |  |  |  |  |

| 13.1 | Do you act as a custodian for health savings accounts?                                   |
|------|------------------------------------------------------------------------------------------|
| 13.2 | If yes, please provide the amount of custodial funds held as of the reporting date0      |
| 13.3 | Do you act as an administrator for health savings accounts?                              |
| 13.4 | If yes, please provide the balance of funds administered as of the reporting date0       |
|      | Are any of the captive affiliates reported on Schedule S, Part 3, authorized reinsurers? |

| 1            | 2       | 3            | 4       | Assets Supporting Reserve Credit |            | e Credit |
|--------------|---------|--------------|---------|----------------------------------|------------|----------|
|              | NAIC    |              |         | 5                                | 6          | 7        |
|              | Company | Domiciliary  | Reserve | Letters of                       | Trust      |          |
| Company Name | Code    | Jurisdiction | Credit  | Credit                           | Agreements | Other    |
|              |         |              |         |                                  |            |          |

Provide the following for individual ordinary life insurance\* policies (U.S. business only) for the current year (prior to reinsurance assumed or 15. ceded):

| 15.1 Direct Premium Written                                                                                        | 15.1 Direct Premium Written                                                                                           | 0 |
|--------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|---|
| 15.2 Total Incurred Claims                                                                                         | 15.2 Total Incurred Claims                                                                                            | 0 |
| 15.3 Number of Covered Lives0                                                                                      | 15.3 Number of Covered Lives                                                                                          | 0 |
| *Ordinary Life Incurance Includes                                                                                  | *Ordinany Life Insurance Includes                                                                                     |   |
| *Ordinary Life Insurance Includes                                                                                  |                                                                                                                       |   |
| Term(whether full underwriting, limited underwriting, jet issue, "short form app")                                 | Term(whether full underwriting, limited underwriting, jet issue, "short form app")                                    |   |
| Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")                          | Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")                             |   |
| Variable Life (with or without secondary gurarantee)                                                               | Variable Life (with or without secondary gurarantee)                                                                  |   |
| Universal Life (with or without secondary gurarantee)                                                              | Universal Life (with or without secondary gurarantee)                                                                 |   |
| Variable Universal Life (with or without secondary gurarantee)                                                     | Variable Universal Life (with or without secondary gurarantee)                                                        |   |
|                                                                                                                    |                                                                                                                       |   |
| eporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states? | e reporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states? |   |

Yes [ ] No [ ]

If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of domicile of the reporting entity? 16.1

16.

|             |                                                                                                          | 1<br>2021   | 2<br>2020   | 3<br>2019   | 4<br>2018     | 5<br>2017 |
|-------------|----------------------------------------------------------------------------------------------------------|-------------|-------------|-------------|---------------|-----------|
|             | Balance Sheet (Pages 2 and 3)                                                                            | 2021        | 2020        | 2013        | 2010          | 2011      |
| 1.          | Total admitted assets (Page 2, Line 28)                                                                  | 355 331 482 |             |             |               |           |
|             | Total liabilities (Page 3, Line 24)                                                                      |             |             |             |               |           |
| 2.          |                                                                                                          |             |             |             |               |           |
| 3.          | Statutory minimum capital and surplus requirement                                                        |             |             |             |               |           |
| 4.          | Total capital and surplus (Page 3, Line 33)                                                              |             |             | 175,548,519 | 147, 160, 409 | 146,074,8 |
|             | Income Statement (Page 4)                                                                                |             |             |             |               |           |
| 5.          | Total revenues (Line 8)                                                                                  |             |             |             |               |           |
| 6.          | Total medical and hospital expenses (Line 18)                                                            |             |             | 634,173,499 |               |           |
| 7.          | Claims adjustment expenses (Line 20)                                                                     |             |             |             |               | 20,492,09 |
| 8.          | Total administrative expenses (Line 21)                                                                  |             |             |             |               |           |
| 9.          | Net underwriting gain (loss) (Line 24)                                                                   |             | 115,456,658 |             |               |           |
| 0.          | Net investment gain (loss) (Line 27)                                                                     | 1,370,924   | 2,457,208   | 4,919,224   | 4,097,034     | 2,367,4   |
| 11.         | Total other income (Lines 28 plus 29)                                                                    | (3,993)     | 12,919      | (21,700)    | 60,112        | (705,2    |
| 12.         | Net income or (loss) (Line 32)                                                                           | 101,714,602 | 90,308,152  | 65,148,842  | 40,916,572    |           |
|             | Cash Flow (Page 6)                                                                                       |             |             |             |               |           |
| 3.          | Net cash from operations (Line 11)                                                                       |             | 70,760,016  |             | 44,891,402    | (22,049,8 |
|             | Risk-Based Capital Analysis                                                                              |             |             |             |               |           |
| 14.         | Total adjusted capital                                                                                   |             |             |             |               | 146,074,8 |
| 15.         | Authorized control level risk-based capital                                                              |             |             |             |               |           |
|             | Enrollment (Exhibit 1)                                                                                   |             |             |             |               |           |
| 16.         | Total members at end of period (Column 5, Line 7)                                                        | 62 565      | 54 362      | 48 154      | 43 645        | 33.2      |
| 17.         | Total members months (Column 6, Line 7)                                                                  |             |             |             |               |           |
| 1.          | Operating Percentage (Page 4)<br>(Item divided by Page 4, sum of Lines 2, 3 and 5) x<br>100.0            |             |             |             |               |           |
| 18.         | Premiums earned plus risk revenue (Line 2 plus<br>Lines 3 and 5)                                         |             |             |             |               |           |
| 19.         | Total hospital and medical plus other non-health<br>(Lines 18 plus Line 19)                              | 79.6        |             |             | 78.7          | 72        |
| 20.         | Cost containment expenses                                                                                |             |             |             |               |           |
|             | Other claims adjustment expenses                                                                         |             |             |             |               |           |
| 21.         | Total underwriting deductions (Line 23)                                                                  |             |             |             |               |           |
| 22.         | Total underwriting gain (loss) (Line 23)                                                                 |             |             |             |               |           |
| 23.         | Total underwriting gain (loss) (Line 24)<br>Unpaid Claims Analysis<br>(U&I Exhibit, Part 2B)             | 10.4        |             | 9.0         | 8.4           | 18        |
| 24.         | Total claims incurred for prior years<br>(Line 13, Col. 5)                                               | 11 150 076  | 11 571 000  | 22 120 240  | 16 210 616    | 00 016 5  |
|             | Estimated liability of unpaid claims-[prior year (Line                                                   |             |             | 2,120,340   | 10,510,010    |           |
| 25.         | 13, Col. 6)]                                                                                             |             |             |             |               | 101,497,7 |
|             | Investments In Parent, Subsidiaries and<br>Affiliates                                                    |             |             |             |               |           |
| 26.         | Affiliated bonds (Sch. D Summary, Line 12, Col. 1)                                                       | 0           | 0           | 0           | 0             |           |
| 27.         | Affiliated preferred stocks (Sch. D Summary,<br>Line 18, Col. 1)                                         | 0           | 0           | 0           | 0             |           |
| 28.         | Affiliated common stocks (Sch. D Summary,<br>Line 24, Col. 1)                                            | 0           | 0           | 0           | 0             |           |
| 29.         | Affiliated short-term investments (subtotal<br>included in Schedule DA Verification, Col. 5,<br>Line 10) | 0           | 0           | 0           | 0             |           |
| 30.         | Affiliated mortgage loans on real estate                                                                 |             |             |             |               |           |
| 31.         | All other affiliated                                                                                     |             |             |             |               |           |
| 32.         | Total of above Lines 26 to 31                                                                            |             |             |             |               |           |
| 33.         | Total investment in parent included in Lines 26 to                                                       |             |             |             |               |           |
| <i>.</i> 0. | 31 above.                                                                                                | 0           | 0           | 0           | 0             |           |

## SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories

|                  |                            |       | Allocated by States and Territories     Direct Business Only |                    |                         |                       |                   |                      |                         |                      |                        |                           |
|------------------|----------------------------|-------|--------------------------------------------------------------|--------------------|-------------------------|-----------------------|-------------------|----------------------|-------------------------|----------------------|------------------------|---------------------------|
|                  |                            |       | -                                                            | 2                  | 3                       | 4                     | 5                 | 6                    | 7                       | 8                    | 9                      | 10                        |
|                  |                            |       |                                                              |                    |                         |                       |                   | Federal<br>Employees | Life and                |                      |                        |                           |
|                  |                            |       |                                                              |                    |                         |                       |                   | Health               | Annuity                 |                      |                        |                           |
|                  |                            |       | Active                                                       | Accident and       |                         |                       |                   | Benefits             | Premiums &              | Property/            | Total                  |                           |
|                  | States, etc.               |       | Status<br>(a)                                                | Health<br>Premiums | Medicare<br>Title XVIII | Medicaid<br>Title XIX | CHIP Title<br>XXI | Program<br>Premiums  | Other<br>Considerations | Casualty<br>Premiums | Columns 2<br>Through 8 | Deposit-Type<br>Contracts |
| 1.               |                            | AL    | (a)<br>N                                                     |                    |                         |                       |                   |                      |                         |                      |                        | 0                         |
| 2.               |                            | AK    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 3.               |                            | AZ    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 4.               | Arkansas                   | AR    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 5.               | California                 | CA    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 6.               | Colorado                   | со    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 7.               | Connecticut                | СТ    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 8.               | Delaware                   | DE    | L                                                            | 0                  | 81,720,875              | 0                     | 0                 | 0                    | 0                       | 0                    | 81,720,875             | 0                         |
| 9.               | District of Columbia       | DC    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 10.              | Florida                    | FL    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 11.              | Georgia                    | GA    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 12.              | Hawaii                     | HI    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 13.              | Idaho                      | ID    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 14.              | Illinois                   | IL    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 15.              | Indiana                    | IN    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 16.              |                            | IA    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 17.              |                            | KS    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 18.              | Kentucky                   |       | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 19.              |                            | LA    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 20.              |                            | ME    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 21.              |                            | MD    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 22.              | Massachusetts              |       | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 23.              | 0                          | MI    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 24.              |                            | MN    | N<br>N                                                       | 0                  | 0<br>0                  | 0<br>0                | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 25.              |                            | MS    | N                                                            | 0                  |                         |                       |                   |                      |                         |                      | 0                      | 0                         |
| 26.<br>27.       |                            | MO    | L<br>N                                                       | 0<br>0             | 0<br>0                  | 0<br>0                | 0<br>0            | 0<br>0               | 0<br>0                  | 0<br>0               | 0                      | 0                         |
| 27.<br>28.       |                            | MT    | N<br>N                                                       | 0                  | 0<br>0                  | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 20.<br>29.       | Nebraska<br>Nevada         | NE    | N<br>N                                                       | 0                  | 0<br>0                  | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 29.<br>30.       | New Hampshire              |       | NN.                                                          | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 30.<br>31.       | New Jersey                 |       | N                                                            | 1,400,483          |                         | 0<br>0                | 0                 | 0                    | 0                       | 0                    |                        | 0                         |
| 31.              | New Mexico                 |       | Ľ                                                            | 1,400,403          |                         | 0                     | 0                 | 0                    | 0                       | 0                    | 004,100,000            | 0                         |
| 33.              |                            | NY    | NN                                                           | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 34.              | North Carolina             |       | NN                                                           | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 35.              |                            | ND    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 36.              |                            | OH    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 37.              |                            | OK    | N                                                            | 0                  |                         | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 38.              |                            | OR    | L                                                            | 0                  | 10,281,594              | 0                     | 0                 | 0                    | 0                       | 0                    | 10,281,594             | 0                         |
| 39.              | Pennsylvania               |       | L                                                            | 0                  | 473,254,958             | 0                     | 0                 | 0                    | 0                       | 0                    | 473,254,958            | 0                         |
| 40.              | Rhode Island               | RI    | L                                                            | 0                  | 103,601,952             | 0                     | 0                 | 0                    | 0                       | 0                    | 103,601,952            | 0                         |
| 41.              | South Carolina             | SC    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 42.              | South Dakota               | SD    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 43.              | Tennessee                  | TN    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 44.              | Texas                      | ТΧ    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 45.              | Utah                       | UT    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 46.              | Vermont                    |       | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 47.              | Virginia                   |       | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 48.              | Washington                 |       | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 49.              | West Virginia              | WV    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 50.              | Wisconsin                  |       | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 51.              | Wyoming                    |       | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 52.              | American Samoa             |       | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 53.              | Guam                       |       | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 54.              |                            | PR    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 55.              | U.S. Virgin Islands        | VI    | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 56.              | Northern Mariana           |       | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | •                         |
| 57.              |                            | MP    | N                                                            | 0                  | 0<br>0                  | 0<br>0                | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 57.<br>58.       | Canada<br>Aggregate Other  | CAN   | N                                                            | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 50.              | Aggregate Other<br>Aliens  | от    | XXX                                                          | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 59.              | Subtotal                   |       | XXX                                                          |                    | 1,221,627,591           | 0                     | 0                 | 0                    | 0                       | 0                    | 1,223,028,074          | 0                         |
| 60.              | Reporting Entity           |       |                                                              | , ,                | , , ,                   |                       |                   |                      |                         |                      | . , .,                 |                           |
|                  | Contributions for Em       |       |                                                              |                    |                         |                       |                   |                      |                         |                      |                        |                           |
|                  | Benefit Plans              |       | XXX                                                          | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 61.              | Totals (Direct Busines     |       | XXX                                                          | 1,400,483          | 1,221,627,591           | 0                     | 0                 | 0                    | 0                       | 0                    | 1,223,028,074          | 0                         |
| E0004            | DETAILS OF WRITE-INS       |       | 1001                                                         |                    |                         |                       |                   |                      |                         |                      |                        |                           |
| 58001.           |                            |       | XXX                                                          |                    |                         |                       |                   | t                    | +                       |                      | t                      |                           |
| 58002.<br>58003. |                            |       | XXX<br>                                                      |                    |                         |                       |                   | <u>+</u>             | +                       |                      | <b>†</b>               |                           |
|                  | Summary of remainin        | а     |                                                              |                    |                         |                       | +                 | t                    | †                       |                      | t                      | <u> </u>                  |
| 55330.           | write-ins for Line 58 fr   |       |                                                              |                    |                         |                       |                   |                      |                         |                      |                        |                           |
|                  | overflow page              |       | XXX                                                          | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
| 58999.           | Totals (Lines 58001 th     |       |                                                              |                    |                         |                       |                   |                      |                         |                      |                        |                           |
|                  | 58003 plus 58998)(Lin      | ne 58 | <b>V</b> VV                                                  | 0                  | 0                       | 0                     | 0                 | 0                    | 0                       | 0                    | 0                      | 0                         |
|                  | above)<br>e Status Counts: |       | XXX                                                          | U                  | J                       | U                     | 0                 | U 0                  | J                       | 0                    | 0                      | L                         |

L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG.....
 E - Eligible - Reporting entities eligible or approved to write surplus lines in the state...
 N - None of the above - Not allowed to write business in the state....

R - Registered - Non-domiciled RRGs... Q - Qualified - Qualified or accredited reinsurer


0

0


(b) Explanation of basis of allocation by states, premiums by state, etc. The premiums are allocated based on the sales location of the group or address of the individual and recorded in the financial system by state as the premiums are received. The premiums are allocated based on the sales location of the group or address of the individual and recorded in the financial system by state as the premiums are received.

6


0




40



40.1






# SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1 – ORGANIZATIONAL CHART


|                                                                                                                                  |                                                                                                                                                   |                                                                                                                                                                                                 |                                                                                             | United HealthCare Services, Inc.                                                                                  |                                                                                                                   |                                                                                                            |                                                                                                                    |                                                                                                                           |                                                                                                            |                                                                                                         |                                                                                                                                                                              |
|----------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Continued from Previous F                                                                                                        | Page                                                                                                                                              |                                                                                                                                                                                                 |                                                                                             |                                                                                                                   |                                                                                                                   |                                                                                                            |                                                                                                                    |                                                                                                                           |                                                                                                            |                                                                                                         | Continued on Next Page                                                                                                                                                       |
| Providers, Inc.<br>41-2014834                                                                                                    | Health Insurance<br>Company<br>52-1803283<br>NAIC No. 60321<br>Prac<br>Associat<br>52-110<br>NAIC No.                                             | o. 96310 HMO                                                                                                                                                                                    | Health Insurance<br>Company<br>35-1137395<br>NAIC No. 70785<br>INS                          | PacifiCare Life<br>Assurance<br>Company<br>95-2829463<br>NAIC No. 84506<br>INS                                    | PacifiCare of<br>Arizona, Inc.<br>94-3267522<br>NAIC No. 95617<br>HCSO (HMO)                                      | PacifiCare of<br>Colorado, Inc.<br>84-1011378<br>NAIC No. 95434<br>HMO                                     | Preferred Care<br>Network of<br>Florida, Inc.<br>20-3391186<br>NAIC No. 12756<br>HMO                               | UnitedHea<br>                                                                                                             | 2511                                                                                                       | Preferred Care<br>Network, Inc.<br>01-0788576<br>NAIC No. 12155<br>HMO                                  | PreferredOne<br>Administrative<br>Services, Inc.<br>41-1846481                                                                                                               |
| (DE) BU 42151 100%                                                                                                               | MD) BU 58050 100% (MD) BU 58                                                                                                                      | (MD) BU 58010 100                                                                                                                                                                               | (IN) BU 35300 100%                                                                          | (Co) BU 35310 100%                                                                                                | (AZ) BU 55300 100%                                                                                                | (CO) BU 55320 100%                                                                                         | (FL) BU 44502 100%                                                                                                 | (DE) BU 595                                                                                                               | 25 100%                                                                                                    | (FL) BU 44501 100%                                                                                      | (MN) BU 26001 100%                                                                                                                                                           |
| New York IPA, Inc.                                                                                                               | Preferred Care<br>Partners<br>Holding, Corp.<br>65-0683927                                                                                        | gs, LLC   Health Holding                                                                                                                                                                        | s,Tufts Health<br>Freedom Plans,<br>Inc                                                     | U <u>HC of Californ</u> ia<br>95-2931460<br>Knox Keene<br>933-0126                                                | Rocky Mountain Health<br>Maintenance<br>Organization,<br>Incorporated<br>84-0614905<br>NAIC No. 95482             | Arizona<br>Physicians IPA,<br>Inc.<br>86-0813232                                                           | Capital City<br>Medical Group,<br>L.L.C.<br>27-3955254                                                             | Harken Health<br>Insurance<br>Company<br>35-1279304<br>NAIC No. 79480                                                     | Neighborhood<br>Health<br>Partnership, Inc.<br>65-0996107<br>NAIC No. 95123                                | Sierra Health<br>Services, Inc.<br>88-0200415                                                           | PreferredOne<br>Insurance<br>Company<br>81-0625135<br>NAIC No. 11817                                                                                                         |
| (NY) BU 42153 100%                                                                                                               | (FL) BU 44600 100% (TX) BU 44                                                                                                                     | (DE) BU 44900 100                                                                                                                                                                               | (DE) BU 28001 100%                                                                          | (CA) BU 55310 100%                                                                                                | HMO<br>(CO) BU 56000 100%                                                                                         | (AZ) BU 50363 100%                                                                                         | (LA) BU 45110 100%                                                                                                 | INS<br>(WI) BU 55010 100%                                                                                                 | HMO<br>(FL) BU 55215 100%                                                                                  | (NV) BU 10700 100%                                                                                      | Property & Casualty<br>(MN) BU 36001 100%                                                                                                                                    |
| Providers of<br>California, Inc.<br>52-1452809<br>Knox Keene<br>933-0255                                                         | Partners Medical<br><u>Group, Inc.</u><br>26-1845018<br>MAIC NG<br>HM                                                                             | Company of<br>America           577255         38-2044243           0.11494         NAIC No. 84549                                                                                              | Freedom Insurance<br>Company<br>47-3788473<br>NAIC No. 15737<br>INS                         | UHIC Holdings,<br>Inc.<br>41-1921008                                                                              |                                                                                                                   | New Orleans Regional<br>Physician Hospital<br>Organization, L.L.C.<br>72-1267232                           | Southwest<br>Michigan Health<br>Network Inc.<br>38-2609888<br>(MI) BU 22402 100%                                   | UnitedHealthcare<br>Insurance Company<br>of the River Valley<br>20-1902768<br>NAIC No. 12231<br>INS<br>(IL) BU 33600 100% | UnitedHealthcare<br>of Alabama, Inc.<br>63-0899562<br>NAIC No. 95784<br>HMO<br>(AL) BU 50100 100%          | Behavioral<br>Healthcare<br>Options, Inc.<br>88-0267857<br>(NV) BU 41292 100%                           | Family Health<br>Care Services<br>88-0223385           (NV)         BU 10463         100%                                                                                    |
| Providers of<br>Illinois, Inc.<br>36-4008355<br>NAIC No. 52053                                                                   | Ovation           Parferred Care           Parfners, Inc.           65-085893           NAIC No. 11176           HMO           (FL) BU 44601 100% |                                                                                                                                                                                                 | Benefits Plan of<br>California<br>47-3221444<br>Knox Keene: 933 0517<br>(CA) - DUATER 1009/ | UnitedHealthcare<br>Insurance<br>Company(13)<br>36-2739571<br>NAIC No. 79413<br>INS<br>(CT) BU 30100 100%         |                                                                                                                   | Peoples Health,<br><u>Inc.</u><br>20-5662149<br>NAIC No. 13607<br>HMO<br>(LA) BU 45101 100%                | UnitedHealthcare<br>of Arizona. Inc.<br>86-0507074<br>NAIC No. 96016<br>HCSO (HMO)<br>(AZ) BU 50300 100%           | UnitedHealthcare<br>of <u>Arkansas. Inc</u> .<br>63-1036819<br>NAIC No. 95446<br>HMO<br>(AR) BU 50400 100%                | UnitedHealthcare<br>of <u>Colorado, Inc</u> .<br>84-1004639<br>NAIC No. 95090<br>HMO<br>(CO) BU 50800 100% | Family Home           Hospice. Inc.           88-0257036           (NV)         BU 10493           100% | Health Plan of           Nevada. Inc.         88-0201035           NAIC No. 96342         HMO           (NV)         BU 55700         100%                                   |
| Dental, Inc.<br>76-0196559<br>NAIC No. 95251<br>HMO                                                                              | Integrated         Communication           Services, Inc.         of Texas           86-0618309         91-200           HMO         NAIC No.     |                                                                                                                                                                                                 | n <u>Kentucky, Ltd.(6)</u><br>62-1240316<br>NAIC No. 96644<br>HMO                           | 5995<br>Minnetonka, LLC<br>35-2607738<br>(DE ) BU 30102 100%                                                      | EP Campus I, LLC<br>35-2607738<br>(DE) BU 30101 100%                                                              | UnitedHealthcare<br>of Florida.Inc.<br>59-1293865<br>NAIC No. 95264<br>HMO<br>(FL) BU 50931 100%           | UnitedHealthcare<br>of Georgia, Inc.<br>58-1653544<br>NAIC No. 95850<br>HMO<br>(GA) BU 51000 100%                  | UnitedHealthcare<br>of Illinois. Inc.<br>36-3280214<br>NAIC No. 95776<br>HMO<br>(IL) BU 51310 100%                        | UnitedHealthcare<br>of Louisiana. Inc.<br>72-1074008<br>NAIC No. 95833<br>HMO<br>(LA) BU 51800 100%        | Mesquite Liberty,<br>                                                                                   | Northern Nevada<br>Health Network,<br>Inc.<br>88-0245121<br>(NV) BU 22770 100%                                                                                               |
| Nevada Pacific           Dental           88-0228572           NAIC No. 95758           PLHSO (HMO)           (NV) BU 42002 100% | <u>Corpo</u><br>52-210                                                                                                                            | ealth<br>oration<br>102846<br>H400 100%                                                                                                                                                         | c. <u>of Ohio, Inc.</u><br>31-1142815<br>NAIC No. 95186<br>HIC (HMO)                        | Oxford Health<br>Insurance, Inc.<br>22-2797560<br>NAIC No. 78026<br>INS<br>(NY) BU 58545 100%                     | Unimerica Life<br>Insurance Company<br>of New York<br>01-0637149<br>NAIC No. 11596<br>INS<br>(NY) BU 30500 100%   | UnitedHealthcare<br>of Mississippi, Inc.<br>63-1036817<br>NAIC No. 95716<br>HMO<br>(MS) BU 52400 100%      | UnitedHealthcare of<br>North Carolina, Inc.<br>56-1461010<br>NAIC No. 95103<br>HMO<br>(NC) BU 53310 100%           | UnitedHealthcare<br>of South<br><u>Carolina, Inc.</u><br>35-2674992<br>NAIC No. 16740<br>HMO<br>(SC) BU 54500 100%        | UnitedHealthcare<br>of Texas, Inc.<br>95-3939697<br>NAIC No. 95765<br>HMO<br>(TX) BU 54300 100%            | Prime Health, Inc.<br>88-0253112                                                                        | Sierra Health and<br>Life Insurance<br>Company, Inc.<br>94-0734600           94-0734600           NAIC No. 71420           INS           INS           (NV)         BU 35700 |
| Plus Group<br>Management,<br>LLC<br>20-8375685                                                                                   | Plus of Texas<br>nsurance Company<br>45-4976934 Plus Sout<br>Insurance<br>20-38                                                                   | UnitedHealthca           0         0           0         0           0         0           12567         NAS           4403         100%                                                        | c. <u>of Oregon. Inc.</u><br>93-0938819<br>NAIC No. 95893<br>HCSC (HMO)                     | UnitedHealthcare<br>Insurance Company<br>of Illinois<br>36-3800349<br>NAIC No. 60318<br>INS<br>(IL) BU 32010 100% | UnitedHealthcare<br>Insurance Company<br>of New York<br>11-3283886<br>NAIC No. 60093<br>INS<br>(NY) BU 30400 100% | UnitedHealthcare of<br>the Mid-Atlantic, Inc.<br>52-1130183<br>NAIC No. 95025<br>HMO<br>(MD) BU 52300 100% | UnitedHealthcare of<br>the Midlands, Inc.<br>47-0676824<br>NAIC No. 95591<br>HMO<br>(NE) BU 52700 100%             | UnitedHealthcare of<br>the Midwest, Inc.<br>43-1361841<br>NAIC No. 96385<br>HMO<br>(MO) BU 52500 100%                     | UnitedHealthcare<br>of Utah, Inc.<br>41-1488563<br>NAIC No. 95501<br>HMO<br>(UT) BU 54400 100%             | Sierra Health-Care<br>Options, Inc.<br>88-0254322<br>(NV) BU 22700 100%                                 | Sierra Home           Medical Products,           Inc.           88-0385705           (NV)         BU 10453                                                                  |
| In                                                                                                                               | Plus Wisconsin<br>nsurance Company Private L                                                                                                      | UnitedHealthca<br>of the Rockies<br><u>inited(4)</u><br>07695<br>44408<br>99.998%<br>UnitedHealthca<br>of the Rockies<br><u>Inc.</u><br>86-0875231<br>NAIC No. 95685<br>HMO<br>(UT) BU55330 100 | , <u>Washington, Inc</u> .<br>91-1312551<br>NAIC No. 48038<br>HCSC (HMO)                    | UnitedHealthcare of<br><u>New Mexico, Inc.</u><br>26-2697886<br>NAIC No. 13214<br>HMO<br>(NM) BU 42073 100%       | UnitedHealthcare<br>Service LLC<br>47-0854646<br>(DE) BU 30310 100%                                               | UnitedHealthcare<br>of <u>Wisconsin, Inc.</u><br>39-1555888<br>NAIC No. 95710<br>HMO<br>(WI) BU 54900 100% | UnitedHealthcare<br>Plan of the River<br>Valley, Inc.<br>36-3379945<br>NAIC No. 95378<br>HMO<br>(IL) BU 55600 100% |                                                                                                                           |                                                                                                            | Southwest<br>Medical           Associates. Inc.           88-0201420           (NV)         BU 122720   | Sierra Nevada<br>Administrators,<br>Inc.<br>88-0264562<br>(NV) BU 22710 100%                                                                                                 |


# SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP


Optum, Inc. 30-0580620





PART 1 - ORGANIZATIONAL CHART




























40.13















# SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1 – ORGANIZATIONAL CHART



# SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1 – ORGANIZATIONAL CHART

| Entity Name                                                            | Juris. Federal Tax ID |            | Entity Name                                               | Juris. | Federal Tax ID |
|------------------------------------------------------------------------|-----------------------|------------|-----------------------------------------------------------|--------|----------------|
| edical Group, PLC AZ 45-2402948 Empire Physicians' Medical Group, Inc. |                       | CA         | 33-0181426                                                |        |                |
| A.G. Dikengil, Inc.                                                    | NJ                    | 22-3149900 | Everett Physicians, Inc. P.S.                             | WA     | 81-1625636     |
| AbleTo Behavioral Health Services of Michigan, P.C.                    | MI                    | 85-4328419 | First Hill Surgery Center, LLC                            | WA     | 47-2066485     |
| AbleTo Behavioral Health Services of New Jersey, P.C.                  | NJ                    | 85-4306375 | Greater Phoenix Collaborative Care, P.C.                  | AZ     | 27-2337725     |
| AbleTo Behavioral Health Services, P.C.                                | СТ                    | 47-5519672 | HealthCare Partners Affiliates Medical Group              | CA     | 95-4526112     |
| AbleTo Licensed Clinical Social Worker Services, P.C.                  | CA                    | 85-0739865 | HealthCare Partners ASC-HB, LLC                           | CA     | 26-4247365     |
| American Health Network of Indiana, LLC                                | IN                    | 35-2108729 | HealthCare Partners Associates Medical Group, P.C.        | CA     | 45-5273760     |
| AHN Accountable Care Orgnization, LLC                                  | IN                    | 45-4171713 | HealthCare Partners Medical Group, P.C.                   | CA     | 95-4340584     |
| AppleCare Hospitalists Medical Group, Inc.                             | CA                    | 14-1890491 | Homecare Dimensions of Florida, Inc.                      | TX     | 81-0884465     |
| AppleCare Medical ACO, LLC                                             | CA                    | 45-2852872 | Homecare Dimensions, Inc.                                 | TX     | 74-2758644     |
| AppleCare Medical Group St. Francis, Inc.                              | CA                    | 33-0845269 | IN Style OPTICAL, LLC                                     | MA     | 27-3296953     |
| AppleCare Medical Group, Inc.                                          | CA                    | 33-0898174 | Inland Faculty Medical Group, Inc.                        | CA     | 33-0618077     |
| ArchWell Health Professional Services Holding Co.                      | DE                    | 86-3278602 | Inspiris Medical Services of New Jersey, P.C.             | NJ     | 45-2563134     |
| ArchWell Health Professional Services of Alabama, LLC                  | AL                    | 86-3152173 | INSPIRIS of Michigan Medical Services, P.C.               | M      | 27-1561674     |
| Archwell Health Professional Services of Arizona, LLC                  | AZ                    | 87-2986923 | INSPIRIS of New York Medical Services, P.C.               | NY     | 13-4168739     |
| ArchWell Health Professional Services of Kansas, P.A.                  | KS                    | 86-3241870 | INSPIRIS of Pennsylvania Medical Services, P.C.           | PA     | 26-2895670     |
| Archwell Health Professional Services of Nebraska, LLC                 | NB *                  | 87-3065955 | Landmark Connect of California, PC                        | CA     | 36-4886532     |
| ArchWell Health Professional Services of North Carolina, P.C.          | NC                    | 86-3222071 | Landmark Connect of Oregon, P.C.                          | OR     | 82-4121823     |
| ArchWell Health Professional Services of Oklahoma, LLC                 | OK                    | 86-3190019 | Landmark Connect of Pennsylvania, PC                      | PA     | 82-4513634     |
| ARTA Western California, Inc.                                          | CA                    | 33-0658815 | Landmark Connect of Washington, P.C.                      | WA     | 82-4273042     |
| Aspectus, Inc.                                                         | MA                    | 04-3403101 | Landmark Medical of Arkansas, P.A.                        | AR     | 85-0997438     |
| Beaver Medical Group, P.C.                                             | CA                    | 33-0645967 | Landmark Medical of California, PC                        | CA     | 47-4553619     |
| Better Health Value Network, LLC                                       | WA                    | 47-4349079 | Landmark Medical of Connecticut, PC                       | CT     | 83-2295301     |
| Bexar Imaging Center, LLC                                              | TX                    | 22-3858211 | Landmark Medical of Florida, P.A.                         | FL     | 85-0838149     |
| California Spring Holdings, PC                                         | CA                    | 81-0881243 | Landmark Medical of Idaho, PC                             | D      |                |
| CareMount Health Solutions ACO, LLC                                    | NY                    |            | Landmark Medical of Kansas, P.A.                          | KS     | 82-4633545     |
| CareMount Medical, P.C.                                                | NY                    | 13-3544120 | Landmark Medical of Kentucky, PSC                         | KY     | 82-4881602     |
| Centers for Family Medicine, GP                                        | CA                    | 33-0483510 | Landmark Medical of Louisiana, a Professional Corporation |        | 82-4881732     |
| Connect Medical, P.C.                                                  | NY                    | 32-0551188 | Landmark Medical of Massachusetts, PLLC                   |        | 81-5364097     |
| David Moen, M.D. P.C.                                                  | NY                    | 81-5101448 | Landmark Medical of Michigan, P.C.                        |        | 86-3599871     |
| David R. Ferrell, M.D., P.C.                                           | NV                    | 45-2380022 | Landmark Medical of Mississippi, P.C.                     | MS     | 82-5084178     |
| Day-OP Center Of Long Island Inc.                                      | NY                    | 11-2811353 | Landmark Medical of Missouri, P.C.                        | MO     | 82-4857713     |
| Durable Medical Equipment, Inc.                                        | MA                    | 04-3106404 | Landmark Medical of New Hampshire, P.C.                   | NH     | 85-1174070     |

# SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1 – ORGANIZATIONAL CHART

| Entity Name                                        | Juris. | Federal Tax ID | Entity Name                                     | Juris. | Federal Tax ID |
|----------------------------------------------------|--------|----------------|-------------------------------------------------|--------|----------------|
| Landmark Medical of North Carolina, P.C.           | NC     | 82-4256752     | MedExpress Primary Care West Virginia, Inc.     | WV     | 82-4401181     |
| Landmark Medical of Ohio, Professional Corporation | OH     | 82-4864947     | MedExpress Primary Care Wisconsin, S.C.         | WI     | 81-4563448     |
| Landmark Medical of Oregon, PC                     | OR     | 47-2926188     | MedExpress Urgent Care - New Jersey, P.C.       | NJ     | 45-5388778     |
| Landmark Medical of Pennsylvania, PC               | PA     | 81-1605378     | MedExpress Urgent Care - Northern New Jersey PC | NJ     | 83-2089623     |
| Landmark Medical of Rhode Island, PC               | RI     | 84-2830065     | MedExpress Urgent Care Arizona, P.C.            | AZ     | 81-4030280     |
| Landmark Medical of Tennessee, PC                  | TN     | 30-1288593     | MedExpress Urgent Care Arkansas, P.A.           | AR     | 46-4348120     |
| Landmark Medical of Texas, PA                      | TX     | 83-2296389     | MedExpress Urgent Care California, P.C.         | CA     | 82-0930142     |
| Landmark Medical of Utah, PC                       | UT     | 84-2660339     | MedExpress Urgent Care Connecticut, P.C.        | CT     | 81-1956812     |
| Landmark Medical of Virginia, P.C.                 | VA     | 85-0839774     | MedExpress Urgent Care Idaho, P.C.              | D      | 82-1135336     |
| Landmark Medical of Washington, PC                 | WA     | 47-3028655     | MedExpress Urgent Care Illinois, P.C.           | L      | 47-4308614     |
| Landmark Medical, P.C.                             | NY     | 47-1588943     | MedExpress Urgent Care Iowa, P.C.               | IA     | 81-5353472     |
| Level2 Medical Services, P.A.                      | DE     | 84-5003916     | MedExpress Urgent Care Kansas, P.A.             | KS     | 47-1919283     |
| Level2 Medical Services, P.A. New Jersey           | NJ     | 87-2684015     | MedExpress Urgent Care Minnesota P.C.           | MN     | 81-1125396     |
| Level2 Medical Services, P.C. Alaska               | AK     | 87-2600511     | MedExpress Urgent Care Missouri P.C.            | MO     | 47-3132625     |
| Level2 Medical Services, P.C. California           | CA     | 84-5003916     | MedExpress Urgent Care North Carolina, P.C.     | NC     | 81-5138747     |
| Level2 Medical Services, P.C. Utah                 | UT     | 87-0989804     | MedExpress Urgent Care Oregon, P.C.             | OR     | 82-1919436     |
| March Vision Care Group, Incorporated              | CA     | 95-4874334     | MedExpress Urgent Care Rhode Island, P.C.       | RI     | 81-5362765     |
| March Vision Care IPA, Inc.                        | NY     | 27-3115058     | MedExpress Urgent Care South Carolina, P.C.     | sc     | 81-5380706     |
| March Vision Care of Texas, Inc.                   | TX     | 45-4227915     | MedExpress Urgent Care Texas, P.A.              | TX     | 47-5147441     |
| MAT-RX DEVELOPMENT, L.L.C.                         | TX     | 43-1967820     | MedExpress Urgent Care Washington, P.C.         | WA     | 82-2443118     |
| Mat-Rx Fort Worth GP, L.L.C.                       | TX     | 35-2262695     | MedExpress Urgent Care Wisconsin, S.C.          | WI     | 81-4281678     |
| ME Urgent Care Nebraska, Inc.                      | NB*    | 81-0936574     | MedExpress Urgent Care, Inc West Virginia       | WV     | 26-4546400     |
| MedExpress Employed Services, Inc.                 | DE     | 81-1265129     | MedExpress Urgent Care, P.C Georgia             | GA     | 47-1804667     |
| MedExpress Primary Care Arizona, P.C.              | AZ     | 81-4550969     | MedExpress Urgent Care, P.C Indiana             | IN     | 90-0929572     |
| MedExpress Primary Care Arkansas, P.A.             | AR     | 84-4234388     | MedExpress Urgent Care, P.C Maryland            | MD     | 45-3461101     |
| MedExpress Primary Care Kansas, P.A.               | KS     | 81-4605885     | MedExpress Urgent Care, P.C Massachusetts       | MA     | 47-1857908     |
| MedExpress Primary Care Maryland, P.C.             | MD     | 82-3384324     | MedExpress Urgent Care, P.C Michigan            | MI     | 46-4793937     |
| MedExpress Primary Care Massachusetts, P.C.        | MA     | 82-1096099     | MedExpress Urgent Care, P.C Oklahoma            | OK     | 47-1824365     |
| MedExpress Primary Care Minnesota P.C.             | MN     | 81-4396738     | MedExpress Urgent Care, P.C Pennsylvania        |        | 26-3750502     |
| MedExpress Primary Care Oklahoma, P.C.             | OK     | 83-1077265     | MedExpress Urgent Care, P.C Tennessee           |        | 45-4973138     |
| MedExpress Primary Care South Carolina, P.C.       | SC     | 83-0764858     | MedExpress Urgent Care, P.C Virginia            |        | 45-3123110     |
| MedExpress Primary Care Texas, P.A.                | ТХ     | 84-2500750     | MedExpress Urgent Care, P.S.C Kentucky          | KY     | 83-1565124     |
| MedExpress Primary Care Virginia, P.C.             | VA     | 82-3395792     | MedExpress, Inc Delaware                        | DE     | 45-5436856     |

# SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1 – ORGANIZATIONAL CHART

| Entity Name                                       | Juris. Federal Tax ID |                                                        | Entity Name                                                 | Juris. | Federal Tax ID |
|---------------------------------------------------|-----------------------|--------------------------------------------------------|-------------------------------------------------------------|--------|----------------|
| Memorial Healthcare IPA, GP                       |                       | 95-4688463 ProHEALTH Care Associates of New Jersey LLP |                                                             | NJ     | 47-5656253     |
| MH Physician Three Holdco, a Medical Corporation  | CA                    | 27-4691544                                             | ProHEALTH Care Associates, L L P.                           | NY     | 11-3355604     |
| MHCH, Inc.                                        | CA                    | 80-0507474                                             | ProHEALTH Medical NY, P.C.                                  | NY     | 47-1388406     |
| MHIPA Physician Two Holdco, a Medical Corporation | CA                    | 27-4691508                                             | ProHealth Physicians, P.C.                                  | СТ     | 06-1469068     |
| Mobile Medical Services of New Jersey, PC         | NJ                    | 81-2977678                                             | ProHEALTH Urgent Care Medicine of New Jersey LLP            | NJ     | 47-5661535     |
| Mobile Medical Services, P.C.                     | NY                    | 30-0445773                                             | ProHEALTH Urgent Care Medicine, PLLC                        | NY     | 46-1883579     |
| Moen, M.D., P.C.                                  | CA                    | 85-3287029                                             | Prospero Health Partners Florida, Inc.                      | FL     | 85-0775386     |
| Monarch Health Plan, Inc.                         | CA                    | 22-3935634                                             | Prospero Health Partners New York, P.C.                     | NY     | 82-2400620     |
| Monarch HealthCare, A Medical Group, Inc.         | CA                    | 33-0587660                                             | Prospero Health Partners North Carolina, P.C.               | NC     | 84-4569314     |
| Monika Roots, M.D., P.C.                          | CA                    | 84-4887072                                             | Prospero Health Partners, P.C.                              | MN     | 84-3234753     |
| Mosaic Management Services, Inc.                  | CA                    | 20-5892451                                             | Prospero Medical Services New Jersey, P.C.                  | NJ     | 84-3844362     |
| NAMM Medical Group Holdings, Inc.                 | CA                    | 56-2627070                                             | Prospero Medical Services, P.A.                             | FL     | 87-2406404     |
| NAMM MGH, Inc.                                    | CA                    | 61-1627269                                             | Psychiatry Services of New York, P.C.                       | NY     | 85-0921665     |
| naviHealth Coordinated Care SC, P.C.              | M                     | 85-0975337                                             | Redlands Family Practice Medical Group, Inc.                | CA     | 56-2627067     |
| naviHealth Michigan HBPC, P.C.                    | M                     | 84-3469040                                             | Reliant Medical Group The Endoscopy Center, LLC             | MA     | 20-5251393     |
| New York Licensed Clinical Social Work, P.C.      | NY                    | 86-3891057                                             | Reliant Medical Group, Inc.                                 | MA     | 04-2472266     |
| Nifty After Fifty/Monarch, LLC                    | CA                    | 26-2995765                                             | Riverside Community Healthplan Medical Group, Inc.          | CA     | 33-0055097     |
| Northwest Medical Group Alliance, LLC             | WA                    | 91-1699944                                             | Riverside Electronic Healthcare Resources, Inc.             | CA     | 20-3420379     |
| NPN IPA Washington, PLLC                          | WA                    | 61-1855159                                             | Riverside Pediatric Group, P.C.                             | NJ     | 22-3624559     |
| OHR Physician Group, P.C.                         | OR                    | 93-0979031                                             | Robert B. McBeath, M.D. II, P.C.                            | NV     | 86-0857176     |
| Optum Clinic, P.A.                                | TX                    | 75-2778455                                             | Robert B. McBeath, M.D. III, P.C.                           | NV     | 46-2662506     |
| Optum Medical Services of California, P.C.        | CA                    | 30-0826311                                             | Robert B. McBeath, M.D., Professional Corporation           | NV     | 88-0310956     |
| Optum Medical Services of Colorado, P.C.          | co                    | 45-5424191                                             | San Bernardino Medical Group, Inc.                          | CA     | -              |
| Optum Medical Services, P.C.                      | NC                    | 45-3866363                                             | Sanvello Behavioral Health Services of Michigan, P.C.       | DE     | 85-1941832     |
| Oregon Healthcare Resources, LLC                  | OR                    | 27-3674492                                             | Sanvello Behavioral Health Services of New Jersey, P.C.     | NJ     | 85-0666386     |
| Physician Partners Medical Group, Inc.            | CA                    | 30-0516435                                             | Sanvello Behavioral Health Services of North Carolina, P.C. | NC     | 85-1959641     |
| Physicians Care Network, L.L.C.                   | WA                    | 91-1822767                                             | Sanvello Behavioral Health Services of Texas, P.A.          | TX     | 84-3152209     |
| Polyclinic Holdings, P.C.                         | WA                    | 83-3042027                                             | Sanvello Behavioral Health Services, P.A.                   |        | 84-1754732     |
| Polyclinic Management Services Company, LLC       | WA                    | 46-0508606                                             | Southern California Medical Practice Concepts, LLC          |        | 30-0743767     |
| Primary Care Associated Medical Group, Inc.       | CA                    | 33-0527335                                             | Surgical Eye Experts, LLC                                   |        | 65-1321064     |
| Prime Community Care, Inc.                        | CA                    | 30-0516440                                             | Talbert Medical Group, P.C.                                 |        | 93-1172065     |
| ProHEALTH Accountable Care Medical Group, PLLC    | NY                    | 45-4469117                                             | TeamMD Physicians, P.C.                                     | IA     | 42-1446216     |
| ProHEALTH Ambulatory Surgery Center, Inc.         | NY                    | 11-3447394                                             | The Everett Clinic, PLLC                                    | WA     | 91-0214500     |

# SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1 – ORGANIZATIONAL CHART

| Entity Name                             | Juris. | Federal Tax ID |
|-----------------------------------------|--------|----------------|
| The Polyclinic, PLLC                    | WA     | 91-0369070     |
| USMD Diagnostic Services, LLC           | TX     | 27-2803133     |
| USMD Hospital at Arlington, L.P.        | TX     | 73-1662763     |
| USMD Hospital at Fort Worth, L.P.       | TX     | 20-3571243     |
| USMD of Arlington GP, L.L.C.            | TX     | 73-1662757     |
| Vitucci, LCSW, P.C.                     | L      | 85-1453387     |
| Waypoint Minnesota PC                   | MN     | 46-2854394     |
| WellMed Florida Medicare ACO, LLC       | TX     | 84-2233329     |
| WellMed Greater Texas Medicare ACO, LLC | TX     | 84-2178104     |
| WellMed Medical Group, P.A.             | TX     | 74-2574229     |
| WellMed Network of Florida, Inc.        | TX     | 35-2314192     |
| WellMed Networks - DFW, Inc.            | ТХ     | 41-2250215     |
| WellMed Networks, Inc.                  | TX     | 74-2889447     |
| WellMed of Las Cruces, Inc.             | TX     | 92-0183013     |
| WellMed Tampa/Orlando Medicare ACO, LLC | TX     | 84-2193803     |
| WellMed Texas Medicare ACO, LLC         | TX     | 84-2219968     |
| WND Medical, PLLC                       | TX     | 45-2158334     |
| XLHome Michigan, P.C.                   | MI     | 46-3537245     |
| XLHome Northeast, P.C.                  | NJ     | 45-5530241     |
| XLHome Oklahoma, Inc.                   | OK     | 46-2931689     |
| XLHome, P.C.                            | MD     | 27-3543997     |

# SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1 – ORGANIZATIONAL CHART

#### **Organizational Chart Footnotes**

- (1) Entity is owned in full or in part by a UnitedHealth Group Incorporated friendly physician.
- (2) Control of the Foundation is based on sole membership, not the ownership of voting securities.
- (3) The remaining percentage is owned either by a non-affiliated entity, outside investor(s), former company officer(s), or third party shareholder(s).
- (4) The minority percentage is owned by one or more affiliated UnitedHealth Group Incorporated subsidiaries. Voting rights do vary.
- (5) No information of the other shareholder(s) has been provided
- (6) General partnership interests are held by United HealthCare Services, Inc. (89.77%) and by UnitedHealthcare, Inc. (10.23%). United HealthCare Services, Inc. also holds 100% of the limited partnership interests. When combining general and limited partner interests, United HealthCare Services, Inc. owns 94.18% and UnitedHealthcare, Inc. owns 5.83%.
- (7) Branch offices in Iraq and Uganda.
- (8) H&W Indemnity (SPC), Ltd. is an exempted segregated portfolio company organized under the laws of the Cayman Islands and holds a Cayman insurance license.
- (9) Registered as a foreign shareholder in Brazil.
- (10) Registered in Nova Scotia and Newfoundland& Labrador.
- (11) Polar II Fundo de Investimento em Participações is a Brazilian private equity investment fund incorporated in the form of a closed-end condominium.
- (12) N/A
- (13) Entity has a representative office in Beijing, China.
- (14) Registered in the Dubai Silicon Oasis free zone.
- (15) Registered branch in the UK.
- (16) Registered in the Dubai Healthcare City free zone.
- (17) Entity is not directly owned by the parent. However, the parent does have a viable economic interest as well as control over the entity through contractual agreements.
- (18) Entity has a branch office in the United Kingdom.

# ANNUAL STATEMENT FOR THE YEAR 2021 OF THE Oxford Health Plans (NJ), Inc. **OVERFLOW PAGE FOR WRITE-INS**

| Addition | al Write-ins for Underwriting and Investment Exhibit P | art 3 Line 25 |              |                |            |            |
|----------|--------------------------------------------------------|---------------|--------------|----------------|------------|------------|
|          |                                                        | Claim Adjustm | ent Expenses | 3              | 4          | 5          |
|          |                                                        | 1             | 2            |                |            |            |
|          |                                                        | Cost          | Other Claim  | General        |            |            |
|          |                                                        | Containment   | Adjustment   | Administrative | Investment |            |
|          |                                                        | Expenses      | Expenses     | Expenses       | Expenses   | Total      |
| 2504.    | Miscellaneous Losses                                   |               | 1,681        |                | 0          |            |
| 2505.    | Professional Fees/Consulting                           |               |              |                | 0          | 1,337,460  |
| 2506.    | Sundry General Expenses                                |               |              | 5, 357, 358    | 0          |            |
| 2597.    | Summary of remaining write-ins for Line 25 from        |               |              |                |            |            |
|          | overflow page                                          | 4,210,937     | 896,960      | 6,139,623      | 0          | 11,247,520 |

# ANNUAL STATEMENT FOR THE YEAR 2021 OF THE Oxford Health Plans (NJ), Inc. OVERFLOW PAGE FOR WRITE-INS

#### Additional Write-ins for Underwriting and Investment Exhibit Part 2D Line 5

| Additional Write-ins for Underwriting and Investment Exhibit Part 2D Line 5 |       |                      |            |             |             |               |          |          |       |
|-----------------------------------------------------------------------------|-------|----------------------|------------|-------------|-------------|---------------|----------|----------|-------|
|                                                                             | 1     | 2                    | 3          | 4           | 5           | 6             | 7        | 8        | 9     |
|                                                                             |       |                      |            |             |             | Federal       |          |          |       |
|                                                                             |       |                      |            |             |             | Employees     | Title    | Title    |       |
|                                                                             |       | Comprehensive        | Medicare   |             |             | Health        | XVIII    | XIX      |       |
|                                                                             | Total | (Hospital & Medical) | Supplement | Dental Only | Vision Only | Benefits Plan | Medicare | Medicaid | Other |
| 0504. High-Cost Risk Pool Contribution Payable                              |       |                      | 0          | 0           | 0           | 0             | 0        | 0        | 0     |
| 0597. Summary of remaining write-ins for Line 5 from overflow page          | 9,132 | 9,132                | 0          | 0           | 0           | 0             | 0        | 0        | 0     |